

0001213900-24-06816510-Q Sensus Healthcare, Inc. 20240813202408113145909145909 0 0001213900-24-068165 10-Q 63 20240630 20240813 Sensus Healthcare, Inc. 0001494891 3841 271647271 DE 1231 10-Q 34 001-37714 241200780 851 BROKEN SOUND PARKWAY NW SUITE 215 BOCA RATON FL 33487 561-922-5808 851 BROKEN SOUND PARKWAY NW SUITE 215 BOCA RATON FL 33487 Sensus Healthcare, LLC 20100622 10-Q 1 ea0210678-10q sensus.htm QUARTERLY REPORT A A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 A FORM 10-Q A a" A QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 A For the quarterly period ended June 30, 2024 A OR A a" A TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 A FOR THE TRANSITION PERIOD FROM TO A Commission File Number: 001-37714 A Sensus Healthcare, Inc. (Exact name of registrant as specified in its charter) A Delaware A 27-1647271 (State or other jurisdiction of incorporation or organization) A (I.R.S. Employer Identification No.) A 851 Broken Sound Pkwy., NW #215, Boca Raton, FL A 33487 (Address of principal executive office) A (Zip Code) A (561) 922-5808 (Registrant's telephone number, including area code) A Securities registered pursuant to Section 12(b) of the Act: A Title of each class A Trading symbol(s) A Name of each exchange on which registered Common Stock, par value \$0.01 per share A SRTS A The NASDAQ Stock Market, LLC A Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes a" No a" A Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (A\$232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes a" No a" A Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an aemerging growth company. See the definitions of aelarge accelerated filer, aeaaccelerated filer, aaesmaaller reporting company, aeaemerging growth company, aelarge accelerated filer in Rule 12b-2 of the Exchange Act. A Large accelerated filer A Accelerated filer A Non-accelerated filer A Smaller reporting company A A A Emerging growth company A A If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. a" A Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes a" No a" A As of August 6, 2024, there were 16,389,051 shares of the registrant's common stock outstanding. A A A A SENSUS HEALTHCARE, INC. QUARTERLY REPORT ON FORM 10-Q TABLE OF CONTENTS A A Page PART I ael Financial Information A Item 1. Condensed Consolidated Financial Statements (unaudited) 1 A Condensed Consolidated Balance Sheets (unaudited) 1 A Condensed Consolidated Statements of Income (Loss) (unaudited) 2 A Condensed Consolidated Statements of Stockholders' Equity (unaudited) 3 A Condensed Consolidated Statements of Cash Flows (unaudited) 4 A Notes to the Condensed Consolidated Financial Statements (unaudited) 5 A A Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 17 A A Item 3. Quantitative and Qualitative Disclosures about Market Risk 21 A A Item 4. Controls and Procedures 21 A A PART II ael Other Information A Item 1. Legal Proceedings 22 A A Item 1A. Risk Factors 22 A A Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 A A Item 3. Defaults Upon Senior Securities 22 A A Item 4. Mine Safety Disclosure 22 A A Item 5. Other Information 22 A A Item 6. Exhibits 23 A A Signatures 24 A i A INTRODUCTORY NOTE A Forward-Looking Statements A This report includes statements that are, or may be deemed, aeforward-looking statements. ael In some cases, these statements can be identified by the use of forward-looking terminology such as aebelieves, ael aeesimates, ael aelanticipates, ael aelexpects, ael aelplans, ael aelintends, ael aelmay, ael aelcould, ael aelmight, ael aelwill, ael aeleshould, ael aelapproximately, ael or aelpotential, ael or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words. A Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus Healthcare, Inc., our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments and circumstances are consistent with the forward-looking statements contained in this report, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this report as a result of the following factors, among others: the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; the performance of the Company's information technology systems and its ability to maintain data security; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission. A To date, the Russian invasion of Ukraine, conditions in the Middle East, and other global geopolitical uncertainties have not had significant impacts on our business, but we continue to monitor developments and will address them in future disclosures, if applicable. A Any forward-looking statements that we make in this report speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this report, except as may be required by applicable law. A ii A PART I. FINANCIAL INFORMATION A Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS A SENSUS HEALTHCARE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS A (in thousands, except shares and per share data) A As of June 30, 2024 A A As of December 31, 2023 A A (unaudited) A A A Assets A A A A Current assets A A A A Cash and cash equivalents A \$18,972 A \$23,148 A Accounts receivable, net A 18,293 A A 10,645 A Inventories A 12,769 A A 11,861 A Prepaid inventory A 4,333 A A 2,986 A Other current assets A 1,106 A A 888 A Total current assets A 54,473 A A 49,528 A Property and equipment, net A 712 A A 464 A Deferred tax asset A 1,644 A A 2,140 A Operating lease right-of-use asset, net A 679 A A 774 A Other noncurrent assets A 655 A A 804 A Total assets A \$58,163 A \$53,710 A A A A Liabilities and stockholders' equity A A A A Current liabilities A A A A Accounts payable and accrued expenses A \$3,284 A \$2,793 A Product warranties A 517 A A 538 A Operating lease liability, current portion A 195 A A 187 A Income tax payable A A A A 37 A Deferred revenue, current portion A 686 A A 657 A Total current liabilities A 4,682 A A 4,212 A Operating lease liability A 503 A A 596 A Deferred revenue, net of current portion A 77 A A 60 A Total liabilities A 5,262 A A 4,868 A Commitments and contingencies A A A A A Stockholders' equity A A A A Preferred stock, 5,000,000 shares authorized and none issued and outstanding A A A A Common stock, \$0.01 par value ael 50,000,000 authorized; 16,927,845 issued and 16,394,921 outstanding at June 30, 2024; 16,907,095 issued and 16,374,171 outstanding at December 31, 2023 A 169 A A 169 A Additional paid in capital A 45,578 A A 45,405 A Treasury stock, 532,924 shares at cost, at June 30, 2024 and December 31, 2023 A (3,519) A (3,519) Retained earnings A 10,673 A A 6,787 A Total stockholders' equity A 52,901 A A 48,842 A Total liabilities and stockholders' equity A \$58,163 A \$53,710 A A See accompanying notes to the condensed consolidated financial statements (unaudited). A 1 A SENSUS HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) (unaudited) A A For the Three Months Ended June 30, A For the Six Months Ended June 30, A (in thousands, except shares and per share data) A 2024 A 2023 A 2024 A 2023 A A A A A Revenues A \$9,239 A \$4,527 A \$19,902 A \$7,941 A Cost of sales A 3,816 A A 1,908 A A 7,817 A A 3,700 A Gross profit A 5,423 A A 2,619 A A 12,085 A A 4,241 A Operating expenses A A A A A Selling and marketing A 996 A A 1,595 A A 2,266 A A 3,693 A General and administrative A 1,579 A A 1,329 A A 3,158 A A 2,693 A Research and development A 866 A A 822 A A 1,792 A A 1,920 A Total operating expenses A 3,441 A A 3,746 A A 7,216 A A 8,306 A Income (loss) from operations A 1,982 A A (1,127) A A 4,869 A A (4,065) Other income: A A A A Interest income, net A 209 A A 245 A A 423 A A 488 A Other income, net A 209 A A 245 A A 423 A A 488 A Income (loss) before income tax A 2,191 A A (882) A A 5,292 A A (3,577) Provision for (benefit from) income taxes A 579 A A (502) A A 1,406 A A (1,303) Net income (loss) A 1,612 A A \$ (380) A \$3,886 A (2,274) Net income (loss) per share ael basic A \$0.10 A \$ (0.02) A \$0.24 A A (0.14) diluted A \$0.10 A A (0.02) A \$0.24 A A (0.14) Weighted average number of shares used in ael computing net income (loss) per share ael basic A 16,298,459 A A 16,249,766 A A 16,296,715 A A 16,247,567 A diluted A 16,333,481 A A 16,249,766 A A 16,325,764 A A 16,247,567 A A See accompanying notes to the condensed consolidated financial statements (unaudited). A 2 A SENSUS HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited) A A Common Stock A Additional Paid-In A Treasury Stock A Retained A A (in thousands, except shares) A Shares A Amount A Capital A Shares A Amount A Earnings A Total A A A A A A A A A A December 31, 2022 A 16,902,761 A A 169 A \$45,031 A A (512,342) A (3,433) \$6,302 A \$48,069 A Stock-based compensation A 10,000 A A A 161 A A A A A A A A 161 A Exercise of stock options A 8,334 A A A 46 A A A A A 46 A Forfeiture of restricted stock units A (7,500) A A A (18) A A A A A A A A (18) Surrender of shares for tax withholding on stock-based compensation A A A A A (4,487) A A (40) A A A (40) Net loss A A A A A A A A (1,894) A (1,894) March 31, 2023 A 16,913,595 A A 169 A \$45,220 A A (516,829) A (3,473) \$4,408 A \$46,324 A Stock-based compensation A A A A A 67 A A A A A A A A 67 A A A A A A A A 67 A Forfeiture of restricted stock units A (1,000) A A A (1) A A A A A (1) Net loss A A A A A A A A (380) A A (380) June 30, 2023 A 16,912,595 A A 169 A \$45,286 A A (516,829) A (3,473) \$4,028 A \$46,010 A A A A A A A A A A December 31, 2023 A 16,907,095 A A 169 A \$45,405 A A (532,924) A (3,519) \$6,787 A \$48,842 A Stock-based compensation A 20,000 A A A 92 A A A A 92 A A A A A A A A 92 A Forfeiture of restricted stock units A (1,500) A A A (1) A A A A A (1) Net income A A A A A 2,274 A A 2,274 A March 31, 2024 A 16,925,595 A A 169 A \$45,496 A A (532,924) A (3,519) \$9,061 A \$51,207 A Stock-based compensation A A A A A 66 A A A A A 66 A Exercise of stock options A 3,000 A A A A 17 A A A A A 17 A Forfeiture of restricted stock units A (750) A A A (1) A A A A A (1) Net income A A A A A A A A 1,612 A A 1,612 A June 30, 2024 A 16,927,845 A A 169 A \$45,578 A A (532,924) A (3,519) \$10,673 A \$52,901 A A See accompanying notes to the condensed consolidated financial statements (unaudited). A 3 A SENSUS HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) A A For the Six Months Ended June 30, A (in thousands) A 2024 A 2023 A Cash flows from operating activities A A A Net income (loss) A \$3,886 A (2,274) Adjustments to reconcile net income (loss) to net cash and cash equivalents used in operating activities: A A A Credit loss expense A 42 A A 5 A Depreciation and amortization A 101 A A 156 A Amortization of right-of-use asset A 95 A A 93 A Provision for product warranties A 186 A A 281 A Stock-based compensation A 156 A A 209 A Deferred income taxes A 496 A A (1,303) Changes in operating assets and liabilities: A A A A Accounts receivable A (7,690) A 8,145 A Inventories A (1,021) A (6,644) Prepaid inventory A (347) A (429) Other current assets A (218) A (709) Other noncurrent assets A 149 A A 118 A Changes in operating assets and liabilities: A A A A Accounts payable and accrued expenses A 491 A A (1,580) Operating lease liability A (85) A (104) Income tax payable A (37) A (890) Deferred revenue A 46 A A (24) Product warranties A (207) A (305) Net cash used in operating activities A (3,957) A (5,255) Cash flows from investing activities A A A Acquisition of property and equipment A (236) A (218) Net cash used in investing activities A (236) A (218) Cash flows from financing activities A A A A Withholding taxes on stock-based compensation A A A (40) Exercise of stock options A 17 A A 46 A Net cash provided by financing activities A 17 A A 6 A Net decrease in cash and cash equivalents A (4,176) A (5,467) Cash and cash equivalents ael beginning of period A 23,148 A A 25,520 A Cash and cash equivalents ael end of period A 18,972 A \$20,053 A Supplemental disclosure of cash flow information: A A A A Interest paid A A A A Income tax paid A 935 A A 1,390 A Supplemental schedule of noncash investing and financing transactions: A A A A Transfer of inventory to property and equipment A 113 A \$14 A A See accompanying notes to the condensed consolidated financial statements (unaudited). A 4 A SENSUS HEALTHCARE, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) A Note 1 ael Organization and Summary of Significant Accounting Policies A Description of the Business A Sensus Healthcare, Inc. (together, with its subsidiaries, unless the context otherwise indicates, aelSensus ael or the aelCompany ael) is a manufacturer of radiation therapy devices sold to healthcare providers globally through its distribution and marketing network. The Company operates from its corporate headquarters located in Boca Raton, Florida. A In February 2024, the Company formed Sensus Healthcare Services, LLC, a wholly-owned subsidiary that provides operational healthcare services in the form of leased equipment, radiation oncology and physics oversight, including radiotherapy technologists for dermatology clinics. A Basis of Presentation and Principles of Consolidation A These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (aelGAAP ael) and include the accounts of the Company and its subsidiaries. Accounts and transactions between condensed consolidated entities have been eliminated. A These financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and notes required by GAAP. In the opinion of management, all adjustments considered necessary for a fair statement of the results have been included. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024 or for any other period. A The condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited financial statements at that date but does not include all of the information and notes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the ael2023 Annual Report ael). A Use of Estimates A The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates. A Reclassification of Prior Year Presentation A Certain prior period amounts have been reclassified for consistency with the current period presentation. The reclassifications are limited to the condensed consolidated statements of cash flow and have no impact on the reported results of operations. A Revenue Recognition A The Company derives revenue from sales of the Company's devices and services related to maintaining and repairing the devices as part of a service contract or on an ad-hoc basis without a service contract. A The Company provides warranties, generally for one year, in conjunction with the sale of its products. These warranties entitle the customer to repair, replacement, or modification of the defective product, subject to the terms of the relevant warranty. The Company has determined that these warranties do not represent separate performance obligations, as the customer does not have the option to purchase the warranty separately and the warranty does not provide the customer with a service in addition to the assurance that the product complies with agreed-upon specifications. The Company records an estimate of future warranty claims at the time it recognizes revenue from the sale of the device based upon management's estimate of the future claims rate. A 5 A Revenue is recognized upon transfer of control of promised goods or services to customers when the product is shipped or the service is rendered, based on the amount the Company expects to receive in exchange for those goods or services. The Company enters into contracts that can include multiple services, which are accounted for separately if they are determined to be distinct. A To determine the transaction price for a contract in which a customer promises consideration in a form other than cash, the Company measures the estimated fair value of the noncash consideration at contract inception. If the Company cannot reasonably estimate the fair value of the noncash consideration, the Company measures the consideration indirectly by reference to the standalone selling price of the products promised to the customer or class of customer in exchange for the consideration. A Our service contracts include maintenance or repair service contracts for device purchases and personnel service contracts to assist the use and operation of leased-out equipment under lessor agreements. A The revenues from maintenance or repair service contracts are recognized over the service contract period on a straight-line basis. In the event that a customer does not sign a service contract, but requests maintenance or repair services after the warranty expires, the Company recognizes revenue when the service is rendered. There is no termination provision in the service contract or any penalties in practice for cancellation of the service

The revenues from service contracts are recognized in the period the work is performed, as the Company has elected the practical expedient to recognize revenue in the amount to which the entity has a right to invoice. The service contracts can be terminated by mutual written agreement. The Company has determined that in practice no significant discount is given on service contracts when offered with the device purchase or equipment lease as compared to when sold on a stand-alone basis. The service level provided is identical whether the service contract is purchased on a stand-alone basis or together with the device purchase or equipment lease. The Company may also incur preparation cost to ensure the customer's space meets the requirement and specifications for the operation of the equipment. The preparation cost is expensed as incurred. The components of disaggregated revenue for the three and six months ended June 30, 2024 and 2023 were as follows:

	2024	2023
Product Revenue	\$8,074	\$3,524
Service Revenue	\$17,566	\$5,993
Other Revenue	\$4,527	\$19,902
Total Revenue	\$29,167	\$29,419

The Company operates in a highly regulated environment, primarily in the U.S. dermatology market, in which state regulatory approval is sometimes required prior to the customer being able to use the product. In cases where such regulatory approval is pending, revenue is deferred until such time as regulatory approval is obtained. Deferred revenue activity as of June 30, 2024 was as follows:

	2024	2023
Product Revenue	\$665	\$763
Service Revenue	\$1,913	\$1,581
Other Revenue	\$1,146	\$1,146
Total Revenue	\$3,724	\$3,290

The Company's remaining performance obligations of deposits for products have original expected durations of one year or less. Estimated service revenue to be recognized in the future related to the performance obligations that are unsatisfied (or partially unsatisfied) as of June 30, 2024 is as follows:

	2024	2023
Product Revenue	\$439	\$172
Service Revenue	\$439	\$172
Other Revenue	\$439	\$172
Total Revenue	\$1,317	\$516

For the six months ended June 30, 2024 and 2023, the Company paid commissions for certain equipment sales. Because the recovery of commissions is expected to occur from product revenue within one year, the Company charges commissions to expense as incurred. In addition, the Company incurs commissions associated with equipment lease agreements, which are accounted as initial direct costs and recorded in other noncurrent assets in the condensed consolidated balance sheets. The commission is capitalized at the commencement of the lease and recognized as an expense in selling and marketing expenses over the lease term. Shipping and handling costs are expensed as incurred and are included in cost of sales. A Concentration of Financial Instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. One customer in the U.S. accounted for 83% and 46% of revenue for the three months ended June 30, 2024 and 2023, respectively, 77% and 52% of revenue for the six months ended June 30, 2024 and 2023, respectively, and 92% and 85% of the accounts receivable as of June 30, 2024 and December 31, 2023, respectively. A Geographical Information The following table illustrates total revenue for the three and six months ended June 30, 2024 and 2023 by country.

	2024	2023
United States	\$8,667	\$3,892
China	\$5,724	\$6,934
Guatemala	\$4,527	\$19,902
Ireland	\$1,146	\$1,146
Other	\$1,146	\$1,146
Total Revenue	\$29,167	\$29,419

The Company uses a fair value hierarchy that prioritizes inputs to valuation approaches used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. Assets and liabilities measured and reported at fair value are classified and disclosed in one of the following categories: A Level 1 Inputs: Quoted prices (unadjusted) in active markets for identical assets or liabilities at the reporting date. A Level 2 Inputs: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities that are not active; quotes from pricing services or brokers for which the Company can determine that orderly transactions took place at the quoted price or that the inputs used to arrive at the price are observable; and inputs other than quoted prices that are observable, such as models or other valuation methodologies. A Level 3 Inputs: Unobservable inputs for the valuation of the asset or liability, which may include nonbinding broker quotes. A Level 3 assets include investments for which there is little, if any, market activity. These inputs require significant management judgment or estimation. A Significance of Inputs: The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the financial instrument. A Cash and Cash Equivalents Cash and cash equivalents primarily consist of cash, money market funds and short-term, highly liquid investments with original maturities of three months or less. A Accounts Receivable The Company does business and extends credit based on an evaluation of each customer's financial condition, generally without requiring collateral. Exposure to losses on receivables is expected to vary by customer due to the financial condition of each customer. The Company estimates future credit losses based on the age of customer receivable balances, collection history and forecasted economic trends. Future collections can be significantly different from historical collection trends or current estimates. The Company monitors exposure to credit losses and maintains allowances for anticipated losses considered necessary under the circumstances. The allowance for expected credit losses was \$2 thousand and \$0 as of June 30, 2024 and December 31, 2023, respectively. Credit loss expense was \$42 thousand and \$5 thousand for the three months ended June, 2024 and 2023, respectively, and \$42 thousand and \$5 thousand for the six months ended June, 2024 and 2023, respectively. A Inventories Inventories consist of finished product and components and are stated at the lower of cost and net realizable value, determined using the first-in-first-out method. A Earnings Per Share A Basic net income (loss) per share is calculated by dividing the net income by the weighted-average number of common shares outstanding for the period using the treasury stock method for options, restricted stocks and warrants. Diluted net income (loss) per share is computed by giving effect to all potential dilutive common share equivalents outstanding for the period. A The factors used in the net income (loss) per share computation are as follows:

	2024	2023
Net income (loss)	\$1,612	\$(380)
Weighted average number of shares used in computing net income (loss) per share	16,298	16,250
Diluted net income (loss) per share	\$0.10	\$(0.02)

The Company's diluted net income (loss) per share is calculated by dividing the net income by the weighted-average number of common shares outstanding for the period using the treasury stock method for options, restricted stocks and warrants. Diluted net income (loss) per share is computed by giving effect to all potential dilutive common share equivalents outstanding for the period. A The factors used in the net income (loss) per share computation are as follows:

	2024	2023
Net income (loss)	\$1,612	\$(380)
Weighted average number of shares used in computing net income (loss) per share	16,298	16,250
Diluted net income (loss) per share	\$0.10	\$(0.02)

The Company's diluted net income (loss) per share is calculated by dividing the net income by the weighted-average number of common shares outstanding for the period using the treasury stock method for options, restricted stocks and warrants. Diluted net income (loss) per share is computed by giving effect to all potential dilutive common share equivalents outstanding for the period. A The factors used in the net income (loss) per share computation are as follows:

	2024	2023
Net income (loss)	\$1,612	\$(380)
Weighted average number of shares used in computing net income (loss) per share	16,298	16,250
Diluted net income (loss) per share	\$0.10	\$(0.02)

The Company's diluted net income (loss) per share is calculated by dividing the net income by the weighted-average number of common shares outstanding for the period using the treasury stock method for options, restricted stocks and warrants. Diluted net income (loss) per share is computed by giving effect to all potential dilutive common share equivalents outstanding for the period. A The factors used in the net income (loss) per share computation are as follows:

	2024	2023
Net income (loss)	\$1,612	\$(380)
Weighted average number of shares used in computing net income (loss) per share	16,298	16,250
Diluted net income (loss) per share	\$0.10	\$(0.02)

The Company's diluted net income (loss) per share is calculated by dividing the net income by the weighted-average number of common shares outstanding for the period using the treasury stock method for options, restricted stocks and warrants. Diluted net income (loss) per share is computed by giving effect to all potential dilutive common share equivalents outstanding for the period. A The factors used in the net income (loss) per share computation are as follows:

	2024	2023
Net income (loss)	\$1,612	\$(380)
Weighted average number of shares used in computing net income (loss) per share	16,298	16,250
Diluted net income (loss) per share	\$0.10	\$(0.02)

The Company's diluted net income (loss) per share is calculated by dividing the net income by the weighted-average number of common shares outstanding for the period using the treasury stock method for options, restricted stocks and warrants. Diluted net income (loss) per share is computed by giving effect to all potential dilutive common share equivalents outstanding for the period. A The factors used in the net income (loss) per share computation are as follows:

	2024	2023
Net income (loss)	\$1,612	\$(380)
Weighted average number of shares used in computing net income (loss) per share	16,298	16,250
Diluted net income (loss) per share	\$0.10	\$(0.02)

The Company's diluted net income (loss) per share is calculated by dividing the net income by the weighted-average number of common shares outstanding for the period using the treasury stock method for options, restricted stocks and warrants. Diluted net income (loss) per share is computed by giving effect to all potential dilutive common share equivalents outstanding for the period. A The factors used in the net income (loss) per share computation are as follows:

	2024	2023
Net income (loss)	\$1,612	\$(380)
Weighted average number of shares used in computing net income (loss) per share	16,298	16,250
Diluted net income (loss) per share	\$0.10	\$(0.02)

The Company's diluted net income (loss) per share is calculated by dividing the net income by the weighted-average number of common shares outstanding for the period using the treasury stock method for options, restricted stocks and warrants. Diluted net income (loss) per share is computed by giving effect to all potential dilutive common share equivalents outstanding for the period. A The factors used in the net income (loss) per share computation are as follows:

	2024	2023
Net income (loss)	\$1,612	\$(380)
Weighted average number of shares used in computing net income (loss) per share	16,298	16,250
Diluted net income (loss) per share	\$0.10	\$(0.02)

The Company's diluted net income (loss) per share is calculated by dividing the net income by the weighted-average number of common shares outstanding for the period using the treasury stock method for options, restricted stocks and warrants. Diluted net income (loss) per share is computed by giving effect to all potential dilutive common share equivalents outstanding for the period. A The factors used in the net income (loss) per share computation are as follows:

	2024	2023
Net income (loss)	\$1,612	\$(380)
Weighted average number of shares used in computing net income (loss) per share	16,298	16,250

terminated by the Company or Comerica at any time without penalty. At June 30, 2024, the available borrowings under this facility were \$10 million. Any borrowings bear interest at the Secured Overnight Financing Rate plus 2.50% (or 7.83% at June 30, 2024) and would be due upon demand by Comerica. The Credit Facility is secured by all of the Company’s assets. The Credit Facility contains a financial covenant requiring that the Company maintain unencumbered liquid assets having a minimum value of \$3,500,000 in a Comerica account. A The Company was in compliance with its financial covenants under the respective facilities as of June 30, 2024 and December 31, 2023. There were no borrowings outstanding under either facility at June 30, 2024 and December 31, 2023. A Note 4 “Product Warranties” Changes in product warranty liability were as follows for the six months ended June 30, 2024: A (in thousands) A Balance, December 31, 2023A \$538A Warranties accrued during the periodA A 186A Payments on warranty claimsA A (207) Balance, June 30, 2024A \$517A A Note 5 “Leases” Operating Lease Agreements A The Company leases its headquarters office from an unrelated third party under a lease expiring in September 2027. The amortization of the right of use lease asset was \$48 thousand and \$46 thousand for the three months ended June 30, 2024 and 2023, respectively, and \$95 thousand and \$90 thousand for the six months ended June 30, 2024 and 2023, respectively. A Future minimum lease payments under the Company’s non-cancellable leases as of June 30, 2024 are as follows: A Maturity of Operating Lease LiabilityA AmountA 2024 (July 1 - December 31, 2024)A \$112A 2025A A 229A 2026A A 236A 2027A A 181A Total undiscounted operating leases paymentsA \$758A Less: Imputed interestA A (60) Present Value of Operating Lease LiabilityA \$698A Operating lease liability, current portionA \$195A Operating lease liability, net of current portionA \$503A A A A Other InformationA A A Weighted-average remaining lease termA A 3.25 yearsA Weighted-average discount rateA A 5% A Cash paid for amounts included in the measurement of operating lease liability was \$85 thousand and \$104 thousand for the six months ended June 30, 2024 and 2023, respectively, and is included in cash flows from operating activities in the accompanying condensed consolidated statement of cash flows. A Operating lease cost recognized as expense was \$57A thousand for the three months ended June 30, 2024 and 2023, and \$114 thousand for the six months ended June 30, 2024 and 2023. The financing component for operating lease liability represents the effect of discounting the operating lease payments to their present value. A 12 A Lessor Accounting A Beginning in the quarter ended June 30, 2024, the Company, through its subsidiary, Sensus Healthcare Services, LLC, leases superficial radiotherapy equipment to dermatology clinics. The leases generally have initial lease terms of sixty months and automatically renew for a one-year period upon the expiration of the initial lease terms. Payments due under the leases may be fixed or variable payments. A The component of lease income for the three and six months ended June 30, 2024 is as follows: A (in thousands)A For the Three Months Ended June 30, 2024A A For the Six Months Ended June 30, 2024A Lease income - operating leasesA \$41A A \$41A A The future minimum fixed lease payments to be received under the lease agreements as of June 30, 2024 are as follows: A (in thousands)A AmountA 2024 (July 1 - December 31, 2024)A \$128A 2025A A 256A 2026A A 256A 2027A A 256A 2028A A 256A ThereafterA A 343A TotalA \$1,495A A Note 6 “Commitments and Contingencies” Manufacturing Agreement A The Company has a contract manufacturing agreement with an unrelated third party for the production and manufacture of the SRT-100 (and subsequently the SRT-100 Vision and the SRT-100+), in accordance with the Company’s product specifications. The agreement renews for successive one-year periods unless either party notifies the other party in writing, at least sixty days prior to the anniversary date of the agreement, that it will not renew the agreement. The Company or the manufacturer may terminate the agreement upon ninety days’ prior written notice. A The Company pays this manufacturer for finished goods in advance of the inventory being received. The Company paid this manufacturer \$0 million and \$1.2 million for finished goods for the three months ended June 30, 2024 and 2023, respectively, and \$5.7 million and \$7.9 million for the six months ended June 30, 2024 and 2023, respectively. Finished goods of \$0.3 million and \$4.5 million were received from this manufacturer for the three months ended June 30, 2024 and 2023, respectively, and \$5.2 million and \$7.7 million for the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024 and December 31, 2023, a prepayment related to these finished goods of \$3.3 million and \$3.0 million, respectively, was presented in prepaid inventory in the accompanying condensed consolidated balance sheets. A Legal contingencies A The Company is party to certain legal proceedings in the ordinary course of business. The Company assesses, in conjunction with its legal counsel, the need to record a liability for litigation and related contingencies. A In 2015, the Company learned that the Department of Justice (the “Department”) had commenced an investigation of the billing to Medicare by a physician who had treated patients with the Company’s SRT-100. The Department subsequently advised the Company that it was considering expanding the investigation to determine whether the Company had any involvements in physician’s use of certain reimbursements codes. The Company has received two Civil Investigative Demands from the Department seeking documents and written responses in connection with its investigation. The Company has fully cooperated with the Department. The Company disputes that it has engaged in any wrongdoing with respect to such reimbursement claims; among other considerations, the Company does not submit claims for reimbursement or provide coding or billing advice to physicians. To the Company’s knowledge, the Department has made no determination as to whether the Company engaged in any wrongdoing, or whether to pursue any legal action against the Company. Should the Department decide to pursue legal action, the Company believes it has strong and meritorious defenses and will vigorously defend itself. As of June 30, 2024, the Company was unable to estimate the cost associated with this matter. A 13 A Note 7 “Stockholders’ Equity” Preferred Stock A The Company has authorized 5 million shares of preferred stock. No shares of preferred stock were issued or outstanding at June 30, 2024 or December 31, 2023. A Treasury stock A Treasury stock includes shares surrendered by employees for tax withholding on the vesting of restricted stock awards and shares repurchased in open market transactions. No shares were surrendered by employees for tax withholding for the three and six months ended June 30, 2024. 0 and 4,487 shares were surrendered by employees for tax withholding for the three and six months ended June 30, 2023, respectively. During three and six months ended June 30, 2024 and 2023, the Company did not repurchase any shares in open market transactions. A Note 8 “Equity-based Compensation” 2016 and 2017 Equity Incentive Plans A The Company’s 2016 Equity Incentive Plan and the 2017 Incentive Plan, as amended in June 2023 (collectively, the “Plans”), provide for the issuance of up to 397,473 shares and 750,000 shares, respectively. In addition, unless the Compensation Committee specifically determines otherwise, the maximum number of shares available under the Plans and the awards granted under the Plans will be subject to appropriate adjustment in the case of any stock dividends, stock splits, recapitalizations, reorganizations, mergers, consolidations, exchanges or other changes in capitalization affecting the Company’s common stock. The awards may be made in the form of restricted stock awards or stock options or other things. As of June 30, 2024 and December 31, 2023, 295,223 and 312,973 shares were available to be granted under the Plans, respectively. A On February 1, 2020, a total of 35,000 shares of restricted stock were issued to employees. The restricted shares vest 25% per year over a four-year period. The grant date fair value of \$4.11 per share is being recognized as expense on a straight-line basis over the vesting period. During the six months ended June 30, 2024, 2,500 shares of common stock vested. As of June 30, 2024, the shares issued on February 1, 2020 were fully vested. A On July 21, 2021, a total of 130,000 shares of restricted stock were issued to employees and board members. The restricted shares vest 25% at grant date and 25% per year over a three-year period. The grant date fair value of \$3.84 per share is being recognized as expense on a straight-line basis over the vesting period. No additional restricted shares vested during the six months ended June 30, 2024. A On December 19, 2022, a total of 77,000 shares of restricted stock were issued to employees. The restricted shares vest 25% per year over a four-year period. The fair value of \$6.40 per share, the stock price on grant date, is being recognized as expense on a straight-line basis over the vesting period. During the six months ended June 30, 2024, 2,250 shares of unvested common stock were forfeited due to the termination of three employees. A On January 26, 2023, 10,000 shares of common stock were issued to an employee and were recorded at the fair value of \$8.96 per share, the stock price on the grant date. The shares were fully vested on the grant date. A On January 11, 2024, 20,000 shares of common stock with a fair value of \$2.65 per share, the stock price on the grant date, were issued to an employee. 10,000 of the shares were vested and the expense related to these shares was recognized on the grant date. The remaining 10,000 shares are scheduled to cliff vest in January 2025. The grant date fair value of \$2.65 per share is being recognized as expense on a straight-line basis over the vesting period. The grant date fair value is being recognized as expense on a straight-line basis over the vesting period. A 14 A Restricted Stock A Restricted stock activity for the six months ended June 30, 2024 is summarized below: A Outstanding at A Restricted Stock A Weighted-Average Grant Date Fair Value A December 31, 2023A A 89,750A A \$5.41A GrantedA A 20,000A A 2.65A VestedA A (12,500)A A 2.94A ForfeitedA A (2,250)A A \$6.40A June 30, 2024A A 95,000A A \$5.13A A The Company recognizes forfeitures as they occur. The reduction of stock compensation expense related to the forfeitures was \$1 thousand and \$1 thousand for the three months ended June 30, 2024 and 2023, respectively, and \$2 thousand and \$19 thousand for the six months ended June 30, 2024 and 2023, respectively. A Stock compensation expense related to restricted stock, excluding the recognition of forfeitures, was \$66 thousand and \$67 thousand for the three months ended June 30, 2024 and 2023, respectively, and \$158 thousand and \$228 thousand for the six months ended June 30, 2024 and 2023, respectively. A Unrecognized stock compensation expense was \$292A thousand as of June 30, 2024, which will be recognized over a weighted-average period of 2.3A years. A Stock Options A Stock options expire ten years after the grant date. Options that have been granted are exercisable and vest based on the terms of the related agreements. A The following table summarizes the Company’s stock options activity: A A Number of OptionsA A Weighted-Average Exercise PriceA A Weighted-Average Remaining Contractual Term (In Years)A Outstanding - December 31, 2023A A 89,550A A \$5.55A A 4.08A GrantedA A -A A -A A ExercisedA A (3,000)A A 5.55A A -A ExpiredA A -A A -A A Outstanding - June 30, 2024A A 86,550A A \$5.55A A 3.58A Exercisable as of June 30, 2024A A 86,550A A \$5.55A A 3.58A A No stock compensation expense related to stock options was incurred for the three and six months ended June 30, 2024 and 2023. The stock options outstanding had an intrinsic value of \$0 as of June 30, 2024 and December 31, 2023. A 15 A Note 9 “Income Taxes” Income Taxes A The Company accounts for income taxes in accordance with ASC 740, Income Taxes, (the “ASC 740”), which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. A Effective income tax rates for interim periods are based upon the Company’s current estimated annual tax rate, which varies based upon the Company’s estimate of taxable earnings or loss and the mix of taxable earnings or loss in the various states in which the Company operates. In addition, the Company recognizes taxes related to unusual or infrequent items or resulting from a change in judgment regarding a position taken in a prior period as discrete items in the interim period in which the event occurs. A As of June 30, 2024 and 2023, management determined there continues to be sufficient positive evidence that it is more likely than not that the net deferred tax asset (other than foreign net operation losses) is realizable. A Income tax expense (benefit) was \$579 thousand and (\$502)A thousand for the three months ended June 30, 2024 and 2023, respectively. Income tax expense (benefit) was \$1,406 thousand and (\$1,303) thousand for the six months ended June 30, 2024 and 2023, respectively. A The effective tax rates for the three months ended June 30, 2024 and 2023 were 26.4% and 36.4%, respectively. The effective tax rates for the three and six months ended June 30, 2024 compared to the prior year periods was primarily due to a decrease in nondeductible expenses and an increase in the estimated tax credits that are expected to be generated and utilized. A The effective tax rate differs from the U.S. federal statutory rate for the three and six months ended June 30, 2024, primarily due to nondeductible expenses, state income taxes and the favorable impact of tax credits. The effective tax rate differs from the U.S. federal statutory rate for the three and six months ended June 30, 2023, primarily due to nondeductible expenses and state income taxes. A As of June 30, 2024, the Company’s U.S. federal and certain state tax returns remain subject to examination, beginning with those filed for the year ended December 31, 2017. A Note 10 “Subsequent Events” The Company has evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued for potential recognition or disclosure. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements. A 16 A Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS A You should read the following discussion and analysis in conjunction with the information set forth within the financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, and with our Management’s Discussion and Analysis of Financial Condition and Results of Operations in the 2023 Annual Report. A Overview A Sensus is a medical device company committed to providing highly effective, non-invasive and cost-effective treatments for both oncological and non- oncological skin conditions. A Segment Information A The Company manages its business globally within one reportable segment, which is consistent with how our management reviews the business, prioritizes investment and resource allocation decisions and assesses operating performance. A Results of Operations A A For the Three Months Ended A A For the Six Months Ended A A June 30, A A June 30, A A (in thousands, except shares and per share data)A 2024A A 2023A A 2024A A 2023A A A A A A RevenuesA \$9,239A A \$4,527A A \$19,902A A \$7,941A Cost of salesA A 3,816A A 1,908A A 7,817A A 3,700A Gross profitA A 5,423A A 2,619A A 12,085A A 4,241A Operating expensesA A A A A A A A A A Selling and marketingA A 996A A 1,595A A 2,167A A 3,693A General and administrativeA A 1,579A A 1,329A A 3,158A A 2,693A Research and developmentA A 866A A 822A A 1,792A A 1,920A Total operating expensesA A 3,441A A 3,746A A 7,216A A 8,306A Income (loss) from operationsA A 1,982A A (1,127)A A 4,869A A (4,065) Other incomeA A A A A A A A Interest incomeA A 209A A 245A A 423A A 488A Other income, netA A 209A A 245A A 423A A 488A Income (loss) before income taxA A 2,191A A (882)A A 5,292A A (3,577) Provision for (benefit from) income taxesA A 579A A (502)A A 1,406A A (1,303) Net income (loss)A \$1,612A A \$380A A \$3,886A A \$(2,274) A Three months ended June 30, 2024 compared to the three months ended June 30, 2023 A Revenues. Revenues were \$9.2 million for the three months ended June 30, 2024 compared to \$4.5 million for the three months ended June 30, 2023, an increase of \$4.7 million, or 104.4%. The increase was primarily driven by a higher number of units sold to a large customer in the three months ended June 30, 2024 compared to the three months ended June 30, 2023. A 17 A A Cost of sales. Cost of sales was \$3.8 million for the three months ended June 30, 2024 compared to \$1.9 million for the three months ended June 30, 2023, an increase of \$1.9 million, or 100.0%. The increase in cost of sales was primarily related to a higher number of units sold and was fairly consistent as a percentage of revenue in the three months ended June 30, 2024 compared to the three months ended June 30, 2023. A Gross profit. Gross profit was \$5.4 million for the three months ended June 30, 2024 compared to \$2.6 million for the three months ended June 30, 2023, an increase of \$2.8 million, or 107.7%. Our overall gross profit percentage remained consistent at 58.7% in the three months ended June 30, 2024 compared to 57.9% in the corresponding period in 2023. A Selling and marketing. Selling and marketing expense was \$1.0 million for the three months ended June 30, 2024 compared to \$1.6 million for the three months ended June 30, 2023, a decrease of \$0.6 million, or 37.5%. The decrease was primarily attributable to the decrease in marketing agency expense, lower headcount and decrease in tradeshow costs. A General and administrative. General and administrative expense was \$1.6 million for the three months ended June 30, 2024 compared to \$1.3 million for the three months ended June 30, 2023, an increase of \$0.3 million, or 23.1%. The net increase in general and administrative expense was primarily due to higher professional fees and compensation. A Research and development. Research and development expense was \$0.9 million for the three months ended June 30, 2024 compared to \$0.8 million for the three months ended June 30, 2023, an increase of \$0.1 million, or 12.5%. The increase was primarily due to expenses related to a project to develop a drug delivery system for aesthetic use. A Other income. Other income of \$0.2 million for the three months ended June 30, 2024 and 2023 relate primarily to interest income. A Six months ended June 30, 2024 compared to the six months ended June 30, 2023 A Revenues. Revenues were \$20.0 million for the six months ended June 30, 2024 compared to \$8.0 million for the six months ended June 30, 2023, an increase of \$12.0 million, or 151.9%. The increase was primarily driven by a higher number of units sold to a large customer in the six months ended June 30, 2024 compared to the six months ended June 30, 2023. A Cost of sales. Cost of sales was \$7.8 million for the six months ended June 30, 2024 compared to \$3.7 million for the six months ended June 30, 2023, an increase of \$4.1 million, or 110.8%. The increase in cost of sales was primarily related to a higher number of units sold in the six months ended June 30, 2024 compared to the six months ended June 30, 2023. A Gross profit. Gross profit was \$12.1 million for the six months ended June 30, 2024 compared to \$4.2 million for the six months ended June 30, 2023, an increase of \$7.9 million, or 188.1%. Our overall gross profit percentage was 60.7% in the six months ended June 30, 2024 compared to 53.4% in the corresponding period in 2023. The increase in gross profit was primarily driven by a higher number of units sold in the six months ended June 30, 2024 compared to the six months ended June 30, 2023. A Selling and marketing. Selling and marketing expense was \$2.3 million for the six months ended June 30, 2024 compared to \$3.7 million for the six months ended June 30, 2023, a decrease of \$1.4 million, or 37.8%. The decrease was primarily attributable to the decrease in marketing agency expense, lower headcount and decrease in tradeshow costs. A General and administrative. General and administrative expense was \$3.2 million for the six months ended June 30, 2024 compared to \$2.7 million for the six months ended June 30, 2023, an increase of \$0.5 million, or 18.5%. The net increase in general and administrative expense was primarily due to higher professional fees and compensation. A Research and development. Research and development expense was \$1.8 million for the six months ended June 30, 2024 compared to \$1.9 million for the six months ended June 30, 2023, a decrease of \$0.1 million, or 5.3%. The decrease was primarily due to expenses related to a project to

provide a drug delivery system for aesthetic use. A 18 A 19 A 20 A 21 A 22 A 23 A 24 A 25 A 26 A 27 A 28 A 29 A 30 A 31 A 32 A 33 A 34 A 35 A 36 A 37 A 38 A 39 A 40 A 41 A 42 A 43 A 44 A 45 A 46 A 47 A 48 A 49 A 50 A 51 A 52 A 53 A 54 A 55 A 56 A 57 A 58 A 59 A 60 A 61 A 62 A 63 A 64 A 65 A 66 A 67 A 68 A 69 A 70 A 71 A 72 A 73 A 74 A 75 A 76 A 77 A 78 A 79 A 80 A 81 A 82 A 83 A 84 A 85 A 86 A 87 A 88 A 89 A 90 A 91 A 92 A 93 A 94 A 95 A 96 A 97 A 98 A 99 A 100 A 101 A 102 A 103 A 104 A 105 A 106 A 107 A 108 A 109 A 110 A 111 A 112 A 113 A 114 A 115 A 116 A 117 A 118 A 119 A 120 A 121 A 122 A 123 A 124 A 125 A 126 A 127 A 128 A 129 A 130 A 131 A 132 A 133 A 134 A 135 A 136 A 137 A 138 A 139 A 140 A 141 A 142 A 143 A 144 A 145 A 146 A 147 A 148 A 149 A 150 A 151 A 152 A 153 A 154 A 155 A 156 A 157 A 158 A 159 A 160 A 161 A 162 A 163 A 164 A 165 A 166 A 167 A 168 A 169 A 170 A 171 A 172 A 173 A 174 A 175 A 176 A 177 A 178 A 179 A 180 A 181 A 182 A 183 A 184 A 185 A 186 A 187 A 188 A 189 A 190 A 191 A 192 A 193 A 194 A 195 A 196 A 197 A 198 A 199 A 200 A 201 A 202 A 203 A 204 A 205 A 206 A 207 A 208 A 209 A 210 A 211 A 212 A 213 A 214 A 215 A 216 A 217 A 218 A 219 A 220 A 221 A 222 A 223 A 224 A 225 A 226 A 227 A 228 A 229 A 230 A 231 A 232 A 233 A 234 A 235 A 236 A 237 A 238 A 239 A 240 A 241 A 242 A 243 A 244 A 245 A 246 A 247 A 248 A 249 A 250 A 251 A 252 A 253 A 254 A 255 A 256 A 257 A 258 A 259 A 260 A 261 A 262 A 263 A 264 A 265 A 266 A 267 A 268 A 269 A 270 A 271 A 272 A 273 A 274 A 275 A 276 A 277 A 278 A 279 A 280 A 281 A 282 A 283 A 284 A 285 A 286 A 287 A 288 A 289 A 290 A 291 A 292 A 293 A 294 A 295 A 296 A 297 A 298 A 299 A 300 A 301 A 302 A 303 A 304 A 305 A 306 A 307 A 308 A 309 A 310 A 311 A 312 A 313 A 314 A 315 A 316 A 317 A 318 A 319 A 320 A 321 A 322 A 323 A 324 A 325 A 326 A 327 A 328 A 329 A 330 A 331 A 332 A 333 A 334 A 335 A 336 A 337 A 338 A 339 A 340 A 341 A 342 A 343 A 344 A 345 A 346 A 347 A 348 A 349 A 350 A 351 A 352 A 353 A 354 A 355 A 356 A 357 A 358 A 359 A 360 A 361 A 362 A 363 A 364 A 365 A 366 A 367 A 368 A 369 A 370 A 371 A 372 A 373 A 374 A 375 A 376 A 377 A 378 A 379 A 380 A 381 A 382 A 383 A 384 A 385 A 386 A 387 A 388 A 389 A 390 A 391 A 392 A 393 A 394 A 395 A 396 A 397 A 398 A 399 A 400 A 401 A 402 A 403 A 404 A 405 A 406 A 407 A 408 A 409 A 410 A 411 A 412 A 413 A 414 A 415 A 416 A 417 A 418 A 419 A 420 A 421 A 422 A 423 A 424 A 425 A 426 A 427 A 428 A 429 A 430 A 431 A 432 A 433 A 434 A 435 A 436 A 437 A 438 A 439 A 440 A 441 A 442 A 443 A 444 A 445 A 446 A 447 A 448 A 449 A 450 A 451 A 452 A 453 A 454 A 455 A 456 A 457 A 458 A 459 A 460 A 461 A 462 A 463 A 464 A 465 A 466 A 467 A 468 A 469 A 470 A 471 A 472 A 473 A 474 A 475 A 476 A 477 A 478 A 479 A 480 A 481 A 482 A 483 A 484 A 485 A 486 A 487 A 488 A 489 A 490 A 491 A 492 A 493 A 494 A 495 A 496 A 497 A 498 A 499 A 500 A 501 A 502 A 503 A 504 A 505 A 506 A 507 A 508 A 509 A 510 A 511 A 512 A 513 A 514 A 515 A 516 A 517 A 518 A 519 A 520 A 521 A 522 A 523 A 524 A 525 A 526 A 527 A 528 A 529 A 530 A 531 A 532 A 533 A 534 A 535 A 536 A 537 A 538 A 539 A 540 A 541 A 542 A 543 A 544 A 545 A 546 A 547 A 548 A 549 A 550 A 551 A 552 A 553 A 554 A 555 A 556 A 557 A 558 A 559 A 560 A 561 A 562 A 563 A 564 A 565 A 566 A 567 A 568 A 569 A 570 A 571 A 572 A 573 A 574 A 575 A 576 A 577 A 578 A 579 A 580 A 581 A 582 A 583 A 584 A 585 A 586 A 587 A 588 A 589 A 590 A 591 A 592 A 593 A 594 A 595 A 596 A 597 A 598 A 599 A 600 A 601 A 602 A 603 A 604 A 605 A 606 A 607 A 608 A 609 A 610 A 611 A 612 A 613 A 614 A 615 A 616 A 617 A 618 A 619 A 620 A 621 A 622 A 623 A 624 A 625 A 626 A 627 A 628 A 629 A 630 A 631 A 632 A 633 A 634 A 635 A 636 A 637 A 638 A 639 A 640 A 641 A 642 A 643 A 644 A 645 A 646 A 647 A 648 A 649 A 650 A 651 A 652 A 653 A 654 A 655 A 656 A 657 A 658 A 659 A 660 A 661 A 662 A 663 A 664 A 665 A 666 A 667 A 668 A 669 A 670 A 671 A 672 A 673 A 674 A 675 A 676 A 677 A 678 A 679 A 680 A 681 A 682 A 683 A 684 A 685 A 686 A 687 A 688 A 689 A 690 A 691 A 692 A 693 A 694 A 695 A 696 A 697 A 698 A 699 A 700 A 701 A 702 A 703 A 704 A 705 A 706 A 707 A 708 A 709 A 710 A 711 A 712 A 713 A 714 A 715 A 716 A 717 A 718 A 719 A 720 A 721 A 722 A 723 A 724 A 725 A 726 A 727 A 728 A 729 A 730 A 731 A 732 A 733 A 734 A 735 A 736 A 737 A 738 A 739 A 740 A 741 A 742 A 743 A 744 A 745 A 746 A 747 A 748 A 749 A 750 A 751 A 752 A 753 A 754 A 755 A 756 A 757 A 758 A 759 A 760 A 761 A 762 A 763 A 764 A 765 A 766 A 767 A 768 A 769 A 770 A 771 A 772 A 773 A 774 A 775 A 776 A 777 A 778 A 779 A 780 A 781 A 782 A 783 A 784 A 785 A 786 A 787 A 788 A 789 A 790 A 791 A 792 A 793 A 794 A 795 A 796 A 797 A 798 A 799 A 800 A 801 A 802 A 803 A 804 A 805 A 806 A 807 A 808 A 809 A 810 A 811 A 812 A 813 A 814 A 815 A 816 A 817 A 818 A 819 A 820 A 821 A 822 A 823 A 824 A 825 A 826 A 827 A 828 A 829 A 830 A 831 A 832 A 833 A 834 A 835 A 836 A 837 A 838 A 839 A 840 A 841 A 842 A 843 A 844 A 845 A

2024-04-01 2024-06-30 0001494891 us-gaap:StockOptionMember srts:EarningsPerShareMember 2023-04-01 2023-06-30 0001494891 us-gaap:StockOptionMember srts:EarningsPerShareMember 2024-01-01 2024-06-30 0001494891 us-gaap:StockOptionMember srts:EarningsPerShareMember 2023-01-01 2023-06-30 0001494891 us-gaap:EquipmentMember 2024-06-30 0001494891 us-gaap:EquipmentMember 2023-12-31 0001494891 srts:MinimumMember us-gaap:EquipmentMember 2024-06-30 0001494891 srts:MaximumMember us-gaap:EquipmentMember 2024-06-30 0001494891 srts:TradeshawAndDemoEquipmentMember 2024-06-30 0001494891 srts:TradeshawAndDemoEquipmentMember 2023-12-31 0001494891 us-gaap:ComputerEquipmentMember 2024-06-30 0001494891 us-gaap:ComputerEquipmentMember 2023-12-31 0001494891 srts:SiliconValleyBankMember 2022-12-31 0001494891 srts:ComerciaBankMember 2023-09-11 0001494891 us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-01-01 2024-06-30 0001494891 srts:OperatingLeaseAgreementsMember 2024-04-01 2024-06-30 0001494891 srts:OperatingLeaseAgreementsMember 2023-04-01 2023-06-30 0001494891 srts:OperatingLeaseAgreementsMember 2024-01-01 2024-06-30 0001494891 srts:OperatingLeaseAgreementsMember 2023-01-01 2023-06-30 0001494891 srts:EquityIncentivePlansMember 2024-01-01 2024-06-30 0001494891 srts:EquityIncentivesPlanI Member 2024-01-01 2024-06-30 0001494891 us-gaap:RestrictedStockMember srts:EquityIncentivePlanMember 2020-02-01 2020-02-01 0001494891 srts:EquityIncentivePlanMember us-gaap:CommonStockMember 2024-06-30 0001494891 us-gaap:RestrictedStockMember srts:EquityIncentivePlanMember srts:BoardOfDirectorsChairmanMember 2021-07-21 2021-07-21 0001494891 us-gaap:RestrictedStockMember srts:EquityIncentivePlanMember 2021-07-21 2021-07-21 0001494891 us-gaap:RestrictedStockMember srts:EquityIncentivePlanMember 2022-12-19 2022-12-19 0001494891 2022-12-19 2022-12-19 0001494891 us-gaap:CommonStockMember 2023-01-26 2023-01-26 0001494891 srts:EquityIncentivePlanMember us-gaap:CommonStockMember 2024-01-11 2024-01-11 0001494891 srts:EquityIncentivePlanMember us-gaap:CommonStockMember 2024-01-11 0001494891 srts:EquityIncentivePlanMember 2024-01-11 2024-01-11 0001494891 us-gaap:RestrictedStockMember 2024-04-01 2024-06-30 0001494891 us-gaap:RestrictedStockMember 2023-04-01 2023-06-30 0001494891 us-gaap:RestrictedStockMember 2024-01-01 2024-06-30 0001494891 us-gaap:RestrictedStockMember 2023-01-01 2023-06-30 0001494891 us-gaap:StockOptionMember srts:EquityIncentivePlanMember 2024-01-01 2024-06-30 0001494891 us-gaap:StockOptionMember 2024-06-30 0001494891 us-gaap:StockOptionMember 2023-12-31 0001494891 us-gaap:RestrictedStockMember 2023-12-31 0001494891 us-gaap:RestrictedStockMember 2024-06-30 0001494891 us-gaap:StockOptionMember 2023-12-31 0001494891 us-gaap:StockOptionMember 2023-12-31 2023-12-31 0001494891 us-gaap:StockOptionMember 2024-01-01 2024-06-30 0001494891 us-gaap:StockOptionMember 2024-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure EX-3.1.2 ea021067801ex3-1 sensus.htm AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SENSUS HEALTHCARE, INC., DATED AS OF JUNE 14, 2024 Exhibit 3.1 A AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SENSUS HEALTHCARE, INC. A Sensus Healthcare, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: A 1. The name of the Corporation is Sensus Healthcare, Inc. The Corporation’s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware effective January 1, 2016. A 2. This Amended and Restated Certificate of Incorporation was duly adopted in accordance with Sections 242, 245, and 228 of the Delaware General Corporation Law, and restates, integrates, and further amends the provisions of the Corporation’s Certificate of Incorporation. A 3. The text of the Certificate of Incorporation of this Corporation is hereby amended and restated in its entirety, effective June 14, 2024, as set forth in Exhibit A attached hereto. A IN WITNESS WHEREOF, the Corporation has caused this Amended and Restated Certificate of Incorporation to be executed by its duly authorized officer this June 14, 2024. A A SENSUS HEALTHCARE, INC. A a Delaware corporation A A By: /s/ Michael Sardano A Name: A Michael Sardano A Title: President, General Counsel and Corporate Secretary A A A EXHIBIT A A ARTICLE I A The name of the corporation is Sensus Healthcare, Inc. (the “Corporation”). A ARTICLE II A The address of the registered office of the Corporation in the State of Delaware will be at 1521 Concord Pike, Suite 201, Wilmington, Delaware 19803. The name of the registered agent of the Corporation at such address is Corporate Creations Network Inc. A ARTICLE III A The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the Delaware General Corporation Law. A ARTICLE IV A The total number of shares and classes of stock that the Corporation will have authority to issue is 55,000,000 shares, which will be divided into two classes, as follows: 5,000,000 shares of preferred stock, with the par value of \$0.01 per share, and 50,000,000 shares of common stock, with the par value of \$0.01 per share. A The Board of Directors is hereby expressly authorized (A) to provide for one or more series of preferred stock out of the unissued shares of preferred stock ¼ and (B) with respect to each such series, to fix (i) the number of shares constituting such series and the designation of such series ¼ (ii) the voting powers (if any) of the shares of such series ¼ and (iii) the preferences and relative, participating, optional, or other special rights (if any), and any qualifications, limitations, or restrictions thereof, of the shares of such series. The powers, preferences and relative, participating, optional, and other special rights of each series of preferred stock (if any), and the qualifications, limitations, or restrictions thereof, may differ from those of any and all other series at any time outstanding. A ARTICLE V A A. Powers of the Board of Directors A The business and affairs of the Corporation will be managed by or under the direction of the Board of Directors. Elections of directors need not be by written ballot unless otherwise provided in the bylaws of the Corporation (the “Bylaws”). A B. Number of Directors ¼ Classes of Directors A Subject to the rights of the holders of one or more series of preferred stock then outstanding, the total number of directors constituting the entire Board of Directors of the Corporation will be as set forth in the Bylaws. Other than those directors (if any) elected by the holders of any series of preferred stock then outstanding, the Board of Directors will be and is divided into three classes, as nearly equal in number as possible, designated: Class I, Class II, and Class III. In case of any increase or decrease, from time to time, in the number of directors, the number of directors in each class will be apportioned as nearly equal as possible. No decrease in the number of directors will shorten the term of any incumbent director. A 2 A C. Term of Office ¼ Qualification A Except for the terms of such additional directors (if any) as elected by the holders of any series of preferred stock then outstanding, each director will serve for a term ending on the date of the third annual meeting following the annual meeting at which such director was elected ¼ provided, that each director initially appointed to Class I will serve for an initial term expiring at the Corporation’s first annual meeting of stockholders following the filing of this Certificate of Incorporation of the Corporation (this “Certificate”) with the Secretary of State of the State of Delaware ¼ each director initially appointed to Class II will serve for an initial term expiring at the Corporation’s second annual meeting of stockholders following the filing of this Certificate with the Secretary of State of the State of Delaware ¼ and each director initially appointed to Class III will serve for an initial term expiring at the Corporation’s third annual meeting of stockholders following the filing of this Certificate with the Secretary of State of the State of Delaware, in all cases subject to such director’s earlier death, resignation, or removal. Directors need not be stockholders unless so required by this Certificate or the Bylaws, wherein other qualifications for directors may be prescribed. A D. Removal A Except for such additional directors (if any) as elected by the holders of any series of preferred stock then outstanding, any director or the entire Board of Directors may be removed from office only for cause and only by the affirmative vote of at least seventy-five percent (75%) of the total voting power of the then-outstanding shares of the common stock of the Corporation entitled to vote in any annual election of directors or class of directors. A ARTICLE VI A A. Special Meetings A A special meeting of the stockholders for any purpose or purposes may be called at any time by resolution of the Board of Directors, and may not be called by any other person or persons. A B. No Stockholder Action Permitted by Written Consent A No action that is required or permitted to be taken by the stockholders of the Corporation at any annual or special meeting of stockholders may be effected by written consent of stockholders in lieu of a meeting. A C. Change of Control Transactions A In addition to any affirmative vote required by applicable law or this Certificate, including, without limitation, any vote of the holders of any class or series of stock of the Corporation required by applicable law or this Certificate, a Change of Control Transaction (as defined below) will require, except as otherwise prohibited by applicable law, the affirmative vote of the holders of at least seventy-five percent (75%) of the total voting power of the shares of the then-outstanding voting stock of the Corporation, voting together as a single class. Such affirmative vote will be required notwithstanding the fact that no vote may be required, or that a lesser percentage may be permitted, by applicable law or in any agreement with any national securities exchange or otherwise. A “Change of Control Transaction” means the occurrence of any of the following events: (i) the sale, encumbrance or disposition (other than non-exclusive licenses in the ordinary course of business and the grant of security interests in the ordinary course of business) by the Corporation of all or substantially all of the Corporation’s assets ¼ (ii) the merger or consolidation of the Corporation with or into any other corporation or entity, other than a merger or consolidation which would result in the voting securities of the Corporation outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) more than fifty percent (50%) of the total voting power represented by the voting securities of the Corporation or such surviving entity or its parent outstanding immediately after such merger or consolidation ¼ or (iii) the issuance by the Corporation, in a transaction or series of related transactions, of voting securities representing more than two percent (2%) of the total voting power of the Corporation before such issuance, to any person or persons acting as a group as contemplated in Rule 13d-5(b) under the Securities Exchange Act of 1934 (or any successor provision) such that, following such transaction or related transactions, such person or group of persons would hold more than fifty percent (50%) of the total voting power of the Corporation, after giving effect to such issuance. A 3 A ARTICLE VII A A. Limitation of Liability A To the fullest extent permitted by the Delaware General Corporation Law, as the same exists or as may hereafter be amended, a director or officer of the Corporation will not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the Delaware General Corporation Law is amended after the filing of this Amended and Restated Certificate of Incorporation to authorize corporate action further eliminating or limiting the personal liability of directors and/or officers, then the liability of a director and/or officer of the Corporation, as applicable, shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended. Any repeal or modification of Section 102(b)(7) of the Delaware General Corporation Law shall not adversely affect any right or protection of a director or officer of the Corporation existing in respect of any act or omission occurring prior to the time of such repeal or modification. All references in this paragraph to an “officer” shall mean only a person who, at the time of an act or omission as to which liability is asserted, falls within the meaning of the term “officer,” as defined in Section 102(b)(7) of the Delaware General Corporation Law. A B. Indemnification of Directors and Officers A The Corporation will indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, any person who was or is made or is threatened to be made a party or is otherwise involved in any action, suit, or proceeding, whether civil, criminal, administrative, or investigative, by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director or officer of the Corporation or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee, or agent of another corporation or of a partnership, joint venture, trust, enterprise, or nonprofit entity, including service with respect to employee benefit plans (each such person, an “Indemnified Party”), against all liability and loss suffered and expenses (including attorneys’ fees) reasonably incurred by such Indemnified Party. The Corporation will be required to indemnify an Indemnified Party in connection with a proceeding (or part thereof) initiated by such Indemnified Party only if the proceeding (or part thereof) was explicitly authorized by the Board of Directors of the Corporation. A C. Amendment or Repeal A Any repeal or modification of the provisions of this Article VII will not adversely affect any right or protection of any person provided in this Article VII with respect to any act or omission occurring prior to the time of such repeal or modification. A ARTICLE VIII A In furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly empowered to adopt, amend, or repeal Bylaws of the Corporation. Any adoption, amendment, or repeal of the Bylaws of the Corporation by the Board of Directors will require the approval of a majority of the entire Board of Directors. The stockholders will also have power to adopt, amend, or repeal the Bylaws of the Corporation ¼ provided, however, that, in addition to any vote of the holders of any class or series of stock of the Corporation required by applicable law or this Certificate, the affirmative vote of the holders of at least seventy-five percent (75%) of the total voting power of the shares of the then-outstanding voting stock of the Corporation, voting together as a single class, will be required to adopt, amend, or repeal any provision of the Bylaws of the Corporation. A 4 A ARTICLE IX A The Corporation will have the right, subject to any express provisions or restrictions contained in this Certificate or the Bylaws, from time to time, to amend, alter, or repeal any provision of this Certificate in any manner now or hereafter provided by applicable law, and all rights and powers of any kind conferred upon a director or stockholder of the Corporation by this Certificate, or any amendment of this Certificate, are conferred subject to such right. A Notwithstanding any other provision of this Certificate, the Bylaws, or any provision of applicable law that might otherwise permit a lesser vote or no vote, but in addition to any vote of the holders of any class or series of the stock of the Corporation, and, as applicable, such other approvals of the Board of Directors of the Corporation, as are required by this Certificate, the Bylaws, or applicable law, the affirmative vote of the holders of at least seventy-five percent (75%) of the total voting power of the shares of the then-outstanding voting stock of the Corporation, voting together as a single class, will be required to amend or repeal any provisions, or adopt any provisions inconsistent with those provisions, set forth in Articles V, VI, VIII, IX, or X of this Certificate. A ARTICLE X A Unless the Corporation consents in writing to the selection of an alternative forum (an “Alternative Forum Consent”), the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (A) any derivative action or proceeding brought on behalf of the Corporation ¼ (B) any action or proceeding asserting a claim for breach of a fiduciary duty owed by any director, officer, employee, or agent of the Corporation to the Corporation or the Corporation’s stockholders ¼ (C) any action or proceeding asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, this Certificate, or the Bylaws of the Corporation ¼ or (D) any action or proceeding asserting a claim governed by the internal affairs doctrine, in each case subject to said Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein ¼ provided, however, that, in the event that the Court of Chancery of the State of Delaware lacks subject matter jurisdiction over any such action or proceeding, the sole and exclusive forum for such action or proceeding will be another state or federal court located within the State of Delaware, in each such case, unless the Court of Chancery (or such other state or federal court located within the State of Delaware, as applicable) has dismissed a prior action by the same plaintiff asserting the same claims because such court lacked personal jurisdiction over an indispensable party named as a defendant therein. If any action the subject matter of which is within the scope of this Article X is filed in a court other than the Court of Chancery of the State of Delaware (or any other state or federal court located within the State of Delaware, as applicable) (a “Foreign Action”) by or in the name of any stockholder, such stockholder will be deemed to have consented to (i) the personal jurisdiction of the Court of Chancery of the State of Delaware (or such other state or federal court located within the State of Delaware, as applicable) in connection with any action brought in any such court to enforce this Article X ¼ and (ii) having service of process made upon such stockholder in any such action by service upon such stockholder’s counsel in the Foreign Action as agent for such stockholder. The existence of any prior Alternative Forum Consent will not act as a waiver of the Corporation’s ongoing consent right as set forth above in this Article X with respect to any current or future actions or claims. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation will be deemed to have notice of and consented to the provisions of this Article X. Failure to enforce the foregoing provisions would cause the Corporation irreparable harm and the Corporation will be entitled to equitable relief, including, without limitation, injunctive relief and specific performance, to enforce the foregoing provisions. A 5 A EX-31.1 3 ea021067801ex31-1 sensus.htm CERTIFICATION Exhibit 31.1 A Certification of CEO Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 A I, Joseph C. Sardano, certify that: A 1. I have reviewed this quarterly report on Form 10-Q of Sensus Healthcare, Inc.; A 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; A 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; A 4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: A a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; A b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; A c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and A d. Disclosed in this report any change in the registrant’s internal control over financial

reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and

Â 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):

Â a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and

Â b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.

Â Date: August 13, 2024 /s/ Joseph C. Sardano

Â Joseph C. Sardano

Â Chairman and Chief Executive Officer

EX-31.2.4 ea021067801ex31-2. sensus.htm

CERTIFICATION Exhibit 31.2

Â Certification of CFO Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Â 1. Javier Rampolla, certify that:

Â 1.1.I have reviewed this quarterly report on Form 10-Q of Sensus Healthcare, Inc.,

Â 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Â 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

Â 4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Â a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Â b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Â c.Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Â d.Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and

Â 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):

Â a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and

Â b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.

Â Date: August 13, 2024 /s/ Javier Rampolla

Â Javier Rampolla

Â Chief Financial Officer

EX-32.1 5 ea021067801ex32-1. sensus.htm

CERTIFICATION Exhibit 32.1

Â Certification of CEO Pursuant to 18 U.S.C. Section 1350

Â Pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that:

Â (1)The Quarterly Report for Sensus Healthcare, Inc. (the â€œCompanyâ€) on Form 10-Q for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (this â€œReportâ€), fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended; and

Â (2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered therein.

Â A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Â /s/ Joseph C. Sardano

Â Joseph C. Sardano

Â Chairman and Chief Executive Officer

Â

Â August 13, 2024

EX-32.2 6 ea021067801ex32-2. sensus.htm

CERTIFICATION Exhibit 32.2

Â Certification of CFO Pursuant to 18 U.S.C. Section 1350

Â Pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned certifies that:

Â (1)the Quarterly Report for Sensus Healthcare, Inc. (the â€œCompanyâ€) on Form 10-Q for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (this â€œReportâ€), fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended; and

Â (2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered therein.

Â A signed original of this written statement required by Section 906, or other document authenticating, acknowledging or otherwise adopting the signature that appears in typed form within the electronic version of this written statement, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Â /s/ Javier Rampolla

Â Javier Rampolla

Â Chief Financial Officer

Â

Â August 13, 2024

Â

EX-101.SCH 7 srts-20240630.xsd

XBRL SCHEMA FILE 995301 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 995302 - Statement - Condensed Consolidated Statements of Income (Loss) (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995304 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 995306 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 995307 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 995308 - Disclosure - Debt link:presentationLink link:definitionLink link:calculationLink 995309 - Disclosure - Product Warranties link:presentationLink link:definitionLink link:calculationLink 995310 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 995311 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 995312 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 995313 - Disclosure - Equity-Based Compensation link:presentationLink link:definitionLink link:calculationLink 995314 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 995315 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 996000 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 996001 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 996002 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 996003 - Disclosure - Product Warranties (Tables) link:presentationLink link:definitionLink link:calculationLink 996004 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 996005 - Disclosure - Equity-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 996006 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 996007 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) - Schedule of Disaggregated Revenue link:presentationLink link:definitionLink link:calculationLink 996008 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) - Schedule of Deferred Revenue link:presentationLink link:definitionLink link:calculationLink 996009 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) - Schedule of Remaining Performance Obligations link:presentationLink link:definitionLink link:calculationLink 996010 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) - Schedule of Total Revenue link:presentationLink link:definitionLink link:calculationLink 996011 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) - Schedule of Earnings Per Share Computation link:presentationLink link:definitionLink link:calculationLink 996012 - Disclosure - Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 996013 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment link:presentationLink link:definitionLink link:calculationLink 996014 - Disclosure - Debt (Details) link:presentationLink link:definitionLink link:calculationLink 996015 - Disclosure - Product Warranties (Details) - Schedule of Changes in Product Warranty Liability link:presentationLink link:definitionLink link:calculationLink 996016 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 996017 - Disclosure - Leases (Details) - Schedule of Maturity Non cancellable leases link:presentationLink link:definitionLink link:calculationLink 996018 - Disclosure - Leases (Details) - Schedule of Operating Lease Income link:presentationLink link:definitionLink link:calculationLink 996019 - Disclosure - Leases (Details) - Schedule of Received Lease Agreements link:presentationLink link:definitionLink link:calculationLink 996020 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 996021 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 996022 - Disclosure - Equity-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 996023 - Disclosure - Equity-Based Compensation (Details) - Schedule of Restricted Stock Activity link:presentationLink link:definitionLink link:calculationLink 996024 - Disclosure - Equity-Based Compensation (Details) - Schedule of Stock Option Activity link:presentationLink link:definitionLink link:calculationLink 996025 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 srts-20240630. cal.xml

XBRL CALCULATION FILE EX-101.DEF 9 srts-20240630. def.xml

XBRL DEFINITION FILE EX-101.LAB 10 srts-20240630. lab.xml

XBRL LABEL FILE

Total current assets

Total assets

Total current liabilities

Total liabilities

Total stockholdersâ€™ equity

Balance

Balance

Total liabilities and stockholdersâ€™ equity

gross profit

Total operating expenses

income (loss) from operations

Other income, net

Income (loss) before income tax

Net income (loss)

Net income (loss)

Net income (loss)

(in Dollars)

Balance

(in Shares)

Balance

(in Shares)

Equity Components

[Axis]

Net cash used in operating activities

Net cash used in investing activities

Net cash provided by financing activities

Net decrease in cash and cash equivalents

Cash and cash equivalents

â€ beginning of period

Cash and cash equivalents

â€ end of period

Organization and Summary of Significant Accounting Policies

[Abstract]

Product

and Service

[Axis]

Balance

Balance

Total Geographical

[Axis]

Concentration Risk Benchmark

[Axis]

Concentration Risk Type

[Axis]

Weighted average number of shares used in computing net income (loss) per share

â€ diluted

(in Shares)

Antidilutive Securities

[Axis]

Sale of Stock

[Axis]

Property and Equipment

[Abstract]

Long-Lived Tangible Asset

[Axis]

Property and Equipment, Net

Property and equipment, net

Statistical Measurement

[Axis]

Debt

[Abstract]

Product Warranties

[Abstract]

Schedule of Changes in Product Warranty Liability

[Abstract]

Balance, Beginning

Balance, Ending

Product warranties

Leases

[Abstract]

Schedule of Operating Leases

[Abstract]

Total undiscounted operating leases payments

Present Value of Operating Lease Liability

Schedule of Operating Lease Income

[Abstract]

Schedule of Received Lease Agreements

[Abstract]

Total Commitments and Contingencies

[Abstract]

Stockholders' Equity

[Abstract]

Stockholdersâ€™ Equity

[Abstract]

Equity-Based Compensation

[Abstract]

Restricted Stock, balance at beginning

Restricted Stock, balance at ending

Weighted-Average Grant Date Fair Value, balance at beginning

Weighted-Average Grant Date Fair Value, balance at ending

Number of Options, Outstanding

Weighted- Average Exercise Price, Outstanding

Income Taxes

[Abstract]

Subsequent Events

[Abstract]

Assets

Current assets

Cash and cash equivalents

Accounts receivable, net

Inventories

Prepaid inventory

Prepayment related to these finished goods

Other current assets

Deferred tax asset

Operating lease right-of-use asset, net

Other noncurrent assets

Liabilities and stockholdersâ€™ equity

Current liabilities

Accounts payable and accrued expenses

Operating lease liability, current portion

Income tax payable

Deferred revenue, current portion

Operating lease liability

Operating lease liability, net of current portion

Deferred revenue, net of current portion

Commitments and contingencies

Stockholdersâ€™ equity

Preferred stock, 5,000,000 shares authorized and none issued and outstanding

Preferred stock, shares authorized

Preferred stock, shares issued

Preferred stock, shares outstanding

Common stock, \$0.01 par value

â€ 50,000,000 authorized;

16,927,845 issued and 16,394,921 outstanding at June 30, 2024;

16,907,095 issued and 16,374,171 outstanding at December 31, 2023

Common stock, par value (in Dollars per share)

Common stock, authorized

Common stock share issued

Common stock shares outstanding

Additional paid-in capital

Treasury stock, shares Retained earnings

Revenues

Revenue

Total Revenue

Cost of sales

Operating expenses

Selling and marketing

General and administrative

Research and development

Other income: Interest income, net

Provision for (benefit from) income taxes

Income tax (benefit) expense

Net income (loss) per share

â€ basic (in Dollars per share)

Net income (loss) per share - basic (in Dollars per share)

Net income (loss) per share

â€ diluted (in Dollars per share)

Net income (loss) per share - diluted (in Dollars per share)

Weighted average number of shares used in Weighted average number of shares used in computing net income (loss) per share

â€ basic (in Shares)

Weighted average number of shares used in computing net income (loss) per share

â€ basic Stock-based compensation

Stock-based compensation (in Shares)

Exercise of stock options

Exercise of stock options (in Shares)

Number of Options, Exercised

Forfeiture of restricted stock units (in Shares)

Surrender of shares for tax withholding on stock-based compensation

Surrender of shares for tax withholding on stock-based compensation (in Shares)

Surrendered by employees for tax withholding

Cash flows from operating activities

Adjustments to reconcile net income (loss) to net cash and cash equivalents used in operating activities: Credit loss expense

Depreciation and amortization

Amortization of right-of-use asset

Amortization of the ROU asset

Stock-based compensation

Deferred income taxes

Changes in operating assets and liabilities: Changes in operating assets and liabilities: Accounts payable and accrued expenses

Operating lease liability

Income tax payable

Deferred revenue

Cash flows from investing activities

Cash flows from financing activities

Exercise of stock options

Supplemental disclosure of cash flow information: Interest paid

Income tax paid

Supplemental schedule of noncash investing and financing transactions: Transfer of inventory to property and equipment

Treasury stock, 532,924 shares at cost, at June 30, 2024 and December 31, 2023

Forfeiture of restricted stock units

Provision for product warranties

Accounts receivable

Inventories

Prepaid inventory

Other current assets

Other noncurrent assets

Product warranties

Acquisition of property and equipment

Withholding taxes on stock-based compensation

Common Stock

Common Stock [Member]

Additional Paid-In Capital

Treasury Stock

Retained Earnings

Organization and Summary of Significant Accounting Policies

Schedule of Total Revenue

Schedule of Deferred Revenue

Revenue recognized

Amounts invoiced

Schedule of Remaining Performance Obligations

2024 (July 1 - December 31, 2024)

2025

2026

2027

Schedule of Total Revenue

Revenue

Percentage

Concentration risk

percentage

Schedule of Earnings Per Share Computation

Basic

Diluted

Dilutive effects of: Restricted stock awards

Restricted shares issued (in Shares)

The shares listed below were not included in the computation of diluted net income (loss) per share because to do so would have been antidilutive for the periods presented: Antidilutive stock

Property and Equipment

Schedule of Property and Equipment

Property, plant and equipment, gross

Property, plant and equipment, estimated useful Life

Construction in progress

Debt

Product Warranties

Schedule of Changes in Product Warranty Liability

Warranties accrued during the period

Leases

Schedule of Received Lease Agreements

2024

2025

2026

2027

Other Information

Weighted-average remaining lease term

Weighted-average discount rate

Schedule of Operating Lease Income

Lease income - operating leases

Schedule of Received Lease Agreements

2024

2025

2026

2027

2028

Thereafter

Commitments and Contingencies

Stockholders' Equity

Equity-Based Compensation

Schedule of Restricted Stock Activity

Restricted Stock, Granted

Weighted-Average Grant Date Fair Value, Granted

Weighted-Average Grant Date Fair Value, Vested

Grant date fair value (in Dollars per share)

Weighted-Average Grant Date Fair Value, Forfeited

Schedule of Stock Option Activity

Weighted- Average Remaining Contractual Term (In Years), Outstanding

Number of Options, Granted

Weighted- Average Exercise Price, Granted

Weighted- Average Remaining Contractual Term (In Years), Granted

Weighted- Average Exercise Price, Exercised

Exercise price (in Dollars per share)

Weighted- Average Remaining Contractual Term (In Years), Exercised

Number of Options, Expired

Weighted- Average Exercise Price, Expired

Weighted- Average Remaining Contractual Term (In Years), Expired

Number of Options, Exercisable

Weighted- Average Exercise Price, Exercisable

Weighted- Average Remaining Contractual Term (In Years), Exercisable

Income Taxes

Subsequent Events

Less accumulated depreciation

Payments on warranty claims

Less: Imputed interest

Restricted Stock, Vested

Restricted Stock, Forfeited

Product Revenue - recognized at a point in time

[Member]

Product

[Member]

Service Revenue - recognized at a point in time

[Member]

Service Revenue

[Member]

Service Revenue - recognized over time

[Member]

Service Revenue

[Member]

United States

[Member]

China

[Member]

Guatemala

[Member]

Ireland

[Member]

Other

[Member]

Revenue

[Member]

Revenue

[Member]

Geographic Concentration Risk

[Member]

Restricted stock awards

[Member]

Restricted Stock

[Member]

Stock Options

[Member]

Stock Option

[Member]

Equity Option

[Member]

Earnings Per Share

[Member]

Operations equipment

[Member]

Tradeshow and demo equipment

[Member]

Computer equipment

[Member]

Minimum

[Member]

Maximum

[Member]

Customer

[Axis]

Lender Name

[Axis]

Variable Rate

[Axis]

Collaborative Arrangement and Arrangement Other than Collaborative

[Axis]

Plan Name

[Axis]

Related and Nonrelated Parties

[Axis]

Derivative Instrument

[Axis]

Allowance for expected credit losses

Revenues from non-lease components

Depreciation expenses

Maximum borrowings amount

Borrowing facility amount

Borrowing interest

Liquid assets

Operating lease liability

Operating lease cost

Inventory finished goods

Finished goods received

Issuance of shares

Shares available, grant

Restricted stock issued

Restricted vested percentage

Grant date fair value (in Dollars per share) Vested shares Restricted grant percentage Common stock shares issued for employee Stock price for grant date (in Dollars per share) Shares vested expense Remaining vested shares Stock compensation expense (in Dollars) Unrecognized stock compensation expense (in Dollars) Recognized over weighted-average period Grant date term Stock options outstanding intrinsic value (in Dollars) Effective tax rate Description of the Business Basis of Presentation and Principles of Consolidation Use of Estimates Reclassification of Prior Year Presentation Revenue Recognition Concentration Geographical Information Fair Value of Financial Instruments Fair Value Measurements Cash and Cash Equivalents Accounts Receivable Inventories Earnings Per Share Leases Income Taxes Recent Accounting Pronouncements Customer [Member] Customer Concentration Risk [Member] Accounts Receivable [Member] Accounts receivable [Member] Silicon Valley Bank [Member] Comerica Bank [Member] Secured Overnight Financing Rate [Member] Operating Lease Agreements [Member] 2016 Equity Incentive Plan [Member] 2017 Equity Incentive Plan [Member] 2016 and 2017 Equity Incentive Plans [Member] Board of Directors Chairman [Member] Equity Component [Domain] Statement [Table] Statement [Line Items] Product and Service [Domain] Disaggregation of Revenue [Table] Schedule of Disaggregated Revenue [Line Items] Organization and Summary of Significant Accounting Policies (Details) - Schedule of Deferred Revenue [Table] Schedule of Deferred Revenue [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Schedule of Remaining Performance Obligations [Line Items] Geographical [Domain] Concentration Risk Type [Domain] Concentration Risk Benchmark [Domain] Organization and Summary of Significant Accounting Policies (Details) - Schedule of Total Revenue [Table] Schedule of Revenue [Line Items] Sale of Stock [Domain] Antidilutive Securities, Name [Domain] Organization and Summary of Significant Accounting Policies (Details) - Schedule of Earnings Per Share Computation [Table] Schedule of Earnings Per Share Computation [Line Items] Long-Lived Tangible Asset [Domain] Statistical Measurement [Domain] Property, Plant and Equipment [Table] Schedule of Property and Equipment [Line Items] Award Type [Domain] Equity-Based Compensation (Details) - Schedule of Restricted Stock Activity [Table] Schedule of Restricted Stock Activity [Line Items] Equity-Based Compensation (Details) - Schedule of Stock Option Activity [Table] Schedule of Stock Option Activity [Line Items] Customer [Domain] Organization and Summary of Significant Accounting Policies (Details) [Table] Organization and Summary of Significant Accounting Policies [Line Items] Variable Rate [Domain] Line of Credit Facility, Lender [Domain] Debt (Details) [Table] Debt [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Leases (Details) [Table] Leases [Line Items] Related and Nonrelated Parties [Domain] Plan Name [Domain] Derivative Contract [Domain] Equity-Based Compensation (Details) [Table] Equity-Based Compensation [Line Items] Represent the amount of contract with customer liability amounts invoiced. Finished goods received. Disclosure of accounting policy for geographical information. Increase decrease product warranties. Represent the amount of payment of inventory finished goods. Amount of provision for product warranties. Restricted vest percentage. Represent the amount of revenue remaining performance obligation next twelve months. Represent the amount of revenue remaining performance obligation fiscal year. Represent the amount of revenue remaining performance obligation year three. Represent the amount of revenue remaining performance obligation year two. Represent the amount of revenue from non lease components. Tabular disclosure of schedule of received lease agreements. Number of shares vested remaining shares. Weighted average remaining contractual term for option awards outstanding, in 'PnYnMndTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term for option awards outstanding, in 'PnYnMndTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term for option awards outstanding, in 'PnYnMndTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Represent the amount of transfer of inventory to property and equipment. Information by benchmark of concentration risk. 2016 Equity Incentive Plan Member Information by type of long-lived, physical assets used to produce goods and services and not intended for resale. Use of Estimates, Policy [Policy Text Block] Assets [Abstract] Commitments and Contingencies Income Taxes Paid, Net Common Stock, Value, Issued Product [Member] GUATEMALA Line of Credit Facility, Current Borrowing Capacity Earnings Per Share, Diluted Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Effective Income Tax Rate Reconciliation, Percent Retained Earnings [Member] Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Equity Incentive Plans Member Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Lessee, Leases [Policy Text Block] Lessor, Operating Lease, Payment to be Received, Year Four Weighted Average Number of Shares Outstanding, Basic Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Sharebased Compensation Arrangement by Sharebased Payment Award Options Exercised Weighted Average Remaining Contractual Term Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year Other Nonoperating Income (Expense) Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statement of Stockholders' Equity [Abstract] Deferred Income Tax Assets, Net Increase (Decrease) in Operating Lease Liability Lessor, Operating Lease, Payment to be Received, after Year Five IRELAND Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Schedule Of Stock Option Activity Abstract Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Fair Value Measurement, Policy [Policy Text Block] Income Tax Expense (Benefit) Paymentof Inventory Finished Goods Equipment [Member] Income Statement [Abstract] Lessee, Operating Leases [Text Block] Schedule of Product Warranty Liability [Table Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Investment Income, Interest Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Schedule Of Property And Equipment Abstract Other Assets, Noncurrent Contract With Customer Liability Amounts Invoiced Additional Paid in Capital Operating Expenses [Abstract] Board of Directors Chairman [Member] Supplemental Cash Flow Information [Abstract] Earnings Per Share, Basic Net Cash Provided by (Used in) Operating Activities [Abstract] Treasury Stock, Value Assets Liabilities Sharebased Compensation Arrangement by Sharebased Payment Award Options Expired Weighted Average Remaining Contractual Term Research and Development Expense Equity, Attributable to Parent [Abstract] Preferred Stock, Shares Issued Sharebased Arrangementby Remaining Shares Schedule Of Received Lease Agreements Table Text Block Accounts Receivable [Member] Operating Lease, Payments, Use Prepaid Expense, Current Subsequent Events [Text Block] Contract with Customer, Liability, Noncurrent Business Description and Accounting Policies [Text Block] Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Transfer Of Inventory To Property And Equipment Debt Disclosure [Text Block] Minimum [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Common Stock, Shares, Outstanding Increase (Decrease) in Operating Assets [Abstract] Changes In Operating Assets And Liabilities Abstract Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Retained Earnings (Accumulated Deficit) CHINA Increase (Decrease) in Inventories Lessee, Operating Lease, Liability, to be Paid, Year Three Depreciation Net Cash Provided by (Used in) Investing Activities Restricted Grant Percentage Proceeds from Stock Options Exercised Inventory, Policy [Policy Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Service [Member] Payments to Acquire Property, Plant, and Equipment Increase Decrease Product Warranties Product Warranty Disclosure [Text Block] Net Income (Loss) Attributable to Parent, Diluted [Abstract] Preferred Stock, Shares Authorized Interest Paid, Excluding Capitalized Interest, Operating Activities Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Treasury Stock, Common [Member] Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Preferred Stock, Shares Outstanding Revenue Remaining Performance Obligation Next Twelve Months Property, Plant and Equipment, Net Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Net Cash Provided by (Used in) Financing Activities Restricted Stock, Shares Issued Net of Shares for Tax Withholdings Maximum [Member] Income Tax, Policy [Policy Text Block] Revenue Remaining Performance Obligation Remainderof Fiscal Year UNITED STATES Common Stock, Shares Authorized Finished Goods Received Property, Plant and Equipment, Gross Construction in Progress, Gross Revenue Remaining Performance Obligation Year Three Operating Lease, Liability, Noncurrent Accounts Receivable [Policy Text Block] Other Member Operating Lease, Weighted Average Discount Rate, Percent Standard and Extended Product Warranty Accrual, Decrease for Payments Earnings Per Share Member Revenues From Non Lease Components Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Concentration Risk, Credit Risk, Policy [Policy Text Block] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Per Share Because To Do So Would Have Been Antidilutive For The Periods Presented Abstract Share-Based Payment Arrangement, Expense Net Cash Provided by (Used in) Financing Activities [Abstract] Additional Paid-in Capital [Member] Schedule Of Earnings Per Share Computation Abstract Accounts Receivable, Credit Loss Expense (Reversal) Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Contract with Customer, Liability Geographical Information Policy Policy Text Block Restricted Stock [Member] Operating Lease Agreements Member Operating Income (Loss) Selling and Marketing Expense Product Warranty Accrual, Current Net Cash Provided by (Used in) Investing Activities [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Revenue Remaining Performance Obligation Year Two Operating Lease, Liability Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Increase (Decrease) in Prepaid Expense Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Stock Issued During Period, Shares, Restricted Stock Award, Gross Lessor, Operating Lease, Payment to be Received, Year Three Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Contract with Customer, Liability, Revenue Recognized Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Depreciation, Depletion and Amortization, Nonproduction Other Income and Expenses [Abstract] Revenue from Contract with Customer [Policy Text Block] Taxes Payable, Current Common Stock [Member] Reclassification, Comparability Adjustment [Policy Text Block] Unlabeled Abstract2 Unlabeled Abstract1 Statement of Cash Flows [Abstract] Unlabeled Abstract0 Property, Plant and Equipment, Useful Life Operating Lease, Liability, Current Lessee, Operating Lease, Liability, to be Paid, Year Two Lessor, Operating Lease, Payment to be Received, Year One Income Tax Disclosure [Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Weighted Average Number Of Shares Used In Abstract Lessor, Operating Lease, Payment to be Received Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Tradeshow And Demo Equipment Member Stock Issued During Period, Shares, Employee Stock Purchase Plans Liabilities, Current [Abstract] Net Cash Provided by (Used in) Operating Activities Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Restricted Vest Percentage Other Assets, Current APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Operating Lease, Lease Income [Table Text Block] Provision For Product Warranties Equity Option [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Lessor, Operating Lease, Payment to be Received, Year Two Operating Lease, Weighted Average Remaining Lease Term Share-Based Payment Arrangement [Text Block] Equity Incentives Plan1 Member Operating Lease, Right-of-Use Asset, Periodic Reduction Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Comerica Bank Member Equity, Attributable to Parent Increase (Decrease) in Accounts Payable and Accrued Liabilities Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Computer Equipment [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares Revenues Stock Issued During Period, Value, Stock Options Exercised Accounts Payable and Accrued Liabilities, Current Geographic Concentration Risk [Member] Equity Incentive Plan Member Treasury Stock, Common, Shares Silicon Valley Bank Member Schedule Of Restricted Stock Activity Abstract Increase (Decrease) in Contract with Customer, Liability Sharebased Compensation Arrangement by Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term Operating Lease, Cost General and Administrative Expense Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) Cash and Cash Equivalents, Policy [Policy Text Block] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Concentration Risk, Percentage Schedule Of Remaining Performance Obligations Abstract Contract with Customer, Liability, Current Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Unlabeled Abstract Common Stock, Par or Stated Value Per Share Standard and Extended Product Warranty Accrual Line of Credit Facility, Maximum Borrowing Capacity Earnings Per Share, Policy [Policy Text Block] Common Stock, Shares, Issued Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Revenue Benchmark [Member] Increase (Decrease) in Other Noncurrent Assets Weighted Average Number of Shares Outstanding, Diluted Gross Profit Property, Plant and Equipment Disclosure [Text Block] Stock Issued During Period, Shares, Employee Benefit Plan Deferred Income Tax Expense (Benefit) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Service Revenue Member Basis of Presentation and Significant Accounting Policies [Text Block] Accounts Receivable, after Allowance for Credit Loss, Current Lessee, Operating Lease, Liability, to be Paid Schedule Of Deferred Revenue Abstract Share-Based Payment Arrangement, Option, Activity [Table Text Block] Disaggregation of Revenue [Table Text Block] Equity [Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Assets, Current [Abstract] Customer Member Schedule Of Total Revenue Abstract Property, Plant and Equipment [Table Text Block] Payment, Tax Withholding, Share-Based Payment Arrangement Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Liabilities, Current Operating Expenses Statement of Financial Position [Abstract] Line of Credit Facility, Interest Rate During Period Cash and Cash Equivalents, at Carrying Value Other Information Abstract Liabilities and Equity [Abstract] Shares, Outstanding Commitments and Contingencies Disclosure [Text Block] The Shares Listed Below Were Not Included In The Computation Of Diluted Net Income Loss Abstract Lessee, Operating Lease, Liability, to be Paid, Year One Customer Concentration Risk [Member] Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Operating Lease, Lease Income Increase (Decrease) in Accounts Receivable Cost of Revenue Preferred Stock, Value, Issued Liabilities and Equity Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] Lessee, Operating Lease, Liability, Undiscounted Excess Amount Share-Based Payment Arrangement, Noncash Expense Restricted Stock, Value, Shares Issued Net of Tax Withholdings Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Line of Credit Facility, Asset Restrictions Schedule Of Disaggregated Revenue Abstract Increase (Decrease) in Other Current Assets Operating Lease, Right-of-Use Asset Assets, Current Inventory, Net Increase (Decrease) in Income Taxes Payable EX-101 PRE 11 srts-20240630_pre.xml XBRL PRESENTATION FILE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover - shares 6 Months Ended Jun. 30, 2024 Aug. 06, 2024 Document Information [Line Items] Á Document Type 10-Q Á Document Quarterly Report true Á Document Transition Report false Á Entity Interactive Data Current Yes Á Amendment Flag false Á Document Period End Date Jun. 30, 2024 Á Document Fiscal Year Focus 2024 Á Document Fiscal Period Focus Q2 Á Entity Information [Line Items] Á Á Entity Registrant Name Sensus Healthcare, Inc. Á Entity Central Index Key 0001494891 Á Entity File Number 001-37714 Á Entity Tax Identification Number 27-1647271 Á Entity Incorporation, State or Country Code DE Á Current Fiscal Year End Date -12-31 Á Entity Current Reporting Status Yes Á Entity Shell Company false Á Entity Filer Category Non-accelerated Filer Á Entity Small Business true Á Entity Emerging Growth Company false Á Entity Contact Personnel [Line Items] Á Á Entity Address, Address Line One 851 Broken Sound Pkwy Á Entity Address, Address Line Two NW #215 Á Entity Address, City or Town Boca Raton Á Entity Address, State or Province FL Á Entity Address, Postal Zip Code 33487 Á Entity Phone Fax Numbers [Line Items] Á Á City Area Code (561) Á Local Phone Number 922-5808 Á Entity Listings [Line Items] Á Á Title of 12(b) Security Common Stock, par value \$0.01 per share Á Trading Symbol SRTS Á Security Exchange Name NASDAQ Á Entity Common Stock, Shares Outstanding Á 16,389,051 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItem Type Balance

Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_Data Type: xbrli:MonthDayItem Type Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_Data Type: dei:fiscalPeriodItem Type Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_Data Type: xbrli:YearItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_Data Type: xbrli:dateItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1:

[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 28: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 30: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1) + Details Name: us-gaap Assets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7) + Details Name: us-gaap Assets Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(15\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1) + Details Name: us-gaap CommitmentsAndContingencies Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1) + Details Name: us-gaap CommonStockValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2> + Details Name: us-gaap ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2> + Details Name: us-gaap ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2> + Details Name: us-gaap ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6> + Details Name: us-gaap DeferredIncomeTaxAssetsNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section](http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10)

FSB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21:](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21:)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22:](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22:)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23:](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23:)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24:](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24:)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25:](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25:)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26:](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26:)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27:](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27:)
[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28:](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28:)
[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29:](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29:)
[http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/214748210/280-10-50-30 + Details Name: us-gaap Liabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1:](http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/214748210/280-10-50-30 + Details Name: us-gaap Liabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1:)
<http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-1Reference 2:>
[http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3:](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3:)
[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4:](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4:)
[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5:](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5:)
[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6:](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6:)
[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478564/942-210-S99-1Reference 7:](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478564/942-210-S99-1Reference 7:)
[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(32\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1:)

-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-1>Reference 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap_StockholdersEquityNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstractNamespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_TaxesPayableCurrentNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481520/505-30-50-4>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481549/505-30-45-1> + Details Name: us-gaap_TreasuryStockValueNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets (Parentheticals) - \$ / shares Jun. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] A A Preferred stock, shares authorized 5,000,000 5,000,000 Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value (in Dollars per share) \$ 0.01 \$ 0.01 Common stock, authorized 50,000,000 50,000,000 Common stock share issued 16,927,845 16,907,095 Common stock shares outstanding 16,394,921 16,374,171 Treasury stock, shares 532,924 532,924 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockParOrStatedValuePerShareNamespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> + Details Name: us-gaap_CommonStockSharesAuthorizedNamespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockSharesIssuedNamespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3> + Details Name: us-gaap_CommonStockSharesOutstandingNamespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13> + Details Name: us-gaap_PreferredStockSharesIssuedNamespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3> + Details Name: us-gaap_PreferredStockSharesOutstandingNamespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstractNamespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481549/505-30-45-1> + Details Name: us-gaap_TreasuryStockCommonSharesNamespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Income (Loss) (Unaudited) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2024 Jun. 30, 2024 Jun. 30, 2023 Income Statement [Abstract] A A A Revenues 9,239 \$ 4,527 \$ 19,902 \$ 7,941 Cost of sales 3,816 1,908 7,817 3,700 Gross profit 5,423 2,619 12,085 4,241 Operating expenses A A A Selling and marketing 996 1,595 2,266 3,693 General and administrative 1,579 1,329 3,158 2,693 Research and development 866 822 1,792 1,920 Total operating expenses 3,441 3,746 7,216 8,306 Income (loss) from operations 1,982 (1,127) 4,869 (4,065) Other income: A A A Interest income, net 209 245 423 488 Other income, net 209 245 423 488 Income (loss) before income tax 2,191 (882) 5,292 (3,577) Provision for (benefit from) income taxes 579 (502) 1,406 (1,303) Net income (loss) \$ 1,612 \$ (380) \$ 3,886 \$ (2,274) Net income (loss) per share A€" basic (in Dollars per share) \$ 0.1 \$ (0.02) \$ 0.24 \$ (0.14) Net income (loss) per share A€" diluted (in Dollars per share) \$ 0.1 \$ (0.02) \$ 0.24 \$ (0.14) Weighted average number of shares used in computing net income (loss) per share A€" basic (in Shares) 16,298,459 16,249,766 16,296,715 16,247,567 Weighted average number of shares used in computing net income (loss) per share A€" diluted (in Shares) 16,333,481 16,249,766 16,325,764 16,247,567 X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 7: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B> + Details Name: us-gaap_CostOfRevenueNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI

Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1-Subparagraph \(SX 210.7-04\(1\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1-Subparagraph (SX 210.7-04(1))-Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph \(a\) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap IncomeTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(7\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap InvestmentIncomeInterest Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13:

SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.5-02(29)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4:

Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-17>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-25>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-2> + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/21474780097/470-10-S99-1A>Reference 23: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 31: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 32: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 37: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-15> + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-13> + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2A> + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479319/326-20-50-13>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.2.1 Organization and Summary of Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Organization and Summary of Significant Accounting Policies [Abstract] Å Organization and Summary of Significant Accounting Policies Note 1 æ Organization and Summary of Significant Accounting Policies Å Description of the Business Å Sensus Healthcare, Inc. (together, with its subsidiaries, unless the context otherwise indicates, æSensusæ or the æCompanyæ) is a manufacturer of radiation therapy devices sold to healthcare providers globally through its distribution and marketing network. The Company operates from its corporate headquarters located in Boca Raton, Florida. Å In February 2024, the Company formed Sensus Healthcare Services, LLC, a wholly-owned subsidiary that provides operational healthcare services in the form of leased equipment, radiation oncology and physics oversight, including radiotherapy technologists for dermatology clinics. Å Basis of Presentation and Principles of Consolidation Å These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (æGAAPæ) and include the accounts of the Company and its subsidiaries. Accounts and transactions between condensed consolidated entities have been eliminated. Å These financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and notes required by GAAP. In the opinion of management, all adjustments considered necessary for a fair statement of the results have been included. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024 or for any other period. Å The condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited financial statements at that date but does not include all of the information and notes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and notes thereto included in the Companyæ™s Annual Report on Form 10-K for the year ended December 31, 2023 (the æ2023 Annual Reportæ). Å Use of Estimates Å The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates. Å Reclassification of Prior Year Presentation Å Certain prior period amounts have been reclassified for consistency with the current period presentation. The reclassifications are limited to the condensed consolidated

of cash flow and have no impact on the reported results of operations. A Revenue Recognition A The Company derives revenue from sales of the Company's devices and services related to maintaining and repairing the devices as part of a service contract or on an ad-hoc basis without a service contract. A The Company provides warranties, generally for one year, in conjunction with the sale of its products. These warranties entitle the customer to repair, replacement, or modification of the defective product, subject to the terms of the relevant warranty. The Company has determined that these warranties do not represent separate performance obligations, as the customer does not have the option to purchase the warranty separately and the warranty does not provide the customer with a service in addition to the assurance that the product complies with agreed-upon specifications. The Company records an estimate of future warranty claims at the time it recognizes revenue from the sale of the device based upon management's estimate of the future claims rate. A Revenue is recognized upon transfer of control of promised goods or services to customers when the product is shipped or the service is rendered, based on the amount the Company expects to receive in exchange for those goods or services. The Company enters into contracts that can include multiple services, which are accounted for separately if they are determined to be distinct. A To determine the transaction price for contracts in which a customer promises consideration in a form other than cash, the Company measures the estimated fair value of the noncash consideration at contract inception. If the Company cannot reasonably estimate the fair value of the noncash consideration, the Company measures the consideration indirectly by reference to the standalone selling price of the products promised to the customer or class of customer in exchange for the consideration. A Our service contracts include maintenance or repair service contracts for device purchases and personnel service contracts to assist the use and operation of leased-out equipment under lessor agreements. A The revenues from maintenance or repair service contracts are recognized over the service contract period on a straight-line basis. In the event that a customer does not sign a service contract, but requests maintenance or repair services after the warranty expires, the Company recognizes revenue when the service is rendered. There is no termination provision in the service contract or any penalties in practice for cancellation of the service contract. A The revenues from personnel service contracts are recognized in the period the work is performed, as the Company has elected the practical expedient to recognize revenue in the amount to which the entity has a right to invoice. The service contracts can be terminated by mutual written agreement. A The Company has determined that in practice no significant discount is given on service contracts when offered with the device purchase or equipment lease as compared to when sold on a stand-alone basis. The service level provided is identical whether the service contract is purchased on a stand-alone basis or together with the device purchase or equipment lease. The Company may also incur preparation cost to ensure the customer's space meets the requirement and specifications for the operation of the equipment. The preparation cost is expensed as incurred. A The components of disaggregated revenue for the three and six months ended June 30, 2024 and 2023 were as follows: A A For the Three Months Ended A For the Six Months Ended A A June 30, A A June 30, A (in thousands) A 2024 A 2023 A 2024 A 2023 A Product Revenue - recognized at a point in time A \$8,074 A \$3,524 A \$17,566 A \$5,993 A Service Revenue - recognized at a point in time A 367 A 306 A A 739 A A 647 A Service Revenue - recognized over time A 798 A A 697 A A 1,597 A A 1,301 A Total Revenue A \$9,239 A \$4,527 A \$19,902 A \$7,941 A The Company operates in a highly regulated environment, primarily in the U.S. dermatology market, in which state regulatory approval is sometimes required prior to the customer being able to use the product. In cases where such regulatory approval is pending, revenue is deferred until such time as regulatory approval is obtained. A Deferred revenue activity as of June 30, 2024 was as follows: A (in thousands) A Product A Service A Total A December 31, 2023 A 36 A \$681 A \$717 A Revenue recognized A (270) A A (1,597) A A (1,867) A Amounts invoiced A 332 A A 1,581 A A 1,913 A June 30, 2024 A \$98 A \$665 A \$763 A A Remaining performance obligations of deposits for products have original expected durations of one year or less. Estimated service revenue to be recognized in the future related to the performance obligations that are unsatisfied (or partially unsatisfied) as of June 30, 2024 is as follows: A Year A Service Revenue A 2024 July 1 - December 31, 2024 A \$439 A 2025 A 172 A 2026 A 44 A 2027 A 10 A Total A \$665 A For the six months ended June 30, 2024 and 2023, the Company paid commissions for certain equipment sales. Because the recovery of commissions is expected to occur from product revenue within one year, the Company charges commissions to expense as incurred. A In addition, the Company incurs commissions associated with equipment lease agreements, which are accounted as initial direct costs and recorded in other noncurrent assets in the condensed consolidated balance sheets. The commission is capitalized at the commencement of the lease and recognized as an expense in selling and marketing expenses over the lease term. A Shipping and handling costs are expensed as incurred and are included in cost of sales. A Concentration A Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. A One customer in the U.S. accounted for 83% and 46% of revenue for the three months ended June 30, 2024 and 2023, respectively, 77% and 52% of revenue for the six months ended June 30, 2024 and 2023, respectively, and 92% and 85% of the accounts receivable as of June 30, 2024 and December 31, 2023, respectively. A Geographical Information A The following table illustrates total revenue for the three and six months ended June 30, 2024 and 2023 by country. A A For the Three Months Ended A A June 30, A (in thousands) A 2024 A 2023 A United States A \$8,667 A A 94% A \$3,892 A A 86% A China A 572 A A 6% A 300 A A 7% A Guatemala A A A 0% A A 190 A A 4% A Ireland A A A 0% A A 135 A A 3% A Other A A A 0% A A 10 A A 0% Total Revenue A \$9,239 A A 100% A \$4,527 A A 100% A A For the Six Months Ended A A June 30, A (in thousands) A 2024 A 2023 A United States A \$19,146 A A 96% A \$7,166 A A 90% A China A 727 A A 4% A 430 A A 5% A Guatemala A A A 0% A A 190 A A 2% A Ireland A A A 0% A A 135 A A 2% A Other A 29 A A 0% A 20 A A 0% Total Revenue A \$19,902 A A 100% A \$7,941 A A 100% A Fair Value of Financial Instruments A Carrying amounts of cash equivalents, accounts receivable, accounts payable and the revolving credit facility approximate fair value due to their relative short maturities. A Fair Value Measurements A The Company uses a fair value hierarchy that prioritizes inputs to valuation approaches used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. Assets and liabilities measured and reported at fair value are classified and disclosed in one of the following categories: A Level 1 Inputs: A Quoted prices (unadjusted) in active markets for identical assets or liabilities at the reporting date. A A—Level 1 assets may include listed mutual funds, ETFs and listed equities A Level 2 Inputs: A Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities that are not active; quotes from pricing services or brokers for which the Company can determine that orderly transactions took place at the quoted price or that the inputs used to arrive at the price are observable; and inputs other than quoted prices that are observable, such as models or other valuation methodologies. A A—Level 2 assets may include debt securities and foreign currency exchange contracts that have inputs to the valuations that generally can be corroborated by observable market data. A Level 3 Inputs: A Unobservable inputs for the valuation of the asset or liability, which may include nonbinding broker quotes. A A—Level 3 assets include investments for which there is little, if any, market activity. These inputs require significant management judgment or estimation. A Significance of Inputs: The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the financial instrument. A Cash and Cash Equivalents A Cash and cash equivalents primarily consist of cash, money market funds and short-term, highly liquid investments with original maturities of three months or less. A Accounts Receivable A The Company does business and extends credit based on an evaluation of each customer's financial condition, generally without requiring collateral. Exposure to losses on receivables is expected to vary by customer due to the financial condition of each customer. The Company estimates future credit losses based on the age of customer receivable balances, collection history and forecasted economic trends. Future collections can be significantly different from historical collection trends or current estimates. The Company monitors exposure to credit losses and maintains allowances for anticipated losses considered necessary under the circumstances. The allowance for expected credit losses was \$42 thousand and \$0 as of June 30, 2024 and December 31, 2023, respectively. Credit loss expense was \$42 thousand and \$5 thousand for the three months ended June, 2024 and 2023, respectively, and \$42 thousand and \$5 thousand for the six months ended June, 2024 and 2023, respectively. A Inventories A Inventories consist of finished product and components and are stated at the lower of cost and net realizable value, determined using the first-in-first-out method. A Earnings Per Share A Basic net income (loss) per share is calculated by dividing the net income by the weighted-average number of common shares outstanding for the period using the treasury stock method for options, restricted stocks and warrants. Diluted net income (loss) per share is computed by giving effect to all potential dilutive common share equivalents outstanding for the period. A The factors used in the net income (loss) per share computation are as follows: A A For the Three Months Ended A For the Six Months Ended A A June 30, A A June 30, A (in thousands) A 2024 A 2023 A 2024 A 2023 A Basic A A A A A A Net income (loss) A \$1,612 A A (\$380) A \$3,886 A A (\$2,274) A Weighted average number of shares used in computing net income (loss) per share A 16,298 A A 16,250 A A 16,297 A A 16,248 A Net income (loss) per share - basic A \$0.10 A A (\$0.02) A A \$0.24 A A (\$0.14) A Diluted A A A A A A Net income (loss) A \$1,612 A A (\$380) A \$3,886 A A (\$2,274) A Weighted average number of shares used in computing net income (loss) per share A 16,250 A A 16,297 A A 16,248 A Dilutive effects of: A A A A A A A A Restricted stock awards A 35 A A A 29 A A A Weighted average number of shares used in computing net income (loss) per share A 16,333 A A 16,250 A A 16,326 A A 16,248 A Net income (loss) per share - diluted A \$0.10 A A (\$0.02) A A \$0.24 A A (\$0.14) A A A A A A A A The shares listed below were not included in the computation of diluted net income (loss) A A A A A A A A per share because to do so would have been antidilutive for the periods presented: A A A A A A A A Restricted stock awards A 52,500 A A 146,000 A A 52,500 A A 146,000 A Stock options A 86,550 A A 89,550 A A 86,550 A A 89,550 A A Diluted net income per share for the three and six months ended June 30, 2024 includes the dilutive effect of restricted stock awards that were issued in July 2021 and January 2024 to our directors, officers, and employees. Diluted weighted average common shares outstanding for the three and six months ended June 30, 2024 excludes stock options whose exercise prices were higher than the average price of our shares of common stock during the period. Diluted weighted average common shares outstanding for the three and six months ended June 30, 2024 also excludes the 52,500 shares issued under restricted stock awards in December 2022 to employees, as the average price of our shares of common stock during the three and six months ended June 30, 2024 was less than average unrecognized compensation expense. Diluted net loss per share for the three and six months ended June 30, 2023 excludes the dilutive effect of stock options and restricted stock awards as they are antidilutive during a period of net loss. The assumed proceeds of stock options and the restricted stock awards for the treasury stock method is the sum of proceeds from exercise and the average amount of unrecognized compensation expense. A Leases A The Company evaluates arrangements at inception to determine if an arrangement is or contains a lease. Operating lease assets represent the Company's right to control an underlying asset for the lease term, and operating lease liability represents the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses an incremental borrowing rate that the Company would expect to incur for a fully collateralized loan over a similar term under similar economic conditions to determine the present value of the lease payments. The Company has lease agreements which include lease and non-lease components, which the Company has elected to account for as a single lease component for all classes of underlying assets. A The lease payments used to determine the Company's operating lease assets may include lease incentives, and stated rent increases are recognized in the Company's operating lease assets in the Company's condensed consolidated balance sheets. Operating lease assets are amortized to rent expense over the lease term and included in operating expenses in the condensed consolidated statements of income. A For leases in which the Company is the lessor, the Company identifies the lease and non-lease components and allocates the contract consideration to the different components on a relative standalone selling price basis at lease inception. The Company uses a residual approach for the components when the standalone selling price is not directly observable or those for which the Company has not established a price. A The Company elects the practical expedient to combine lease and non-lease components when the components qualify to be combined. Continuous supporting services are the primary non-lease components and are not predominant. As a result, the combined components are accounted for as a lease under ASC 842, Leases. The revenues from non-lease components that are not qualified to be combined are recognized when the services are rendered under ASC 606, Revenue from Contracts with Customers. The revenues from non-lease components were \$50 thousand for the three and six months ended June 30, 2024. A For operating leases where the Company is the lessor, the Company recognizes the underlying assets and depreciates them over the estimated useful life which is based upon to estimate the residual value expected at the end of the lease term. Lease income is recognized on a straight-line basis over the lease term. Leasing revenue is not recognized when collection of all contractual rents over the term of the agreement is not probable. When collection is not probable, the Company limits the lease revenue to the lesser of the revenue recognized on a straight-line basis or cash basis. The lease income is included in revenues in the condensed consolidated statements of income (loss). A Variable lease payments associated with the leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented within revenues in the condensed consolidated statements of income (loss). A Income Taxes A The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected

â€œScopeâ€ and â€œScope Exceptionsâ€ sections of Topic 718 to improve its clarity and operability without changing the guidance. The ASU is effective for fiscal years beginning after December 15, 2024, and interim periods within those annual periods. Early adoption is permitted. These updates are not expected to have a significant impact on the Companyâ€™s condensed consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContent>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 250 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/250/tableOfContent> + Details Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property and Equipment 6 Months Ended Jun. 30, 2024 Property and Equipment [Abstract] Â Property and Equipment Note 2 â€œ Property and Equipment Â Property and equipment consist of the following: Â (in thousands)Â As of June 30, 2024Â Â As of December 31, 2023Â Â Estimated Useful Lives Operations equipmentÂ \$1,129Â Â \$1,018Â Â 3-10Â years Tradeshaw and demo equipmentÂ 1,181Â Â 1,184Â Â 3Â years Computer equipmentÂ 1,484Â Â 1,454Â Â 3Â years SubtotalÂ 2,458Â Â 2,347Â Â Â Construction in progressÂ 228Â Â 228Â Â Â Â Â Less accumulated depreciationÂ 1,974Â Â 1,883Â Â Â Property and Equipment, NetÂ \$712Â Â \$464Â Â Â A Depreciation expense was \$31 thousand and \$59 thousand for the three months ended June 30, 2024 and 2023, respectively, and \$101 thousand and \$107 thousand for the six months ended June 30, 2024 and 2023, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -SubTopic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7> + Details Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt 6 Months Ended Jun. 30, 2024 Debt [Abstract] Â Debt Note 3 â€œ Debt Â As of December 31, 2022, the Company had a revolving credit facility with Silicon Valley Bank (â€œSVBâ€) that provided for maximum borrowings equal to the lesser of (a) the \$15 million commitment amount or (b) the borrowing base plus a \$7.5 million non-formula sublimit. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (â€œFDICâ€) was appointed receiver. On March 13, 2023, the FDIC transferred all deposits, both insured and uninsured, and substantially all assets of SVB to a newly created, full-service FDIC-operated â€œbridge bankâ€, Silicon Valley Bridge Bank, N.A. (â€œSVBBâ€), chartered by the Office of the Comptroller of the Currency as a national bank. Subsequently, on March 27, 2023, the FDIC entered into a purchase and assumption agreement for all deposits and loans, as well as certain other assets, of SVBB, with First-Citizens Bank & Trust Company (â€œFCBâ€), a subsidiary of First Citizens BancShares, Inc. (â€œFirst Citizensâ€). As a result of this transaction, SVB became a wholly owned subsidiary of FCB. Â On September 11, 2023, the Company entered into a new revolving credit facility (the â€œCredit Facilityâ€) with Comerica Bank (â€œComericaâ€), replacing the prior facility with SVB, that provides for maximum borrowings of \$10 million. The Credit Facility may be terminated by the Company or Comerica at any time without penalty. At June 30, 2024, the available borrowings under this facility were \$10 million. Any borrowings bear interest at the Secured Overnight Financing Rate plus 2.50% (or 7.83% at June 30, 2024) and would be due upon demand by Comerica. The Credit Facility is secured by all of the Companyâ€™s assets. The Credit Facility contains a financial covenant requiring that the Company maintain unencumbered liquid assets having a minimum value of \$3,500,000 in a Comerica account. Â The Company was in compliance with its financial covenants under the respective facilities as of June 30, 2024 and December 31, 2023. There were no borrowings outstanding under either facility at June 30, 2024 and December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef-Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-11) + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Product Warranties 6 Months Ended Jun. 30, 2024 Product Warranties [Abstract] Â Product Warranties Note 4 â€œ Product Warranties Â Changes in product warranty liability were as follows for the six months ended June 30, 2024: Â (in thousands)Â Â Balance, December 31, 2023Â \$538Â Warranties accrued during the periodÂ 186Â Payments on warranty claimsÂ 207 Balance, June 30, 2024Â \$517Â X - ReferencesNo definition available. + Details Name: us-gaap_ProductWarrantiesDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\)\(5\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4) + Details Name: us-gaap_ProductWarrantyDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases 6 Months Ended Jun. 30, 2024 Leases [Abstract] Â Leases Note 5 â€œ Leases Â Operating Lease Agreements Â The Company leases its headquarters office from an unrelated third party under a lease expiring in September 2027. The amortization of the right of use lease asset was \$48 thousand and \$46 thousand for the three months ended June 30, 2024 and 2023, respectively, and \$95 thousand and \$90 thousand for the six months ended June 30, 2024 and 2023, respectively. Â Future minimum lease payments under the Companyâ€™s non-cancellable leases as of June 30, 2024 are as follows: Â Maturity of Operating Lease LiabilityÂ AmountÂ 2024 (July 1 - December 31, 2024)Â \$112Â 2025Â 229Â 2026Â 236Â 2027Â 181Â Total undiscounted operating leases paymentsÂ \$758Â Less: Imputed interestÂ 60 Present Value of Operating Lease LiabilityÂ \$698Â Operating lease liability, current portionÂ 195Â Operating lease liability, net of current portionÂ \$503Â Â Â Â Other InformationÂ Â Â Weighted-average remaining lease termÂ 3.25 yearsÂ Weighted-average discount rateÂ 5 % Â Cash paid for amounts included in the measurement of operating lease liability was \$85 thousand and \$104 thousand for the six months ended June 30, 2024 and 2023, respectively, and is included in cash flows from operating activities in the accompanying condensed consolidated statement of cash flows. Â Operating lease cost recognized as expense was \$57Â thousand for the three months ended June 30, 2024 and 2023, and \$114 thousand for the six months ended June 30, 2024 and 2023. The financing component for operating lease liability represents the effect of discounting the operating lease payments to their present value. Â Lessor Accounting Â Beginning in the quarter ended June 30, 2024, the Company, through its subsidiary, Sensus Healthcare Services, LLC, leases superficial radiotherapy equipment to dermatology clinics. The leases generally have initial lease terms of sixty months and automatically renew for a one-year period upon the expiration of the initial lease terms. Payments due under the leases may be fixed or variable payments. Â The component of lease income for the three and six months ended June 30, 2024 is as follows: Â (in thousands)Â For the Three MonthsÂ Ended June 30, 2024Â Â For the Six MonthsÂ Ended June 30, 2024Â Lease income - operating leasesÂ \$414Â \$414 Â The future minimum fixed lease payments to be received under the lease agreements as of June 30, 2024 are as follows: Â (in thousands)Â AmountÂ 2024 (July 1 - December 31, 2024)Â \$128Â 2025Â 256Â 2026Â 256Â 2027Â 256Â 2028Â 256Â ThereafterÂ 343Â TotalÂ \$1,495Â X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent> + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Commitments and Contingencies [Abstract] Â Commitments and Contingencies Note 6 â€œ Commitments and Contingencies Â Manufacturing Agreement Â The Company has a contract manufacturing agreement with an unrelated third party for the production and manufacture of the SRT-100 (and subsequently the SRT-100 Vision and the SRT-100+), in accordance with the Companyâ€™s product specifications. The agreement renews for successive one-year periods unless either party notifies the other party in writing, at least sixty days prior to the anniversary date of the agreement, that it will not renew the agreement. The Company or the manufacturer may terminate the agreement upon ninety daysâ€™ prior written notice. Â The Company pays this manufacturer for finished goods in advance of the inventory being received. The Company paid this manufacturer \$0 million and \$1.2 million for finished goods for the three months ended June 30, 2024 and 2023, respectively, and \$5.7 million and \$7.9 million for the six months ended June 30, 2024 and 2023, respectively. Finished goods of \$0.3 million and \$4.5 million were received from this manufacturer for the three months ended June 30, 2024 and 2023, respectively, and \$5.2 million and \$7.7 million for the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024 and December 31, 2023, a prepayment related to these finished goods of \$3.3 million and \$3.0 million, respectively, was presented in prepaid inventory in the accompanying condensed consolidated balance sheets. Â Legal contingencies Â The Company is party to certain legal proceedings in the ordinary course of business. The Company assesses, in conjunction with its legal counsel, the need to record a liability for litigation and related contingencies. Â In 2015, the Company learned that the Department of Justice (the â€œDepartmentâ€) had commenced an investigation of the billing to Medicare by a physician who had treated patients with the Companyâ€™s SRT-100. The Department subsequently advised the Company that it was considering expanding the investigation to determine whether the Company had any involvements in physicianâ€™s use of certain reimbursements codes. The Company has received two Civil Investigative Demands from the Department seeking documents and written responses in connection with its investigation. The Company has fully cooperated with the Department. The Company disputes that it has engaged in any wrongdoing with respect to such reimbursement claims; among other considerations, the Company does not submit claims for reimbursement or provide coding or billing advice to physicians. To the Companyâ€™s knowledge, the Department has made no determination as to whether the Company engaged in any wrongdoing, or whether to pursue any legal action against the Company. Should the Department decide to pursue legal action, the Company believes it has strong and meritorious defenses and will vigorously defend itself. As of June 30, 2024, the Company was unable to estimate the cost associated with this matter.Â X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3](http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3): <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5](http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5): [http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6): [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity 6 Months Ended Jun. 30, 2024 Stockholders' Equity [Abstract] A Stockholders' Equity Note 7 â€” Stockholders' Equity A Preferred Stock A The Company has authorized 5 million shares of preferred stock. No shares of preferred stock were issued or outstanding at June 30, 2024 or December 31, 2023. A Treasury stock A Treasury stock includes shares surrendered by employees for tax withholding on the vesting of restricted stock awards and shares repurchased in open market transactions. No shares were surrendered by employees for tax withholding for the three and six months ended June 30, 2024. 0 and 4,487 shares were surrendered by employees for tax withholding for the three and six months ended June 30, 2023, respectively. During three and six months ended June 30, 2024 and 2023, the Company did not repurchase any shares in open market transactions. X - ReferencesNo definition available. + Details Name: us-gaap EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: <a href=): [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3): [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6): <https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8): [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9): [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(e\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10): <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13): [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14): [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16): [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17): [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18): [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19): [http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-Based Compensation 6 Months Ended Jun. 30, 2024 Equity-Based Compensation [Abstract] A Equity-Based Compensation Note 8 â€” Equity-based Compensation A 2016 and 2017 Equity Incentive Plans A The Companyâ€™s 2016 Equity Incentive Plan and the 2017 Incentive Plan, as amended in June 2023 (collectively, the â€œPlansâ€), provide for the issuance of up to 397,473 shares and 750,000 shares, respectively. In addition, unless the Compensation Committee specifically determines otherwise, the maximum number of shares available under the Plans and the awards granted under the Plans will be subject to appropriate adjustment in the case of any stock dividends, stock splits, recapitalizations, reorganizations, mergers, consolidations, exchanges or other changes in capitalization affecting the Companyâ€™s common stock. The awards may be made in the form of restricted stock awards or stock options, among other things. As of June 30, 2024 and December 31, 2023, 295,223 and 312,973 shares were available to be granted under the Plans, respectively. A A On February 1, 2020, a total of 35,000A shares of restricted stock were issued to employees. The restricted shares vest 25% per year over a four-year period. The grant date fair value of $4.11 per share is being recognized as expense on a straight-line basis over the vesting period. During the six months ended June 30, 2024, 2,500 shares of common stock vested. As of June 30, 2024, the shares issued on February 1, 2020 were fully vested. A On July 21, 2021, a total of 130,000A shares of restricted stock were issued to employees and board members. The restricted shares vest 25% at grant date and 25% per year over a three-year period. The grant date fair value of $3.84 per share is being recognized as expense on a straight-line basis over the vesting period. No additional restricted shares vested during the six months ended June 30, 2024. A On December 19, 2022, a total of 77,000A shares of restricted stock were issued to employees. The restricted shares vest 25% per year over a four-year period. The fair value of $6.40 per share, the stock price on grant date, is being recognized as expense on a straight-line basis over the vesting period. During the six months ended June 30, 2024, 2,250 shares of unvested common stock were forfeited due to the termination of three employees. A On January 26, 2023, 10,000 shares of common stock were issued to an employee and were recorded at the fair value of $8.96 per share, the stock price on the grant date. The shares were fully vested on the grant date. A On January 11, 2024, 20,000 shares of common stock with a fair value of $2.65 per share, the stock price on the grant date, were issued to an employee. 10,000 of the shares were vested and the expense related to these shares was recognized on the grant date. The remaining 10,000 shares are scheduled to cliff vest in January 2025. The grant date fair value of $2.65 per share is being recognized as expense on a straight-line basis over the vesting period. The grant date fair value is being recognized as expense on a straight-line basis over the vesting period.A Restricted Stock A Restricted stock activity for the six months ended June 30, 2024 is summarized below: A Outstanding at A Restricted Stock A Weighted- Average Grant Date Fair ValueA December 31, 2023A A 89,750A A $5.41A GrantedA A 20,000A A 2.65A VestedA A (12,500)A A 2.94A ForfeitedA A (2,250)A A $6.40A June 30, 2024A A 95,000A A $5.13A A The Company recognizes forfeitures as they occur. The reduction of stock compensation expense related to the forfeitures was $1 thousandA and $1 thousand for the three months ended June 30, 2024 and 2023, respectively, and $2 thousand and $19 thousand for the six months ended June 30, 2024 and 2023, respectively. A Stock compensation expense related to restricted stock, excluding the recognition of forfeitures, was $66 thousand and $67 thousand for the three months ended June 30, 2024 and 2023, respectively, and $158 thousand and $228 thousand for the six months ended June 30, 2024 and 2023, respectively. A Unrecognized stock compensation expense was $292A thousand as of June 30, 2024, which will be recognized over a weighted-average period of 2.3A years. A Stock Options A Stock options expire ten years after the grant date. Options that have been granted are exercisable and vest based on the terms of the related agreements. A The following table summarizes the Companyâ€™s stock options activity: A A Number of OptionsA A Weighted- Average Exercise PriceA A Weighted- Average Remaining Contractual Term (In Years)A Outstanding - December 31, 2023A A 89,550A A $5.55A A 4.08A GrantedA A -A A -A A -A ExercisedA A (3,000)A A 5.55A A -A A -A A -A Outstanding - June 30, 2024A A 86,550A A $5.55A A 3.58A Exercisable â€” June 30, 2024A A 86,550A A $5.55A A 3.58A A No stock compensation expense related to stock options was incurred for the three and six months ended June 30, 2024 and 2023. The stock options outstanding had an intrinsic value of $0 as of June 30, 2024 and December 31, 2023. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: <a href=): <http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4): [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5): [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6): [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income Taxes 6 Months Ended Jun. 30, 2024 Income Taxes [Abstract] A Income Taxes Note 9 â€” Income Taxes A The Company accounts for income taxes in accordance with ASC 740, Income Taxes, (â€œASC 740â€), which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. A Effective income tax rates for interim periods are based upon the Companyâ€™s current estimated annual tax rate, which varies based upon the Companyâ€™s estimate of taxable earnings or loss and the mix of taxable earnings or loss in the various states in which the Company operates. In addition, the Company recognizes taxes related to unusual or infrequent items or resulting from a change in judgment regarding a position taken in a prior period as discrete items in the interim period in which the event occurs. A As of June 30, 2024 and 2023, management determined there continues to be sufficient positive evidence that it is more likely than not that the net deferred tax asset (other than foreign net operation losses) is realizable. A Income tax expense (benefit) was $79 thousand and ($502)A thousand for the three months ended June 30, 2024 and 2023, respectively. Income tax expense (benefit) was $1,406 thousand and ($1,303) thousand for the six months ended June 30, 2024 and 2023, respectively. A The effective tax rates for the three months ended June 30, 2024 and 2023 were 26.4% and 56.9%, respectively. The effective tax rates for the six months ended June 30, 2024 and 2023 were 26.6% and 36.4%, respectively. The decrease in the effective tax rate for the three and six months ended June 30, 2024 compared to the prior year periods was primarily due to a decrease in nondeductible expenses and an increase in the estimated tax credits that are expected to be generated and utilized. A The effective tax rate differs from the U.S. federal statutory rate for the three and six months ended June 30, 2024, primarily due to nondeductible expenses, state income taxes and the favorable impact of tax credits. The effective tax rate differs from the U.S. federal statutory rate for the three and six months ended June 30, 2023, primarily due to nondeductible expenses and state income taxes. A As of June 30, 2024, the Companyâ€™s U.S. federal and certain state tax returns remain subject to examination, beginning with those filed for the year ended December 31, 2017. X - ReferencesNo definition available. + Details Name: us-gaap IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: <a href=): <http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 6.1.5.Q1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.1.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7): <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(h\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9): <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13): [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SAB Topic 11.C\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14):

statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1:

The following table illustrates total revenue for the three months ended June 30, 2024 and December 31, 2023, respectively.

	June 30, 2024	December 31, 2023
Total Revenue	\$8,667A	\$9,239A
Cash and Cash Equivalents	\$4,327A	\$4,527A
Accounts Receivable	\$1,161A	\$1,161A
Inventories	\$1,161A	\$1,161A
Other Assets	\$2,008A	\$2,450A

The Company uses a fair value hierarchy that prioritizes inputs to valuation approaches used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. Assets and liabilities measured and reported at fair value are classified and disclosed in one of the following categories:

- Level 1 Inputs: Quoted prices (unadjusted) in active markets for identical assets or liabilities at the reporting date.
- Level 2 Inputs: Inputs other than Level 1 inputs which are based on observable market data.
- Level 3 Inputs: Unobservable inputs for the valuation of the asset or liability, which may include nonbinding broker quotes.

Significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the financial instrument. Cash and Cash Equivalents primarily consist of cash, money market funds and short-term, highly liquid investments with original maturities of three months or less. Accounts Receivable consists of business and extends credit based on an evaluation of each customer's financial condition, generally without requiring collateral. Exposure to losses on receivables is expected to vary by customer due to the financial condition of each customer. The Company estimates future credit losses based on the age of customer receivable balances, collection history and forecasted economic trends. Future collections can be significantly different from historical collection trends or current estimates. The Company monitors exposure to credit losses and maintains allowances for anticipated losses considered necessary under the circumstances. The allowance for expected credit losses was \$42 thousand and \$0 as of June 30, 2024 and December 31, 2023, respectively. Credit loss expense was \$42 thousand and \$5 thousand for the three months ended June, 2024 and 2023, respectively, and \$42 thousand and \$5 thousand for the six months ended June, 2024 and 2023, respectively.

Inventories consist of finished product and components and are stated at the lower of cost and net realizable value, determined using the first-in-first-out method. Basic net income (loss) per share is calculated by dividing the net income by the weighted-average number of common shares outstanding for the period using the treasury stock method for options, restricted stocks and warrants. Diluted net income (loss) per share is computed by giving effect to all potential dilutive common share equivalents outstanding for the period. The factors used in the net income (loss) per share computation are as follows:

	Basic	Diluted
Net Income (Loss)	\$1,612A	\$(380)A
Weighted Average Number of Shares Used in Computing Net Income (Loss) Per Share	16,298A	16,297A
Net Income (Loss) Per Share - Basic	\$0.10A	\$(0.02)A
Net Income (Loss) Per Share - Diluted	\$0.10A	\$(0.02)A

The diluted effects of the Restricted Stock Awards were immaterial for the periods presented below were not included in the computation of diluted net income (loss).

The Company evaluates arrangements at inception to determine if an arrangement is or contains a lease. Operating lease assets represent the company's right to control an underlying asset for the lease term, and operating lease liability represents the company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the company if the company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the company includes options to extend or terminate the lease when it is reasonably certain that the company will exercise that option. The company uses an incremental borrowing rate that the company would expect to incur for a fully collateralized loan over a similar term under similar economic conditions to determine the present value of the lease payments. The company has lease agreements which include lease and non-lease components, which the company has elected to account for as a single lease component for all classes of underlying assets. The lease payments used to determine the company's operating lease assets may include lease incentives, and stated rent increases are recognized in the company's operating lease assets in the condensed consolidated balance sheets. Operating lease assets are amortized to rent expense over the lease term and included in operating expenses in the condensed consolidated statements of income. For leases in which the company is the lessor, the company identifies the lease and non-lease components and allocates the contract consideration to the different components on a relative standalone selling price basis at lease inception. The company uses a residual approach for the components when the standalone selling price is not directly observable or those for which the company has not established a price. The company elects the practical expedient to combine lease and non-lease components when the components qualify to be combined. Continuous supporting services are the primary non-lease components and are not predominant. As a result, the combined components are accounted for as a lease under ASC 842. Leases. The revenues from non-lease components that are not qualified to be combined are recognized when the services are rendered under ASC 606, Revenue from Contracts with Customers. The revenues from non-lease components were \$50 thousand for the three and six months ended June 30, 2024. For operating leases where the company is the lessor, the company recognizes the underlying assets and depreciates them over the estimated useful life which is based upon to estimate the residual value expected at the end of the lease term. Lease income is recognized on a straight-line basis over the lease term. Leasing revenue is not recognized when collection of all contractual rents over the term of the agreement is not probable. When collection is not probable, the company limits the lease revenue to the lesser of the revenue recognized on a straight-line basis or cash basis. The lease income is included in revenues in the condensed consolidated statements of income. Variable lease payments associated with the leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented within revenues in the condensed consolidated statements of income. Income Taxes. The company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the company's financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Uncertain tax positions are recognized in the financial statements only if that position is more likely than not to be sustained upon examination by taxing authorities, based on the technical merits of the position. The company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. Recent Accounting Pronouncements. In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-4, Reference Rate Reform (Topic 848). Facilitation of the Effects of Reference Rate Reform on Financial Reporting, to provide temporary optional expediting and exceptions to U.S. GAAP guidance on contract modifications to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate, or LIBOR, to alternative reference rates, such as the Secured Overnight Financing Rate. Entities can elect not to apply certain modification accounting requirements to contracts affected by what the guidance calls reference rate reform if certain criteria are met. An entity that makes this election would not have to remeasure the contracts at the modification date or reassess a previous accounting determination. The guidance was originally effective as of March 12, 2020 through December 31, 2022 and interim periods within those fiscal years. In December 2022, the FASB issued ASU 2022-06, Deferral of the Sunset Date of Topic 848 which was issued to defer the sunset date of Topic 848 to December 31, 2024. These updates are not expected to have a significant impact on the company's condensed consolidated financial statements. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures, to enhance disclosures about significant segment expenses for public entities reporting segment information under ASC Topic 280. The amendments require public entities to disclose significant expense categories for each reportable segment, other segment items, the title and position of the chief operating decision-maker, and interim disclosures of certain segment-related information previously required only on an annual basis. The amendments clarify that entities reporting single segments must disclose both the new and existing segment disclosures under Topic 280, and a public entity is permitted to disclose multiple measures of segment profit or loss if certain criteria are met. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The company is currently evaluating the impact of this standard on its condensed consolidated financial statements and related disclosures. In March 2024, the FASB issued ASU 2024-01, Compensation - Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards, to clarify how an entity determines whether a profits interest or similar award is within the scope of Topic 718 or is not a share-based payment arrangement and therefore within the scope of other guidance. ASU 2024-01 provides an illustrative example with multiple fact patterns and also amends certain language in the "Scope" sections of Topic 718 to improve its clarity and operability without changing the guidance. The ASU is effective for fiscal years beginning after December 15, 2024, and interim periods within those annual periods. Early adoption is permitted. These updates are not expected to have a significant impact on the company's condensed consolidated financial statements. X - Definition Disclosure of accounting policy for geographical information. + References No definition available. + Details Name: srts :GeographicalInformationPolicyTextBlock Namespace Prefix: srts Data Type: dtr:textBlockItemType Balance Type: us-gaap Duration X - References No definition available. + Details Name: us-gaap AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: us-gaap Duration X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent+Details Name: us-gaap BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: us-gaap Duration X - DefinitionThe entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent+Details Name: us-gaap BusinessDescriptionAndAccountingPoliciesTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: us-gaap Duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1+Details Name: us-gaap CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: us-gaap Duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/214748898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1+Details Name: us-gaap ConcentrationRiskCreditRiskNamespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: us-gaap Duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2+Details Name: us-gaap EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: us-gaap Duration X - DefinitionDisclosure of accounting

policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + ReferencesNo definition available. + Details Name: us-gaap FairValueMeasurementPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-1> + Details Name: us-gaap FairValueOffinancialInstrumentsPolicy Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-20>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-19>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482525/740-10-45-25>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 999 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-50-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-17>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-9>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482525/740-10-45-28>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-1> + Details Name: us-gaap IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 999 -Paragraph 1 -Subparagraph (SX 210.5-02(g)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483080/330-10-50-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483489/210-10-50-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483426/235-10-50-4>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478411/912-330-50-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/330/tableOfContent>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483080/330-10-50-4>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 270 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482989/270-10-45-6> + Details Name: us-gaap InventoryPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-1> + Details Name: us-gaap LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483504/205-10-50-1> + Details Name: us-gaap PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-17>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-19>Reference 3:

3Ã years Computer equipmentÃ Ã 148ÃÃ Ã 145ÃÃ Ã 3Ã years SubtotalÃ Ã 2,458ÃÃ Ã 2,347ÃÃ Ã Ã Construction in progressÃ Ã 228ÃÃ Ã Ã Ã Ã Less accumulated depreciationÃ Ã 1,974ÃÃ Ã 1,883ÃÃ Ã Property and Equipment, NetÃ Ã \$712ÃÃ Ã \$464ÃÃ Ã X - ReferencesNo definition available. + Details Name: us-gaap PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Product Warranties (Tables) 6 Months Ended Jun. 30, 2024 Product Warranties [Abstract]Ã Ã Schedule of Changes in Product Warranty Liability Changes in product warranty liability were as follows for the six months ended Jun. 30, 2024: (in thousands)Ã Ã Ã Balance, December 31, 2023Ã Ã \$538Ã Ã Warranties accrued during the periodÃ Ã Ã 186Ã Ã Payments on warranty claimsÃ Ã Ã (207)Ã Ã Balance, June 30, 2024Ã Ã \$517Ã Ã X - ReferencesNo definition available. + Details Name: us-gaap ProductWarrantiesDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482425/460-10-50-8> + Details Name: us-gaap ScheduleOfProductWarrantyLiabilityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases (Tables) 6 Months Ended Jun. 30, 2024 Leases [Abstract]Ã Ã Schedule of Received Lease Agreements Future minimum lease payments under the CompanyÃ Ã s non-cancellable leases as of June 30, 2024 are as follows: Maturity of Operating Lease LiabilityÃ Ã AmountÃ Ã 2024 (July 1 - December 31, 2024)Ã Ã \$112Ã Ã 2025Ã Ã Ã 229Ã Ã 2026Ã Ã Ã 236Ã Ã 2027Ã Ã Ã 181Ã Ã Total undiscounted operating leases paymentsÃ Ã \$758Ã Ã Less: Imputed interestÃ Ã Ã (60)Ã Ã Present Value of Operating Lease LiabilityÃ Ã \$698Ã Ã Operating lease liability, current portionÃ Ã \$195Ã Ã Operating lease liability, net of current portionÃ Ã \$503Ã Ã Ã Ã Ã Ã Other InformationÃ Ã Ã Ã Ã Ã Weighted-average remaining lease termÃ Ã Ã 3.25 yearsÃ Ã Weighted-average discount rateÃ Ã Ã 5%Ã Ã Schedule of Operating Lease Income The component of lease income for the three and six months ended June 30, 2024 is as follows: (in thousands)Ã Ã For the ThreeÃ Ã MonthsÃ Ã Ended June 30, 2024Ã Ã Ã For the SixÃ Ã MonthsÃ Ã Ended June 30, 2024Ã Ã Lease income - operating leasesÃ Ã \$41Ã Ã Ã \$41Ã Ã Schedule of Received Lease Agreements The future minimum fixed lease payments to be received under the lease agreements as of June 30, 2024 are as follows: (in thousands)Ã Ã AmountÃ Ã 2024 (July 1 - December 31, 2024)Ã Ã \$128Ã Ã 2025Ã Ã Ã 256Ã Ã 2026Ã Ã Ã 256Ã Ã 2027Ã Ã Ã 256Ã Ã 2028Ã Ã Ã 256Ã Ã ThereafterÃ Ã Ã 343Ã Ã TotalÃ Ã \$1,495Ã Ã X - DefinitionTabular disclosure of schedule of received lease agreements. + ReferencesNo definition available. + Details Name: srts ScheduleOfReceivedLeaseAgreementsTableTextBlock Namespace Prefix: srts_ Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of components of income from operating lease. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479773/842-30-50-5>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-6A> + Details Name: us-gaap OperatingLeaseLeaseIncomeTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-Based Compensation (Tables) 6 Months Ended Jun. 30, 2024 Equity-Based Compensation [Abstract]Ã Ã Schedule of Restricted Stock Activity Restricted stock activity for the six months ended June 30, 2024 is summarized below: Outstanding atÃ Ã Restricted StockÃ Ã Ã Weighted- Average Grant Date Fair ValueÃ Ã December 31, 2023Ã Ã Ã 89,750Ã Ã Ã \$5.41Ã Ã GrantedÃ Ã Ã 20,000Ã Ã Ã Ã 2.65Ã Ã VestedÃ Ã Ã (12,500)Ã Ã Ã 2.94Ã Ã ForfeitedÃ Ã Ã (2,250)Ã Ã Ã \$6.40Ã Ã June 30, 2024Ã Ã Ã 95,000Ã Ã Ã \$5.13Ã Ã Schedule of Stock Option Activity The following table summarizes the CompanyÃ Ã s stock options activity:Ã Ã Ã Number of OptionsÃ Ã Ã Weighted- Average Exercise PriceÃ Ã Ã Weighted- Average Remaining Contractual Term (in Years)Ã Ã Outstanding - December 31, 2023Ã Ã Ã 89,550Ã Ã Ã \$5.55Ã Ã Ã 4.08Ã Ã GrantedÃ Ã Ã -Ã Ã Ã -Ã Ã Ã -Ã Ã ExercisedÃ Ã Ã (3,000)Ã Ã Ã 5.55Ã Ã Ã -Ã Ã ExpiredÃ Ã Ã -Ã Ã Ã -Ã Ã Ã -Ã Ã Outstanding - June 30, 2024Ã Ã Ã 86,550Ã Ã Ã \$5.55Ã Ã Ã 3.58Ã Ã Exercisable æ“ June 30, 2024Ã Ã Ã 86,550Ã Ã Ã \$5.55Ã Ã Ã 3.58Ã Ã X - ReferencesNo definition available. + Details Name: us-gaap DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Organization and Summary of Significant Accounting Policies (Details) - USD (\$) (in Thousands 3 Months Ended 6 Months Ended 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2023 Jun. 30, 2023 Dec. 31, 2023 Organization and Summary of Significant Accounting Policies [Line Items]Ã Ã Ã Ã Ã Ã Allowance for expected credit lossesÃ Ã Ã Ã \$2 Ã Ã \$0Ã Ã Credit loss expenseÃ Ã \$2 Ã Ã \$5Ã Ã \$2 Ã Ã \$5Ã Ã Restricted shares issued (in Shares)Ã Ã Ã 52,500Ã Ã Ã Ã Revenues from non-lease componentsÃ Ã \$50Ã Ã Ã Ã Ã Ã Customer Concentration Risk [Member] | Customer [Member] | Revenue [Member]Ã Ã Ã Ã Ã Ã Organization and Summary of Significant Accounting Policies [Line Items]Ã Ã Ã Ã Ã Ã Concentration risk percentage 83.00% 46.00% 77.00% 52.00%Ã Ã Ã Customer Concentration Risk [Member] | Customer [Member] | Accounts receivable [Member]Ã Ã Ã Ã Ã Ã Organization and Summary of Significant Accounting Policies [Line Items]Ã Ã Ã Ã Ã Ã Concentration risk percentageÃ Ã Ã 92.00%Ã Ã 85.00%Ã Ã X - DefinitionRepresent the amount of revenue from non lease components. + ReferencesNo definition available. + Details Name: srts RevenuesFromNonLeaseComponents Namespace Prefix: srts_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in allowance for credit loss on accounts receivable. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479319/326-20-50-13> + Details Name: us-gaap AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4> + Details Name: us-gaap ChangeInAccountingEstimateLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-21>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-20>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-18>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482861/275-10-50-20> + Details Name: us-gaap ConcentrationRiskPercentagel1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479319/326-20-50-13>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.0-3(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap ConcentrationRiskByTypeAxis=us-gaap CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt MajorCustomersAxis=srts CustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ConcentrationRiskByBenchmarkAxis=us-gaap SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ConcentrationRiskByBenchmarkAxis=us-gaap AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Organization and Summary of Significant Accounting Policies (Details) - Schedule of Disaggregated Revenue - USD (\$) (in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2023 Jun. 30, 2023 Schedule of Disaggregated Revenue [Line Items]Ã Ã Ã Ã Ã Ã Revenue 9,239 4,527 19,902 7,941 Product Revenue - recognized at a point in time [Member]Ã Ã Ã Ã Ã Ã Schedule of Disaggregated Revenue [Line Items]Ã Ã Ã Ã Ã Ã Revenue 8,074 3,524 17,566 5,993 Service Revenue - recognized at a point in time [Member]Ã Ã Ã Ã Ã Ã Schedule of Disaggregated Revenue [Line Items]Ã Ã Ã Ã Ã Ã Revenue 367 306 739 647 Service Revenue - recognized over time [Member]Ã Ã Ã Ã Ã Ã Schedule of Disaggregated Revenue [Line Items]Ã Ã Ã Ã Ã Ã Revenue 798 697 1,597 1,301Ã Ã - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-5>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91>Reference 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91>Reference 6: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91>Reference 7: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91>Reference 8: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91> + Details Name: us-gaap DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-41>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 5: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher

FSB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 13:

Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_CN Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_IE Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=srts_OtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42.R30.htm IDEA: XBRL DOCUMENT v3.24.2.1 Organization and Summary of Significant Accounting Policies (Details) - Schedule of Earnings Per Share Computation - Earnings Per Share [Member] - USD (\$) \$ / shares in Units, \$ in Thousands 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Basic A A A A Net income (loss) (in Dollars) \$ 1,612 \$ (380) \$ 3,886 \$ (2,274) Weighted average number of shares used in computing net income (loss) per share â€” basic 16,298 16,250 16,297 16,248 Dilutive effects of: A A A A Restricted stock awards 35 29 Net income (loss) per share - basic (in Dollars per share) \$ 0.1 \$ (0.02) \$ 0.24 \$ (0.14) Diluted A A A A Net income (loss) (in Dollars) \$ 1,612 \$ (380) \$ 3,886 \$ (2,274) Weighted average number of shares used in computing net income (loss) per share â€” basic 16,298 16,250 16,297 16,248 Weighted average number of shares used in computing net income (loss) per share â€” diluted 16,333 16,250 16,326 16,248 Net income (loss) per share - diluted (in Dollars per share) \$ 0.1 \$ (0.02) \$ 0.24 \$ (0.14) Restricted stock awards [Member] A A A A per share because to do so would have been antidilutive for the periods presented: A A A A Antidilutive stock 52,500 146,000 52,500 146,000 Stock Options [Member] A A A A per share because to do so would have been antidilutive for the periods presented: A A A A Antidilutive stock 86,550 89,550 86,550 89,550 X - References No definition available. + Details Name: srts_PerShareBecauseToDoSoWouldHaveBeenAntidilutiveForThePeriodsPresentedAbstract Namespace Prefix: srts_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1) + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - References No definition available. + Details Name: us-gaap_DilutiveSecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6> Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2) Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3> Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15> Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1) Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1) Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11) Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11) Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11) Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2> Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2> Reference 14: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4> Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1) Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10> Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1) Reference 20: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dt:types:perShareItem Type Balance Type: na Period Type: duration X - Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6> Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2) Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3> Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15> Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1) Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1) Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11) Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11) Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11) Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2> Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2> Reference 14: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4> Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1) Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1) Reference 19: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dt:types:perShareItem Type Balance Type: na Period Type: duration X - Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3) Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28) Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6> Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3> Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1) Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1) Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8> Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11) Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11) Reference 16:

Section 45 - Paragraph 60B - Publisher FASB - URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33:

gaap DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDescription of restrictions on the entity's other assets as required by the terms of the credit facility. + ReferencesReference 1:

Balance Type: debit Period Type: instant X - DefinitionAmount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <https://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI> [http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI](https://asc.fasb.org/1943274/2147479773/842-30-50-12 + Details Name: us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-12 + Details Name: us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-12 + Details Name: us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-12 + Details Name: us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-12 + Details Name: us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Commitments and Contingencies [Abstract] A A A Inventory finished goods $ 0 $ 1,200 $ 5,700 $ 7,900 Finished goods received 300 $ 4,500 5,200 $ 7,700 A Prepayment related to these finished goods $ 3,333 A $ 3,333 A $ 2,986 X - DefinitionFinished goods received. + ReferencesNo definition available. + Details Name: srts_FinishedGoodsReceived Namespace Prefix: srts_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresent the amount of payment of inventory finished goods. + ReferencesNo definition available. + Details Name: srts_PaymentofInventoryFinishedGoods Namespace Prefix: srts_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: <a href=)

<https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25:](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25:) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26:](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26:) [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27:](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27:)

Section 50 - Paragraph 2 - Subparagraph (c)(2)(ii) Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(2)(iii) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(2)(iii)(01) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(2)(iii)(02) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(2)(iii)(03) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (d)(1) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (d)(2) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (e)(1) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (e)(2) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (f)(2)(i) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (f)(2)(ii) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (f)(2)(iii) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (f)(2)(iv) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (f)(2)(v) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap AwardTypeAxis=us-gaap RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML \$S R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Equity-Based Compensation (Details) - Schedule of Stock Option Activity - Stock Options [Member] 6 Months Ended Dec. 31, 2023 \$ / shares shares Jun. 30, 2024 \$ / shares shares Schedule of Stock Option Activity [Line Items] A Number of Options, Outstanding | shares 89,550 86,550 Weighted- Average Exercise Price, Outstanding | \$ / shares \$ 5.55 \$ 5.55 Weighted- Average Remaining Contractual Term (In Years), Outstanding 4 years 29 days 3 years 6 months 29 days Number of Options, Exercisable | shares A 86,550 Weighted- Average Exercise Price, Exercisable | \$ / shares A \$ 5.55 Weighted- Average Remaining Contractual Term (In Years), Exercisable A 3 years 6 months 29 days Number of Options, Granted | shares A Weighted- Average Exercise Price, Granted | \$ / shares A Weighted- Average Remaining Contractual Term (In Years), Granted A Number of Options, Exercised | shares A (3,000) Weighted- Average Exercise Price, Exercised | \$ / shares A \$ 5.55 Weighted- Average Remaining Contractual Term (In Years), Exercised A Number of Options, Expired | shares A Weighted- Average Exercise Price, Expired | \$ / shares A Weighted- Average Remaining Contractual Term (In Years), Expired A X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYmMndTnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days, + ReferencesNo definition available, + Details Name: srts SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm Namespace Prefix: srts Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYmMndTnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days, + ReferencesNo definition available, + Details Name: srts SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm Namespace Prefix: srts Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYmMndTnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days, + ReferencesNo definition available, + Details Name: srts SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm Namespace Prefix: srts Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table, + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 35 - Paragraph 3 - Publisher FASB - URI https://asc.fasb.org/1943274/2147480483/718-10-35-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 35 - Paragraph 3 - Publisher FASB - URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (a)(1) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (a)(2) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (a)(3) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(i) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(ii) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(iii) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(iv) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(iv)(01) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(iv)(02) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(iv)(03) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(iv)(04) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(2)(i) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(2)(ii) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(2)(iii) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(2)(iii)(01) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(2)(iii)(02) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef - Topic

[illegible]

M3P0W\$07SZ4M>B+[,7FK71/(RVVNWW>U7UGY[IJW7.6ALW.U -KK&S=AE2V/D #1#ZN2DN #5%GNG;6&[XJ]>=OT)A*A=XY[MZ510%Y7;IE7U1Z>:ERW9DI""W G MEUWD)<RHRNNU:9%HSCLP1%?@i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s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~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i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

[illegible]

[The following text contains extremely dense, non-readable characters and symbols, likely representing corrupted or encrypted data.]

(@/C&W=VJR;W-H965T&UL4\$L! A0#% @ 8W<-60J[F]>6 @ 808 M ID ("ID+P 'AL+W=O&P=VJR;W-H965TS' IX; "JW;W)K&UL4\$L! A0#% @ 8W<-66N=N") @ P < ID M ("I9LL 'AL+W=O&P=VJR;W-H965T M&UL4\$L! A0# M% @ 8W<-6<0C>>V? @ >08 ID ("IB-8 'AL+W=O MV0 >&P=VJR;W-H965T&UL4\$L! A0#% @ 8W<-633 MY&98 @ '04 ID ("I. 'AL+W=O+I,&-" #!1 @ &O M @ (SWXP >&P=VJR;W-H965T&UL4\$L! A0#% @ 8W<-64&OIJ^ @ .PD ID M ("I^D 'AL+W=O&P M=VJR;W-H965T&UL4\$L! A0#% @ 8W<-6>U.S. Securities and Exchange Commission. Data and content created by government employees under the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {} ;Show.LastAR=null, Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeNamed!= 'TABLE')e=e.nextSibling;if(!e/e.nodeNamed!= 'TABLE'){var ref= ((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e.le.style.display='block';Show.LastAR=);Show.hideAR=function(){Show.LastAR.style.display='none';Show.toggleNext=function(a){var e=a;while(e.nodeNamed!= 'DIV')e=e.nextSibling;if(!e.style){e.style.display=''} else{var d,p;e.style.display='none'} } } else{d='none';p='+' } e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)} else{a.innerHTML=p+a.innerHTML.substring(1)}} } } XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.0.24 */ /* DeRef Styles */ .report table.authRefData { background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table { font-size: 1em; } /* Report Styles */ .pl a .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; } /* word-wrap: break-word; */ } .report td.pl a a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div a { width: 200px; } .report td.pl a: hover { background-color: #ffc; } /* Header rows... */ .report tr.th { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report rc { background-color: #f0f0f0; } /* Even rows... */ .report re .report reu { background-color: #def; } .report reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report ro .report rou { background-color: white; } .report rou td { border-bottom: 1px solid black; } .report rou table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report fn { white-space: nowrap; } /* styles for numeric types */ .report .num .report .num { text-align: right; white-space: nowrap; } .report .num { padding-left: 2em; } .report .num { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 174 244 1 false 36 0 false 4 false false R1.htm 995100 - Document - Cover Sheet http://xbrl.sec.gov/dei/role/document/Cover Cover Cover 1 false false R2.htm 995301 - Statement - Condensed Consolidated Balance Sheets Sheet http://sensushhealthcare.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 995302 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://sensushhealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 995303 - Statement - Condensed Consolidated Statements of Income (Loss) (Unaudited) Sheet http://sensushhealthcare.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Income (Loss) (Unaudited) Statements 4 false false R5.htm 995304 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://sensushhealthcare.com/role/ShareholdersEquityType2or3 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://sensushhealthcare.com/role/ConsolidatedCashFlow Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 995306 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 7 false false R8.htm 995307 - Disclosure - Property and Equipment Sheet http://sensushhealthcare.com/role/PropertyandEquipment Property and Equipment Notes 8 false false R9.htm 995308 - Disclosure - Debt Sheet http://sensushhealthcare.com/role/Debt Debt Notes 9 false false R10.htm 995309 - Disclosure - Product Warranties Sheet http://sensushhealthcare.com/role/ProductWarranties Product Warranties Notes 10 false false R11.htm 995310 - Disclosure - Leases Sheet http://sensushhealthcare.com/role/Leases Leases Notes 11 false false R12.htm 995311 - Disclosure - Commitments and Contingencies Sheet http://sensushhealthcare.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 12 false false R13.htm 995312 - Disclosure - Stockholders' Equity Sheet http://sensushhealthcare.com/role/StockholdersEquity Stockholders' Equity Notes 13 false false R14.htm 995313 - Disclosure - Equity-Based Compensation Sheet http://sensushhealthcare.com/role/EquityBasedCompensation Equity-Based Compensation Notes 14 false false R15.htm 995314 - Disclosure - Income Taxes Sheet http://sensushhealthcare.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 995315 - Disclosure - Subsequent Events Sheet http://sensushhealthcare.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 17 false false R18.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 18 false false R19.htm 996000 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://sensushhealthcare.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies 19 false false R20.htm 996001 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) Sheet http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables Organization and Summary of Significant Accounting Policies (Tables) Tables http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPolicies 20 false false R21.htm 996002 - Disclosure - Property and Equipment (Tables) Sheet http://sensushhealthcare.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://sensushhealthcare.com/role/PropertyandEquipment 21 false false R22.htm 996003 - Disclosure - Product Warranties (Tables) Sheet http://sensushhealthcare.com/role/ProductWarrantiesTables Product Warranties (Tables) Tables http://sensushhealthcare.com/role/ProductWarranties 22 false false R23.htm 996004 - Disclosure - Leases (Tables) Sheet http://sensushhealthcare.com/role/LeasesTables Leases (Tables) Tables http://sensushhealthcare.com/role/Leases 23 false false R24.htm 996005 - Disclosure - Equity-Based Compensation (Tables) Sheet http://sensushhealthcare.com/role/EquityBasedCompensationTables Equity-Based Compensation (Tables) Tables http://sensushhealthcare.com/role/EquityBasedCompensation 24 false false R25.htm 996006 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) Sheet http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails Organization and Summary of Significant Accounting Policies (Details) Details http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables 25 false false R26.htm 996007 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) - Schedule of Disaggregated Revenue Sheet http://sensushhealthcare.com/role/ScheduleofDisaggregatedRevenueTable Organization and Summary of Significant Accounting Policies (Details) - Schedule of Disaggregated Revenue Details http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables 26 false false R27.htm 996008 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) - Schedule of Deferred Revenue Sheet http://sensushhealthcare.com/role/ScheduleofDeferredRevenueTable Organization and Summary of Significant Accounting Policies (Details) - Schedule of Deferred Revenue Details http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables 27 false false R28.htm 996009 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) - Schedule of Remaining Performance Obligations Sheet http://sensushhealthcare.com/role/ScheduleofRemainingPerformanceObligationsTable Organization and Summary of Significant Accounting Policies (Details) - Schedule of Remaining Performance Obligations Details http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables 28 false false R29.htm 996010 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) - Schedule of Total Revenue Sheet http://sensushhealthcare.com/role/ScheduleofTotalRevenueTable Organization and Summary of Significant Accounting Policies (Details) - Schedule of Total Revenue Details http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables 29 false false R30.htm 996011 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) - Schedule of Earnings Per Share Computation Sheet http://sensushhealthcare.com/role/ScheduleofEarningsPerShareComputationTable Organization and Summary of Significant Accounting Policies (Details) - Schedule of Earnings Per Share Computation Details http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables 30 false false R31.htm 996012 - Disclosure - Property and Equipment (Details) Sheet http://sensushhealthcare.com/role/PropertyandEquipmentDetails Property and Equipment (Details) Details http://sensushhealthcare.com/role/PropertyandEquipmentTables 31 false false R32.htm 996013 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment Sheet http://sensushhealthcare.com/role/ScheduleofPropertyandEquipmentTable Property and Equipment (Details) - Schedule of Property and Equipment Details http://sensushhealthcare.com/role/PropertyandEquipmentTables 32 false false R33.htm 996014 - Disclosure - Debt (Details) Sheet http://sensushhealthcare.com/role/DebtDetails Debt (Details) Details http://sensushhealthcare.com/role/Debt 33 false false R34.htm 996015 - Disclosure - Product Warranties (Details) - Schedule of Changes in Product Warranty Liability Sheet http://sensushhealthcare.com/role/ScheduleofChangesinProductWarrantyLiabilityTable Product Warranties (Details) - Schedule of Changes in Product Warranty Liability Details http://sensushhealthcare.com/role/ProductWarrantiesTables 34 false false R35.htm 996016 - Disclosure - Leases (Details) Sheet http://sensushhealthcare.com/role/LeasesDetails Leases (Details) Details http://sensushhealthcare.com/role/LeasesTables 35 false false R36.htm 996017 - Disclosure - Leases (Details) - Schedule of Maturity Non cancellable leases Sheet http://sensushhealthcare.com/role/ScheduleofMaturityNoncancellableleasesTable Leases (Details) - Schedule of Maturity Non cancellable leases Details http://sensushhealthcare.com/role/LeasesTables 36 false false R37.htm 996018 - Disclosure - Leases (Details) - Schedule of Operating Lease Income Sheet http://sensushhealthcare.com/role/ScheduleofOperatingLeaseIncomeTable Leases (Details) - Schedule of Operating Lease Income Details http://sensushhealthcare.com/role/LeasesTables 37 false false R38.htm 996019 - Disclosure - Leases (Details) - Schedule of Received Lease Agreements Sheet http://sensushhealthcare.com/role/ScheduleofReceivedLeaseAgreementsTable Leases (Details) - Schedule of Received Lease Agreements Details http://sensushhealthcare.com/role/LeasesTables 38 false false R39.htm 996020 - Disclosure - Commitments and Contingencies (Details) Sheet http://sensushhealthcare.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://sensushhealthcare.com/role/CommitmentsandContingencies 39 false false R40.htm 996021 - Disclosure - Stockholders' Equity (Details) Sheet http://sensushhealthcare.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://sensushhealthcare.com/role/StockholdersEquity 40 false false R41.htm 996022 - Disclosure - Equity-Based Compensation (Details) Sheet http://sensushhealthcare.com/role/EquityBasedCompensationDetails Equity-Based Compensation (Details) Details http://sensushhealthcare.com/role/EquityBasedCompensationTables 41 false false R42.htm 996023 - Disclosure - Equity-Based Compensation (Details) - Schedule of Restricted Stock Activity Sheet http://sensushhealthcare.com/role/ScheduleofRestrictedStockActivityTable Equity-Based Compensation (Details) - Schedule of Restricted Stock Activity Details http://sensushhealthcare.com/role/EquityBasedCompensationTables 42 false false R43.htm 996024 - Disclosure - Equity-Based Compensation (Details) - Schedule of Stock Option Activity Sheet http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable Equity-Based Compensation (Details) - Schedule of Stock Option Activity Details http://sensushhealthcare.com/role/EquityBasedCompensationTables 43 false false R44.htm 996025 - Disclosure - Income Taxes (Details) Sheet http://sensushhealthcare.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://sensushhealthcare.com/role/IncomeTaxes 44 false false All Reports Book All Reports ea0210678-10q sensus.htm srts-20240630.xsd srts-20240630 cal.xml srts-20240630 def.xml srts-20240630 lab.xml srts-20240630 pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 63 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0210678-10q sensus.htm": { "nsprefix": "srts", "nsuri": "http://sensushhealthcare.com/role/20240630", "dts": { "inline": { "local": { "ea0210678-10q sensus.htm" } }, "schema": { "local": { "srts-20240630.xsd" }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024 def.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024 lab.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024 pre.xsd", "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" } } }, "calculationLink": { "local": { "srts-20240630 cal.xml" } } }, "definitionLink": { "local": { "srts-20240630 def.xml" } } }, "labelLink": { "local": { "srts-20240630 lab.xml" } } }, "presentationLink": { "local": { "srts-20240630 pre.xml" } } } }, "keyStandard": 225, "keyCustom": 19, "axisStandard": 17, "axisCustom": 0, "memberStandard": 22, "memberCustom": 11, "hidden": { "total": 81, "http://fasb.org/us-gaap/2024": 74, "http://sensushhealthcare.com/20240630": 3, "http://xbrl.sec.gov/dei/2024": 4, "contextCount": 174, "entityCount": 1, "segmentCount": 36, "elementCount": 608, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 616, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4, "report": { "R1": { "role": "http://xbrl.sec.gov/dei/role/document/Cover", "longName": "995100 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "R2": { "role": "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet", "longName": "995301 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "R3": { "role": "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "995302 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": "null", "decimals": "2", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true }, "R4": { "role": "http://sensushhealthcare.com/role/ConsolidatedIncomeStatement", "longName": "995303 - Statement - Condensed Consolidated Statements of Income (Loss) (Unaudited)", "shortName": "Condensed Consolidated Statements of Income (Loss) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements",

"order": 4, "firstAnchor": { "contextRef": "c4", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:CostOfRevenue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "unique": true } }, "R5": { "role": "http://sensushhealthcare.com/role/ShareholdersEquityText2or3", "longName": "995304 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c7", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true }, "uniqueAnchor": { "contextRef": "c13", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "unique": true } }, "R6": { "role": "http://sensushhealthcare.com/role/ConsolidatedCashFlow", "longName": "995305 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "unique": true } }, "R7": { "role": "http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPolicies", "longName": "995306 - Disclosure - Organization and Summary of Significant Accounting Policies", "shortName": "Organization and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R8": { "role": "http://sensushhealthcare.com/role/PropertyandEquipment", "longName": "995307 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R9": { "role": "http://sensushhealthcare.com/role/Debt", "longName": "995308 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R10": { "role": "http://sensushhealthcare.com/role/ProductWarranties", "longName": "995309 - Disclosure - Product Warranties", "shortName": "Product Warranties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R11": { "role": "http://sensushhealthcare.com/role/Leases", "longName": "995310 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R12": { "role": "http://sensushhealthcare.com/role/CommitmentsandContingencies", "longName": "995311 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R13": { "role": "http://sensushhealthcare.com/role/StockholdersEquity", "longName": "995312 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R14": { "role": "http://sensushhealthcare.com/role/EquityBasedCompensation", "longName": "995313 - Disclosure - Equity-Based Compensation", "shortName": "Equity-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R15": { "role": "http://sensushhealthcare.com/role/IncomeTaxes", "longName": "995314 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R16": { "role": "http://sensushhealthcare.com/role/SubsequentEvents", "longName": "995315 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R17": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "

"contextRef": "c3", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R28": { "role": "http://sensushealthcare.com/role/ScheduleofRemainingPerformanceObligationsTable", "longName": "996009 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) - Schedule of Remaining Performance Obligations", "shortName": "Organization and Summary of Significant Accounting Policies (Details) - Schedule of Remaining Performance Obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c76", "name": "srts:RevenueRemainingPerformanceObligationRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c76", "name": "srts:RevenueRemainingPerformanceObligationRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R29": { "role": "http://sensushealthcare.com/role/ScheduleofTotalRevenueTable", "longName": "996010 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) - Schedule of Total Revenue", "shortName": "Organization and Summary of Significant Accounting Policies (Details) - Schedule of Total Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true }, "uniqueAnchor": { "contextRef": "c97", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "unique": true } }, "R30": { "role": "http://sensushealthcare.com/role/ScheduleofEarningsPerShareComputationTable", "longName": "996011 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) - Schedule of Earnings Per Share Computation", "shortName": "Organization and Summary of Significant Accounting Policies (Details) - Schedule of Earnings Per Share Computation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c121", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true }, "uniqueAnchor": { "contextRef": "c121", "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "unique": true } }, "R31": { "role": "http://sensushealthcare.com/role/PropertyandEquipmentDetails", "longName": "996012 - Disclosure - Property and Equipment (Details)", "shortName": "Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true }, "R32": { "role": "http://sensushealthcare.com/role/ScheduleofPropertyandEquipmentTable", "longName": "996013 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment", "shortName": "Property and Equipment (Details) - Schedule of Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R33": { "role": "http://sensushealthcare.com/role/DebtDetails", "longName": "996014 - Disclosure - Debt (Details)", "shortName": "Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c11", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c11", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R34": { "role": "http://sensushealthcare.com/role/ScheduleofChangesInProductWarrantyLiabilityTable", "longName": "996015 - Disclosure - Product Warranties (Details) - Schedule of Changes in Product Warranty Liability", "shortName": "Product Warranties (Details) - Schedule of Changes in Product Warranty Liability", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:ProductWarrantyAccrualClassifiedCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:ProductWarrantyAccrual", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:ProductWarrantyDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "unique": true } }, "R35": { "role": "http://sensushealthcare.com/role/LeasesDetails", "longName": "996016 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeasePaymentsUsd", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "unique": true } }, "R36": { "role": "http://sensushealthcare.com/role/ScheduleofMaturityNoncancellableLeasesTable", "longName": "996017 - Disclosure - Leases (Details) - Schedule of Maturity Non cancellable leases", "shortName": "Leases (Details) - Schedule of Maturity Non cancellable leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R37": { "role": "http://sensushealthcare.com/role/ScheduleofOperatingLeaseIncomeTable", "longName": "996018 - Disclosure - Leases (Details) - Schedule of Operating Lease Income", "shortName": "Leases (Details) - Schedule of Operating Lease Income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R38": { "role": "http://sensushealthcare.com/role/ScheduleofReceivedLeaseAgreementsTable", "longName": "996019 - Disclosure - Leases (Details) - Schedule of Received Lease Agreements", "shortName": "Leases (Details) - Schedule of Received Lease Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R39": { "role": "http://sensushealthcare.com/role/CommitmentsandContingenciesDetails", "longName": "996020 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c4", "name": "srts:PaymentofInventoryFinishedGoods", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "srts:PaymentofInventoryFinishedGoods", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R40": { "role": "http://sensushealthcare.com/role/StockholdersEquityDetails", "longName": "996021 - Disclosure - Stockholders Equity (Details)", "shortName": "Stockholders Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true }, "uniqueAnchor": null, "R41": { "role": "http://sensushealthcare.com/role/EquityBasedCompensationDetails", "longName": "996022 - Disclosure - Equity-Based Compensation (Details)", "shortName": "Equity-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true }, "uniqueAnchor": { "contextRef": "c3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "unique": true } }, "R42": { "role": "http://sensushealthcare.com/role/ScheduleofRestrictedStockOptionActivityTable", "longName": "996023 - Disclosure - Equity-Based Compensation (Details) - Schedule of Restricted Stock Activity", "shortName": "Equity-Based Compensation (Details) - Schedule of Restricted Stock Activity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c168", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c168", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R43": { "role": "http://sensushealthcare.com/role/ScheduleofStockOptionActivityTable", "longName": "996024 - Disclosure - Equity-Based Compensation (Details) - Schedule of Stock Option Activity", "shortName": "Equity-Based Compensation (Details) - Schedule of Stock Option Activity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c170", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c170", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true, "unique": true } }, "R44": { "role": "http://sensushealthcare.com/role/IncomeTaxesDetails", "longName": "996025 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c4", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "first": true }, "uniqueAnchor": { "contextRef": "c4", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "ea0210678-10q sensus.htm", "unique": true } } }, "tag": { "us-gaap:AccountingPoliciesAbstract": { "xbrltype": "stringItemText", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Organization and Summary of Significant Accounting Policies [Abstract]" } } }, "auth ref": [] }, "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemText", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://sensushealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://sensushealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth ref": ["r34", "r35"] }, "us-gaap:AccountsReceivableMember": { "xbrltype": "domainItemText", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": ["http://sensushealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable [Member]", "verboseLabel": "Accounts receivable [Member]", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth ref": ["r539"] }, "us-gaap:AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemText", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://sensushealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap:AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://sensushealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth ref": ["r760"] }, "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemText", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://sensushealthcare.com/role/ScheduleofPropertyandEquipmentTable": { "parentTag": "us-gaap:PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://sensushealthcare.com/role/ScheduleofPropertyandEquipmentTable"], "lang": { "en-us": { "role": { "negatedLabel": "Less accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct

of business to produce goods and services." } } } , "auth_ref": ["r23", "r108", "r438"] } , "ecd Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } } , "auth_ref": ["r673"] } , "us-gaap AdditionalPaidInCapital": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet", { "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 4.0 } } , "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } } , "auth_ref": ["r44", "r589", "r862"] } , "us-gaap AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://sensushhealthcare.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } } , "auth_ref": ["r465", "r749", "r750", "r751", "r752", "r807", "r863"] } , "dei AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b)" } } } , "auth_ref": ["r729"] } , "dei AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecurities462bFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } } , "auth_ref": ["r729"] } , "dei AdditionalSecuritiesEffective413b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdditionalSecuritiesEffective413b", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } } , "auth_ref": ["r727"] } , "dei AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } } , "auth_ref": [] } , "ecd AdjToCompAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } } , "auth_ref": ["r686"] } , "ecd AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation." } } } , "auth_ref": ["r686"] } , "ecd AdjToNonPeeoNecompFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeeoNecompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } } , "auth_ref": ["r686"] } , "ecd AdjToPeeoCompFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Adjustment to PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment to PEO Compensation, Footnote" } } } , "auth_ref": ["r686"] } , "us-gaap AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income (loss) to net cash and cash equivalents used in operating activities:", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } } , "auth_ref": [] } , "us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": ["http://sensushhealthcare.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } } , "auth_ref": [] } , "ecd AggtChngPnsnValInSummaryCompstnTblForApblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummaryCompstnTblForApblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } } , "auth_ref": ["r720"] } , "ecd AggtErrCompAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } } , "auth_ref": ["r636", "r647", "r663", "r698"] } , "ecd AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } } , "auth_ref": ["r639", "r650", "r666", "r701"] } , "ecd AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } } , "auth_ref": ["r721"] } , "ecd AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } } , "auth_ref": ["r686"] } , "ecd AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } } , "auth_ref": ["r693"] } , "ecd AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } } , "auth_ref": ["r640", "r651", "r667", "r693", "r702", "r706", "r714"] } , "ecd AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } } , "auth_ref": ["r712"] } , "us-gaap AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://sensushhealthcare.com/role/EquityBasedCompensationDetails", "lang": { "en-us": { "role": { "terseLabel": "Stock compensation expense (in Dollars)", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } } , "auth_ref": ["r307", "r312"] } , "us-gaap AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease", "presentation": ["http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Allowance for expected credit losses", "label": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable." } } } , "auth_ref": ["r765"] } , "dei AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } } , "auth_ref": [] } , "dei AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } } , "auth_ref": [] } , "dei AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } } , "auth_ref": ["r643"] } , "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://sensushhealthcare.com/role/ScheduleOfEarningsPerShareComputationTable", "lang": { "en-us": { "role": { "terseLabel": "Antidilutive stock", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } } , "auth_ref": ["r158"] } , "us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://sensushhealthcare.com/role/ScheduleOfEarningsPerShareByAntidilutiveSecuritiesAxis", "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } } , "auth_ref": ["r14"] } , "us-gaap AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://sensushhealthcare.com/role/ScheduleOfEarningsPerShareComputationTable", "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } } , "auth_ref": ["r14"] } , "dei ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } } , "auth_ref": [] } , "us-gaap ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://sensushhealthcare.com/role/LeasesDetails", "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } } , "auth_ref": ["r346"] } , "us-gaap Assets": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet", { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } } , "auth_ref": ["r75", "r84", "r110", "r134", "r161", "r164", "r170", "r171", "r177", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r347", "r349", "r362", "r430", "r493", "r564", "r565", "r589", "r615", "r775", "r776", "r823"] } , "us-gaap AssetsCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet", { "parentTag": "us-gaap Assets", "weight": 1.0, "order": 1.0 } } , "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } } , "auth_ref": ["r103", "r115", "r134", "r177", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r347", "r349", "r362", "r589", "r775", "r776", "r823"] } , "us-gaap AssetsCurrentAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } } , "auth_ref": [] } , "dei AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } } , "auth_ref": ["r643"] } , "dei AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation", "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } } , "auth_ref": ["r628", "r631", "r643"] } , "dei AuditorLineItems": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLineItems", "lang": { "en-us": { "role": { "label": "Auditor [Line Items]" } } } , "auth_ref": [] } , "dei AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation", "lang": { "en-us": { "role": { "label": "Auditor Location" } } } , "auth_ref": ["r628", "r631", "r643"] } , "dei AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation", "lang": { "en-us": { "role": { "label": "Auditor Name" } } } , "auth_ref": ["r628", "r631", "r643"] } , "dei AuditorOpinionTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorOpinionTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation", "lang": { "en-us": { "role": { "label": "Auditor Opinion [Text Block]" } } } , "auth_ref": ["r725"] } , "dei AuditorTable": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation", "lang": { "en-us": { "role": { "label": "Auditor [Table]" } } } , "auth_ref": [] } , "ecd AwardExercPrice": { "xbrltype": "perShareItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExercPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } } , "auth_ref": ["r709"] } , "ecd AwardGrantDateFairValue": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } } , "auth_ref": ["r710"] } , "ecd AwardTmgDiscLineItems": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } } , "auth_ref": ["r705"] } , "ecd AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } } , "auth_ref": ["r705"] } , "ecd AwardTmgMethodTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } } , "auth_ref": ["r705"] } , "ecd AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } } , "auth_ref": ["r705"] } , "ecd AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024",

"localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth ref": ["r705"] }, "ecd AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth ref": ["r705"] }, "us-gaap AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://sensushhealthcare.com/role/EquityBasedCompensationDetails", "http://sensushhealthcare.com/role/ScheduleofRestrictedStockActivityTable", "http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth ref": ["r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306"] }, "ecd AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth ref": ["r708"] }, "ecd AwardsCloseToMnpiDiscLndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscLndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth ref": ["r707"] }, "ecd AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth ref": ["r706"] }, "ecd AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth ref": ["r706"] }, "us-gaap BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://sensushhealthcare.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Principles of Consolidation", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth ref": ["r59"] }, "srt BoardOfDirectorsChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "BoardOfDirectorsChairmanMember", "presentation": ["http://sensushhealthcare.com/role/EquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Board of Directors Chairman [Member]", "label": "Board of Directors Chairman [Member]" } } }, "auth ref": ["r759"] }, "dei BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "BusinessContactMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth ref": ["r631", "r643"] }, "us-gaap BusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": ["http://sensushhealthcare.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Description of the Business", "label": "Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth ref": ["r59", "r61"] }, "country CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CN", "presentation": ["http://sensushhealthcare.com/role/ScheduleofTotalRevenueTable"], "lang": { "en-us": { "role": { "terseLabel": "China [Member]", "label": "CHINA" } } }, "auth ref": [] }, "us-gaap CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth ref": ["r11", "r106", "r556"] }, "us-gaap CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://sensushhealthcare.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth ref": ["r12"] }, "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents [u2013 beginning of period", "periodEndLabel": "Cash and cash equivalents [u2013 end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth ref": ["r11", "r56", "r131"] }, "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth ref": ["r0", "r56"] }, "us-gaap CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Supplemental schedule of noncash investing and financing transactions", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth ref": [] }, "us-gaap ChnglnAcctngEstimateLnItem": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChnglnAcctngEstimateLnItem", "presentation": ["http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Organization and Summary of Significant Accounting Policies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": ["r145"] }, "ecd ChngedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth ref": ["r684"] }, "srts ChangesInOperatingAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "ChangesInOperatingAssetsAndLiabilitiesAbstract", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities", "label": "Changes In Operating Assets And Liabilities Abstract" } } }, "auth ref": [] }, "ecd ChnglnFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChnglnFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth ref": ["r681"] }, "ecd ChnglnFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdlnPrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChnglnFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdlnPrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth ref": ["r679"] }, "dei CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth ref": [] }, "ecd CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth ref": ["r685"] }, "ecd CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth ref": ["r685"] }, "srts ComericaBankMember": { "xbrltype": "domainItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "ComericaBankMember", "presentation": ["http://sensushhealthcare.com/role/DebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Comerica Bank [Member]", "label": "Comerica Bank Member" } } }, "auth ref": [] }, "us-gaap CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth ref": ["r40", "r77", "r432", "r480"] }, "us-gaap CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth ref": [] }, "us-gaap CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://sensushhealthcare.com/role/CommitmentsandContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth ref": ["r67", "r192", "r193", "r540", "r766", "r768"] }, "us-gaap CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://sensushhealthcare.com/role/EquityBasedCompensationDetails", "http://sensushhealthcare.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "verboseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth ref": ["r606", "r607", "r608", "r610", "r611", "r612", "r613", "r749", "r750", "r752", "r807", "r861", "r863"] }, "us-gaap CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in Dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth ref": ["r43"] }, "us-gaap CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth ref": ["r43", "r481"] }, "us-gaap CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock share issued", "label": "Common Stock, Shares Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth ref": ["r43"] }, "us-gaap CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth ref": ["r6", "r43", "r481", "r499", "r863", "r864"] }, "us-gaap CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, \$0.01 par value [u2013 50,000,000 authorized; 16,927,845 issued and 16,394,921 outstanding at June 30, 2024; 16,907,095 issued and 16,374,171 outstanding at December 31, 2023", "label": "Common Stock Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth ref": ["r43", "r434", "r589"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",

"localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth ref": ["r690"] }, "ecd CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth ref": ["r689"] }, "ecd CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth ref": ["r691"] }, "ecd CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth ref": ["r688"] }, "us-gaap ComputerEquipmentMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": ["http://sensushhealthcare.com/role/ScheduleofPropertyandEquipmentTable"], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment [Member]", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth ref": [] }, "us-gaap ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "http://sensushhealthcare.com/role/ScheduleofTotalRevenueTable"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth ref": ["r16", "r18", "r30", "r31", "r175", "r539"] }, "us-gaap ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "http://sensushhealthcare.com/role/ScheduleofTotalRevenueTable"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth ref": ["r16", "r18", "r30", "r31", "r175", "r539", "r739"] }, "us-gaap ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://sensushhealthcare.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Concentration", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth ref": ["r32", "r92"] }, "us-gaap ConcentrationRiskPercentage1": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": ["http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "http://sensushhealthcare.com/role/ScheduleofTotalRevenueTable"], "lang": { "en-us": { "role": { "terseLabel": "Revenue Percentage", "verboseLabel": "Concentration risk percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the benchmark (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth ref": ["r16", "r18", "r30", "r31", "r175"] }, "us-gaap ConcentrationRiskTypeDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "http://sensushhealthcare.com/role/ScheduleofTotalRevenueTable"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth ref": ["r16", "r18", "r30", "r31", "r175", "r539"] }, "us-gaap ConstructionInProgressGross": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressGross", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ScheduleofPropertyandEquipmentTable"], "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 }, "presentation": ["http://sensushhealthcare.com/role/ScheduleofPropertyandEquipmentTable"], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress, Gross", "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth ref": ["r66"] }, "dei ContactPersonnelEmailAddress": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelEmailAddress", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contact Personnel Email Address", "documentation": "Email address of contact personnel." } } }, "auth ref": [] }, "dei ContactPersonnelFaxNumber": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelFaxNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contact Personnel Fax Number", "documentation": "Fax Number of contact personnel." } } }, "auth ref": ["r631"] }, "dei ContactPersonnelName": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel." } } }, "auth ref": [] }, "dei ContainedFileInformationFileDescription": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Description", "documentation": "The description of the contained file." } } }, "auth ref": [] }, "dei ContainedFileInformationFileName": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Name", "documentation": "The name of the contained file." } } }, "auth ref": [] }, "dei ContainedFileInformationFileNumber": { "xbrltype": "fileNumberItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Number", "documentation": "The SEC Document Number of the contained file." } } }, "auth ref": [] }, "dei ContainedFileInformationFileType": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContainedFileInformationFileType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Contained File Information, File Type", "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc)." } } }, "auth ref": [] }, "us-gaap ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": ["http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Revenue", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth ref": ["r778"] }, "us-gaap ContractWithCustomerLiability": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ScheduleofRemainingPerformanceObligationsTable"], "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": ["http://sensushhealthcare.com/role/ScheduleofDeferredRevenueTable", "http://sensushhealthcare.com/role/ScheduleofRemainingPerformanceObligationsTable"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance", "periodEndLabel": "Balance", "totalLabel": "Total", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth ref": ["r261", "r262", "r272"] }, "srts ContractWithCustomerLiabilityAmountsInvoiced": { "xbrltype": "monetaryItem", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "ContractWithCustomerLiabilityAmountsInvoiced", "crdr": "credit", "presentation": ["http://sensushhealthcare.com/role/ScheduleofDeferredRevenueTable"], "lang": { "en-us": { "role": { "terseLabel": "Amounts invoiced", "documentation": "Represent the amount of contract with customer liability amounts invoiced." } } }, "auth ref": [] }, "us-gaap ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, current portion", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth ref": ["r261", "r262", "r272"] }, "us-gaap ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, net of current portion", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth ref": ["r261", "r262", "r272"] }, "us-gaap ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": ["http://sensushhealthcare.com/role/ScheduleofDeferredRevenueTable"], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth ref": ["r273"] }, "us-gaap CostOfRevenue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement"], "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth ref": ["r51", "r134", "r177", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r362", "r564", "r775"] }, "dei CountryRegion": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country." } } }, "auth ref": [] }, "dei CoverAbstract": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth ref": [] }, "dei CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth ref": [] }, "us-gaap CustomerConcentrationRiskMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": ["http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk [Member]", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth ref": ["r62", "r175"] }, "srts CustomerMember": { "xbrltype": "domainItem", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "CustomerMember", "presentation": ["http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer [Member]", "documentation": "Information by benchmark of concentration risk." } } }, "auth ref": [] }, "srts DebtDetailsTable": { "xbrltype": "stringItem", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "DebtDetailsTable", "presentation": ["http://sensushhealthcare.com/role/DebtDetailsTable"], "lang": { "en-us": { "role": { "label": "Debt [Details] [Table]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": ["r136", "r221", "r222", "r223", "r224", "r225", "r227", "r232", "r233", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r245", "r567", "r568", "r569", "r570", "r571", "r587", "r746", "r818", "r819"] }, "us-gaap DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth ref": ["r318", "r319"] }, "us-gaap DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth ref": ["r3", "r98", "r748"] }, "us-gaap DeferredRevenueArrangementLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueArrangementLineItems", "presentation": ["http://sensushhealthcare.com/role/ScheduleofDeferredRevenueTable"], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": [] }, "dei DelayedOrContinuousOffering": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DelayedOrContinuousOffering", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "auth ref": ["r655", "r656", "r670"] }, "us-gaap Depreciation": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": ["http://sensushhealthcare.com/role/PropertyandEquipmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expenses", "label": "Depreciation" } } }, "auth ref": [] }

"documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth ref": ["r3", "r22"] }, "us-gaap DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "cldr": "debit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"] }, "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth ref": ["r3", "r22"] }, "us-gaap DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://sensushhealthcare.com/role/EquityBasedCompensationDetails"] }, "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth ref": ["r470", "r472", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r494", "r495", "r496", "r497", "r506", "r507", "r508", "r509", "r512", "r513", "r514", "r515", "r531", "r532", "r533", "r534", "r559", "r606", "r608", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816"] }, "us-gaap DilutiveSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DilutiveSecuritiesAbstract", "presentation": ["http://sensushhealthcare.com/role/ScheduleOfEarningsPerShareComputationTable"] }, "lang": { "en-us": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]" } } }, "auth ref": [] }, "us-gaap DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://sensushhealthcare.com/role/ScheduleOfDisaggregatedRevenueTable"] }, "lang": { "en-us": { "role": { "label": "Schedule of Disaggregated Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": ["r271", "r573", "r574", "r575", "r576", "r577", "r578", "r579"] }, "us-gaap DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://sensushhealthcare.com/role/ScheduleOfDisaggregatedRevenueTable"] }, "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth ref": ["r271", "r573", "r574", "r575", "r576", "r577", "r578", "r579"] }, "us-gaap DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://sensushhealthcare.com/role/ScheduleOfDisaggregatedRevenueTableTextBlock"] }, "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth ref": ["r779"] }, "us-gaap DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://sensushhealthcare.com/role/EquityBasedCompensation"] }, "lang": { "en-us": { "role": { "terseLabel": "Equity-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth ref": ["r277", "r280", "r308", "r309", "r311", "r581"] }, "us-gaap DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Equity-Based Compensation [Abstract]" } } }, "auth ref": [] }, "dei DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth ref": ["r655", "r656", "r670"] }, "dei DocumentAccountingStandard": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing this can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth ref": ["r631"] }, "dei DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth ref": ["r628", "r631", "r643"] }, "dei DocumentCopyrightInformation": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCopyrightInformation", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Copyright Information", "documentation": "The copyright information for the document." } } }, "auth ref": [] }, "dei DocumentCreationDate": { "xbrltype": "dateTimeType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentCreationDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Creation Date", "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different." } } }, "auth ref": [] }, "dei DocumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Description", "documentation": "The description of the document." } } }, "auth ref": [] }, "dei DocumentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentDomain", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document [Domain]", "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards." } } }, "auth ref": [] }, "dei DocumentEffectiveDate": { "xbrltype": "dateTimeType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentEffectiveDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Effective Date", "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases." } } }, "auth ref": [] }, "dei DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth ref": ["r628", "r631", "r643", "r694"] }, "dei DocumentFinStmtRestatementRecoveryAnalysisFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Financial Statement Restatement Recovery Analysis [Flag]", "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to u00a07240.10D-1(b)." } } }, "auth ref": ["r628", "r631", "r643", "r694"] }, "dei DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth ref": [] }, "dei DocumentFiscalYearFocus": { "xbrltype": "yearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth ref": [] }, "dei DocumentInformationDocumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationDocumentAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Information, Document [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth ref": [] }, "dei DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": [] }, "dei DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth ref": [] }, "dei DocumentInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Information [Text Block]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth ref": [] }, "dei DocumentName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Name", "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the <FILENAME> field of EDGAR filings, such as 'htm 25911.htm', 'exhibit1.htm', 'v105727.8k.txt'." } } }, "auth ref": [] }, "dei DocumentPeriodEndDate": { "xbrltype": "dateTimeType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth ref": [] }, "dei DocumentPeriodStartDate": { "xbrltype": "dateTimeType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth ref": [] }, "dei DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as a quarterly report." } } }, "auth ref": ["r629"] }, "dei DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth ref": ["r617"] }, "dei DocumentShellCompanyEventDate": { "xbrltype": "dateTimeType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth ref": ["r631"] }, "dei DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth ref": ["r631"] }, "dei DocumentSubTitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSubTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Subtitle", "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'." } } }, "auth ref": [] }, "dei DocumentSynopsis": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentSynopsis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Synopsis", "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'." } } }, "auth ref": [] }, "dei DocumentTitle": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Title", "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'." } } }, "auth ref": [] }, "dei DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth ref": ["r671"] }, "dei DocumentType": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth ref": [] }, "dei DocumentVersion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentVersion", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Document Version", "documentation": "The version identifier of the document." } } }, "auth ref": [] }, "dei DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] }, "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth ref": ["r620"] }, "dei DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "documentation": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth ref": ["r683"] }, "us-gaap EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement", "http://sensushhealthcare.com/role/ScheduleOfEarningsPerShareComputationTable"] }, "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) per share u2013 basic (in Dollars per share)", "verboseLabel": "Net income (loss) per share - basic (in Dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth ref": ["r123", "r142", "r143", "r144", "r145", "r146", "r147", "r151", "r153", "r155", "r156", "r157", "r160", "r342", "r345", "r359", "r360", "r427", "r443", "r561"] }, "us-gaap EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement", "http://sensushhealthcare.com/role/ScheduleOfEarningsPerShareComputationTable"] }, "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) per share u2013 diluted (in Dollars per

share)”, “verboseLabel”: “Net income (loss) per share - diluted (in Dollars per share)”, “label”: “Earnings Per Share, Diluted”, “documentation”: “The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.” } } }, “auth_ref”: [“r123”, “r142”, “r143”, “r144”, “r145”, “r146”, “r147”, “r153”, “r155”, “r156”, “r157”, “r160”, “r342”, “r345”, “r359”, “r360”, “r427”, “r443”, “r561”] }, “srts EarningsPerShareMember”: { “xbrltype”: “domainItemtype”, “nsuri”: “http://sensushhealthcare.com/Date2046030”, “localname”: “EarningsPerShareMember”, “presentation”: [“http://sensushhealthcare.com/role/ScheduleofEarningsPerShareComputationTable”], “lang”: { “en-us”: { “role”: { “terseLabel”: “Earnings Per Share [Member]”, “label”: “Earnings Per Share Member” } } }, “auth_ref”: [] }, “us-gaap_EarningsPerSharePolicyTextBlock”: { “xbrltype”: “textBlockItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “EarningsPerSharePolicyTextBlock”, “presentation”: [“http://sensushhealthcare.com/role/AccountingPoliciesByPolicy”], “lang”: { “en-us”: { “role”: { “terseLabel”: “Earnings Per Share”, “label”: “Earnings Per Share, Policy [Policy Text Block]”, “documentation”: “Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.” } } }, “auth_ref”: [“r14”, “r15”, “r159”] }, “dei EffectiveAfter60Days486a”: { “xbrltype”: “booleanItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EffectiveAfter60Days486a”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Effective after 60 Days, 486(a)” } } }, “auth_ref”: [“r733”] }, “us-gaap_EffectiveIncomeTaxRateContinuingOperations”: { “xbrltype”: “percentItemtype”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “EffectiveIncomeTaxRateContinuingOperations”, “presentation”: [“http://sensushhealthcare.com/role/IncomeTaxesDetails”], “lang”: { “en-us”: { “role”: { “terseLabel”: “Effective tax rate”, “label”: “Effective Income Tax Rate Reconciliation, Percent”, “documentation”: “Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.” } } }, “auth_ref”: [“r321”, “r582”] }, “dei EffectiveOnDate486a”: { “xbrltype”: “dateItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EffectiveOnDate486a”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Effective on Date, 486(a)” } } }, “auth_ref”: [“r733”] }, “dei EffectiveOnDate486b”: { “xbrltype”: “dateItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EffectiveOnDate486b”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Effective on Date, 486(b)” } } }, “auth_ref”: [“r734”] }, “dei EffectiveOnSetDate486a”: { “xbrltype”: “booleanItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EffectiveOnSetDate486a”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Effective on Set Date, 486(a)” } } }, “auth_ref”: [“r733”] }, “dei EffectiveOnSetDate486b”: { “xbrltype”: “booleanItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EffectiveOnSetDate486b”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Effective on Set Date, 486(b)” } } }, “auth_ref”: [“r734”] }, “dei EffectiveUponFiling462e”: { “xbrltype”: “booleanItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EffectiveUponFiling462e”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Effective upon Filing, 462(e)” } } }, “auth_ref”: [“r732”] }, “dei EffectiveUponFiling486b”: { “xbrltype”: “booleanItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EffectiveUponFiling486b”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Effective upon Filing, 486(b)” } } }, “auth_ref”: [“r734”] }, “dei EffectiveWhenDeclaredSection8c”: { “xbrltype”: “booleanItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EffectiveWhenDeclaredSection8c”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Effective when Declared, Section 8(c)” } } }, “auth_ref”: [“r736”] }, “us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized”: { “xbrltype”: “monetaryItemtype”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized”, “crdr”: “debit”, “presentation”: [“http://sensushhealthcare.com/role/EquityBasedCompensationDetails”], “lang”: { “en-us”: { “role”: { “terseLabel”: “Unrecognized stock compensation expense (in Dollars)”, “label”: “Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount”, “documentation”: “Amount of cost not yet recognized for nonvested award under share-based payment arrangement.” } } }, “auth_ref”: [“r310”] }, “us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1”: { “xbrltype”: “durationItemtype”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1”, “presentation”: [“http://sensushhealthcare.com/role/EquityBasedCompensationDetails”], “lang”: { “en-us”: { “role”: { “terseLabel”: “Recognized over weighted-average period”, “label”: “Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition”, “documentation”: “Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in PnYnMndTnHnMns format, for example, ‘PIYSM13D’ represents reported fact of one year, five months, and thirteen days.” } } }, “auth_ref”: [“r310”] }, “us-gaap_EmployeeStockOptionMember”: { “xbrltype”: “domainItemtype”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “EmployeeStockOptionMember”, “presentation”: [“http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure”], “lang”: { “en-us”: { “role”: { “label”: “Employee Stock Option [Member]”, “terseLabel”: “Employee Stock Option”, “documentation”: “Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.” } } }, “auth_ref”: [] }, “dei EntitiesTable”: { “xbrltype”: “stringItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntitiesTable”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entities [Table]”, “documentation”: “Container to assemble all relevant information about each entity associated with the document instance” } } }, “auth_ref”: [] }, “dei EntityAccountingStandard”: { “xbrltype”: “stringItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityAccountingStandard”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Accounting Standard”, “documentation”: “The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: ‘US GAAP’, ‘IFRS’. This is distinct from the Document Accounting Standard element.” } } }, “auth_ref”: [] }, “dei EntityAddressAddressDescription”: { “xbrltype”: “stringItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityAddressAddressDescription”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Address, Address Description”, “documentation”: “Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses.” } } }, “auth_ref”: [] }, “dei EntityAddressAddressLine1”: { “xbrltype”: “normalizedStringItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityAddressAddressLine1”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Address, Address Line One”, “documentation”: “Address Line 1 such as Attn, Building Name, Street Name” } } }, “auth_ref”: [] }, “dei EntityAddressAddressLine2”: { “xbrltype”: “normalizedStringItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityAddressAddressLine2”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Address, Address Line Two”, “documentation”: “Address Line 2 such as Street or Suite number” } } }, “auth_ref”: [] }, “dei EntityAddressAddressLine3”: { “xbrltype”: “normalizedStringItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityAddressAddressLine3”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Address, Address Line Three”, “documentation”: “Address Line 3 such as an Office Park” } } }, “auth_ref”: [] }, “dei EntityAddressCityOrTown”: { “xbrltype”: “normalizedStringItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityAddressCityOrTown”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Address, City or Town”, “documentation”: “Name of the City or Town” } } }, “auth_ref”: [] }, “dei EntityAddressCountry”: { “xbrltype”: “countryCodeItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityAddressCountry”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Address, Country”, “documentation”: “ISO 3166-1 alpha-2 country code” } } }, “auth_ref”: [] }, “dei EntityAddressPostalZipCode”: { “xbrltype”: “normalizedStringItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityAddressPostalZipCode”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Address, Postal Zip Code”, “documentation”: “Code for the postal or zip code” } } }, “auth_ref”: [] }, “dei EntityAddressStateOrProvince”: { “xbrltype”: “stateOrProvinceItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityAddressStateOrProvince”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Address, State or Province”, “documentation”: “Name of the state or province.” } } }, “auth_ref”: [] }, “dei EntityAddressesAddressTypeAxis”: { “xbrltype”: “stringItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityAddressesAddressTypeAxis”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Addresses, Address Type [Axis]”, “documentation”: “The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.” } } }, “auth_ref”: [] }, “dei EntityAddressesLineItems”: { “xbrltype”: “stringItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityAddressesLineItems”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Addresses [Line Items]”, “documentation”: “Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.” } } }, “auth_ref”: [] }, “dei EntityAddressesTable”: { “xbrltype”: “stringItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityAddressesTable”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Addresses [Table]”, “documentation”: “Container of address information for the entity” } } }, “auth_ref”: [“r619”] }, “dei EntityBankruptcyProceedingsReportingCurrent”: { “xbrltype”: “booleanItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityBankruptcyProceedingsReportingCurrent”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Bankruptcy Proceedings, Reporting Current”, “documentation”: “For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.” } } }, “auth_ref”: [“r623”] }, “dei EntityCentralIndexKey”: { “xbrltype”: “centralIndexKeyItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityCentralIndexKey”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Central Index Key”, “documentation”: “A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.” } } }, “auth_ref”: [“r619”] }, “dei EntityCommonStockSharesOutstanding”: { “xbrltype”: “sharesItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityCommonStockSharesOutstanding”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Common Stock, Shares Outstanding”, “documentation”: “Indicate number of shares or other units outstanding of each of registrant’s classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.” } } }, “auth_ref”: [] }, “dei EntityContactPersonnelLineItems”: { “xbrltype”: “stringItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityContactPersonnelLineItems”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Contact Personnel [Line Items]”, “documentation”: “Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.” } } }, “auth_ref”: [] }, “dei EntityCurrentReportingStatus”: { “xbrltype”: “yesNoItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityCurrentReportingStatus”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Current Reporting Status”, “documentation”: “Indicate ‘Yes’ or ‘No’ whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant’s current or most recent filing containing the related disclosure.” } } }, “auth_ref”: [] }, “dei EntityDomain”: { “xbrltype”: “domainItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityDomain”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/AuditInformation”, “http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity [Domain]”, “documentation”: “All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.” } } }, “auth_ref”: [] }, “dei EntityEmergingGrowthCompany”: { “xbrltype”: “booleanItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityEmergingGrowthCompany”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Emerging Growth Company”, “documentation”: “Indicate if registrant meets the emerging growth company criteria.” } } }, “auth_ref”: [“r619”] }, “dei EntityExTransitionPeriod”: { “xbrltype”: “booleanItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityExTransitionPeriod”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Ex Transition Period”, “documentation”: “Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.” } } }, “auth_ref”: [“r735”] }, “dei EntityFileNumber”: { “xbrltype”: “fileNumberItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityFileNumber”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity File Number”, “documentation”: “Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.” } } }, “auth_ref”: [] }, “dei EntityFilerCategory”: { “xbrltype”: “filerCategoryItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityFilerCategory”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Filer Category”, “documentation”: “Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant’s current or most recent filing containing the related disclosure.” } } }, “auth_ref”: [“r619”] }, “dei EntityHomeCountryISOCode”: { “xbrltype”: “countryCodeItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityHomeCountryISOCode”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Home Country ISO Code”, “documentation”: “ISO 3166-1 alpha-2 country code for the Entity’s home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the ‘Entity Incorporation, State Country Code’ element.” } } }, “auth_ref”: [] }, “dei EntityIncorporationDateOffIncorporation”: { “xbrltype”: “dateItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityIncorporationDateOffIncorporation”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Incorporation, Date of Incorporation”, “documentation”: “Date when an entity was incorporated” } } }, “auth_ref”: [] }, “dei EntityIncorporationStateCountryCode”: { “xbrltype”: “edgarStateCountryItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityIncorporationStateCountryCode”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Incorporation, State or Country Code”, “documentation”: “Two-character EDGAR code representing the state or country of incorporation.” } } }, “auth_ref”: [] }, “dei EntityInformationFormerLegalOrRegisteredName”: { “xbrltype”: “normalizedStringItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityInformationFormerLegalOrRegisteredName”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Information, Former Legal or Registered Name”, “documentation”: “Former Legal or Registered Name of an entity” } } }, “auth_ref”: [] }, “dei EntityInformationLineItems”: { “xbrltype”: “stringItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityInformationLineItems”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Information [Line Items]”, “documentation”: “Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.” } } }, “auth_ref”: [] }, “dei EntityInteractiveDataCurrent”: { “xbrltype”: “yesNoItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityInteractiveDataCurrent”, “presentation”: [“http://xbrl.sec.gov/dei/role/document/Cover”], “lang”: { “en-us”: { “role”: { “label”: “Entity Interactive Data Current”, “documentation”: “Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during

preceding 12 months (or for such shorter period as the registrant was required to submit such files) } } } , "auth_ref": ["r724"] } , "dei_EntityInvCompanyType": { "xbrltype": "invCompanyType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInvCompanyType", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Inv Company Type", "documentation": "One of N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)." } } } , "auth_ref": ["r723"] } , "dei_EntityLegalForm": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityLegalForm", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Legal Form", "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc." } } } , "auth_ref": [] } , "dei_EntityListingDepositoryReceiptRatio": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDepositoryReceiptRatio", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Listing, Depository Receipt Ratio", "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5.'" } } } , "auth_ref": [] } , "dei_EntityListingDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Listing, Description", "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security." } } } , "auth_ref": [] } , "dei_EntityListingForeign": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingForeign", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Listing, Foreign", "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt." } } } , "auth_ref": [] } , "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01.'" } } } , "auth_ref": [] } , "dei_EntityListingPrimary": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingPrimary", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Listing, Primary", "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity." } } } , "auth_ref": [] } , "dei_EntityListingSecurityTradingCurrency": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingSecurityTradingCurrency", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Listing, Security Trading Currency", "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'" } } } , "auth_ref": [] } , "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsExchangeAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } } , "auth_ref": [] } , "dei_EntityListingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Listings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": [] } , "dei_EntityListingsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Listings [Table]", "documentation": "Container for exchange listing information for an entity." } } } , "auth_ref": [] } , "dei_EntityNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityNumberOfEmployees", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Number of Employees", "documentation": "Number of persons employed by the Entity." } } } , "auth_ref": [] } , "dei_EntityPhoneFaxNumbersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPhoneFaxNumbersLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Phone Fax Numbers [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": [] } , "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } } , "auth_ref": ["r643"] } , "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } } , "auth_ref": [] } , "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } } , "auth_ref": ["r619"] } , "dei_EntityReportingCurrencyISOCODE": { "xbrltype": "currencyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityReportingCurrencyISOCODE", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Reporting Currency ISO Code", "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD.'" } } } , "auth_ref": [] } , "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } } , "auth_ref": ["r619"] } , "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } } , "auth_ref": ["r619"] } , "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } } , "auth_ref": ["r619"] } , "dei_EntityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTextBlock", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity [Text Block]", "documentation": "Container to serve as parent of six Entity related Table concepts." } } } , "auth_ref": [] } , "dei_EntityVoluntaryFilings": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilings", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Voluntary Filings", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } } , "auth_ref": [] } , "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Well-Known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } } , "auth_ref": ["r726"] } , "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote", "documentation": "Equity Awards Adjustments, Footnote" } } } , "auth_ref": ["r677"] } , "ecd_EqtyAwrdsAdjExclgValRptdInSummaryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRptdInSummaryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "documentation": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } } , "auth_ref": ["r719"] } , "ecd_EqtyAwrdsAdjPvpDisclosure": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjPvpDisclosure", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "documentation": "Equity Awards Adjustments [Member]" } } } , "auth_ref": ["r719"] } , "ecd_EqtyAwrdsAdjSummaryCompstnTblForApblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjSummaryCompstnTblForApblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "documentation": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } } , "auth_ref": ["r719"] } , "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": ["http://sensushhealthcare.com/role/ScheduleofPropertyandEquipmentTable"] , "lang": { "en

"r640", "r651", "r667", "r702"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r640", "r651", "r667", "r702"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r640", "r651", "r667", "r702"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r640", "r651", "r667", "r702"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r640", "r651", "r667", "r702"] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerAddressMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": ["r630", "r654"] }, "dei_FormerFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerFiscalYearEndDate", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Former Fiscal Year End Date", "documentation": "Former end date of previous fiscal years" } } }, "auth_ref": [] }, "ecd_FrVaLaOsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrVaLaOsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r682"] }, "country_GT": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "GT", "presentation": ["http://sensushhealthcare.com/role/ScheduleofTotalRevenueTable"], "lang": { "en-us": { "role": { "terseLabel": "Guatemala [Member]", "label": "GUATEMALA" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement"], "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r53", "r503"] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeographicConcentrationRiskMember", "presentation": ["http://sensushhealthcare.com/role/ScheduleofTotalRevenueTable"], "lang": { "en-us": { "role": { "terseLabel": "Geographic Concentration Risk [Member]", "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": ["r17", "r539"] }, "srts_GeographicalInformationPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "GeographicalInformationPolicyPolicyTextBlock", "presentation": ["http://sensushhealthcare.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Geographical Information", "documentation": "Disclosure of accounting policy for geographical information." }, "label": "Geographical Information Policy Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement"], "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r49", "r51", "r83", "r134", "r177", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r362", "r563", "r564", "r754", "r755", "r756", "r757", "r758", "r775"] }, "country_IE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "IE", "presentation": ["http://sensushhealthcare.com/role/ScheduleofTotalRevenueTable"], "lang": { "en-us": { "role": { "terseLabel": "Ireland [Member]", "label": "IRELAND" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": ["r628", "r631", "r643"] }, "us-gaap_ImpairmentEffectsOnEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentEffectsOnEarningsPerShareLineItems", "presentation": ["http://sensushhealthcare.com/role/ScheduleofEarningsPerShareComputationTable"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share Computation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement"], "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) before income tax", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r50", "r79", "r83", "r428", "r440", "r563", "r564", "r754", "r755", "r756", "r757", "r758"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://sensushhealthcare.com/role/IncomeTaxes"], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r135", "r315", "r321", "r322", "r323", "r324", "r325", "r328", "r334", "r336", "r337", "r338", "r464", "r582"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement"], "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Income tax (benefit) expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r88", "r99", "r149", "r150", "r161", "r168", "r171", "r320", "r321", "r335", "r444", "r582"] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://sensushhealthcare.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r118", "r316", "r317", "r325", "r326", "r327", "r331", "r462"] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Income tax paid", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r13", "r130", "r329", "r330"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Income tax payable", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r394", "r743"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities", "label": "Increase (Decrease) in Operating Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r740", "r743"] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": ["r743"] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Other noncurrent assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": ["r743"] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid inventory", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": ["r2"] }, "srts_IncreaseDecreaseProductWarranties": { "xbrltype": "monetaryItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "IncreaseDecreaseProductWarranties", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "role": { "negatedLabel": "Product warranties", "label": "Product warranties", "documentation": "Increase decrease product warranties." }, "label": "Increase Decrease Product Warranties" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual" } } }, "auth_ref": ["r640", "r651", "r667", "r693", "r702", "r706", "r714"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements" }, "label": "Insider Trading Arrangements [Line Items]", "documentation": "Insider Trading Policies ProclLineItems" }, "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProclLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures" } } } } } }

[Line Items]", "terseLabel": "Insider Trading Policies and Procedures: " } } } , "auth_ref": ["r632", "r718"] } , "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"] , "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } } , "auth_ref": ["r632", "r718"] } , "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"] , "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } } , "auth_ref": ["r632", "r718"] } , "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"] , "lang": { "en-us": { "role": { "terseLabel": "Interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } } , "auth_ref": ["r126", "r128", "r129"] } , "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } } , "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"] , "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } } , "auth_ref": ["r112", "r557", "r589"] } , "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": ["http://sensushhealthcare.com/role/AccountingPoliciesByPolicy"] , "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } } , "auth_ref": ["r89", "r105", "r111", "r181", "r182", "r183", "r395", "r560"] } , "dei_InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } } , "auth_ref": ["r656", "r657", "r658", "r659"] } , "dei_InvestmentCompanyActRegistration": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyActRegistration", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } } , "auth_ref": ["r672"] } , "dei_InvestmentCompanyRegistrationAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } } , "auth_ref": ["r672"] } , "dei_InvestmentCompanyRegistrationAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } } , "auth_ref": ["r672"] } , "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } } , "presentation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement"] , "lang": { "en-us": { "role": { "terseLabel": "Interest income, net", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } } , "auth_ref": ["r161", "r167", "r171", "r564", "r742"] } , "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } } , "auth_ref": [] } , "srts_LeasesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "LeasesDetailsTable", "presentation": ["http://sensushhealthcare.com/role/LeasesDetails"] , "lang": { "en-us": { "role": { "label": "Leases (Details) [Table]" } } } , "auth_ref": [] } , "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/AuditInformation", "http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } } , "auth_ref": [] } , "dei_LegalEntityIdentifier": { "xbrltype": "legalEntityIdentifierItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityIdentifier", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"] , "lang": { "en-us": { "role": { "label": "Legal Entity Identifier", "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI." } } } , "auth_ref": ["r616"] } , "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": ["http://sensushhealthcare.com/role/AccountingPoliciesByPolicy"] , "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } } , "auth_ref": ["r376"] } , "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://sensushhealthcare.com/role/LeasesTables"] , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Received Lease Agreements", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } } , "auth_ref": ["r820"] } , "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ScheduleofMaturityNoncancellableleasesTable": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": ["http://sensushhealthcare.com/role/ScheduleofMaturityNoncancellableleasesTable"] , "lang": { "en-us": { "role": { "totalLabel": "Total undiscounted operating leases payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } } , "auth_ref": ["r381"] } , "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ScheduleofMaturityNoncancellableleasesTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } } , "presentation": ["http://sensushhealthcare.com/role/ScheduleofMaturityNoncancellableleasesTable"] , "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } , "auth_ref": ["r381"] } , "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ScheduleofMaturityNoncancellableleasesTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } } , "presentation": ["http://sensushhealthcare.com/role/ScheduleofMaturityNoncancellableleasesTable"] , "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } , "auth_ref": ["r381"] } , "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ScheduleofMaturityNoncancellableleasesTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } } , "presentation": ["http://sensushhealthcare.com/role/ScheduleofMaturityNoncancellableleasesTable"] , "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } , "auth_ref": ["r381"] } , "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ScheduleofMaturityNoncancellableleasesTable": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } } , "presentation": ["http://sensushhealthcare.com/role/ScheduleofMaturityNoncancellableleasesTable"] , "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } } , "auth_ref": ["r820"] } , "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://sensushhealthcare.com/role/ScheduleofMaturityNoncancellableleasesTable"] , "lang": { "en-us": { "role": { "negatedLabel": "Less: Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } } , "auth_ref": ["r381"] } , "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://sensushhealthcare.com/role/Leases"] , "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } } , "auth_ref": ["r371"] } , "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Received Lease Agreements [Abstract]" } } } , "auth_ref": [] } , "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceived", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ScheduleofReceivedLeaseAgreementsTable": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": ["http://sensushhealthcare.com/role/ScheduleofReceivedLeaseAgreementsTable"] , "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessor, Operating Lease, Payment to be Received", "documentation": "Amount of lease payments to be received by lessor for operating lease." } } } , "auth_ref": ["r384"] } , "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ScheduleofReceivedLeaseAgreementsTable": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 5.0 } } , "presentation": ["http://sensushhealthcare.com/role/ScheduleofReceivedLeaseAgreementsTable"] , "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } , "auth_ref": ["r384"] } , "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ScheduleofReceivedLeaseAgreementsTable": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 2.0 } } , "presentation": ["http://sensushhealthcare.com/role/ScheduleofReceivedLeaseAgreementsTable"] , "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } , "auth_ref": ["r384"] } , "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOffFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOffFiscalYear", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ScheduleofReceivedLeaseAgreementsTable": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 1.0 } } , "presentation": ["http://sensushhealthcare.com/role/ScheduleofReceivedLeaseAgreementsTable"] , "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year", "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } , "auth_ref": ["r821"] } , "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ScheduleofReceivedLeaseAgreementsTable": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 6.0 } } , "presentation": ["http://sensushhealthcare.com/role/ScheduleofReceivedLeaseAgreementsTable"] , "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } , "auth_ref": ["r384"] } , "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "crdr": "debit", "calculation": ["http://sensushhealthcare.com/role/ScheduleofReceivedLeaseAgreementsTable": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 3.0 } } , "presentation": ["http://sensushhealthcare.com/role/ScheduleofReceivedLeaseAgreementsTable"] , "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } , "auth_ref": ["r384"] } , "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } } , "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"] , "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } } , "auth_ref": ["r10", "r34", "r35", "r36", "r38", "r39", "r40", "r41", "r134", "r177", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r348", "r349", "r350", "r362", "r479", "r562", "r615", "r775", "r823", "r824"] } , "us-gaap_LiabilitiesAndStockholdersEquity": {

"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders'2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." }, "auth ref": ["r48", "r78", "r436", "r589", "r747", "r764", "r817"] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth ref": ["r36", "r104", "r134", "r177", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r348", "r349", "r350", "r362", "r589", "r775", "r823", "r824"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth ref": [] }, "us-gaap_LineOfCreditFacilityAssetRestrictions": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAssetRestrictions", "presentation": ["http://sensushhealthcare.com/role/DebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liquid assets", "label": "Line of Credit Facility, Asset Restrictions", "documentation": "Description of restrictions on the entity's other assets as required by the terms of the credit facility." } } }, "auth ref": ["r745"] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": ["http://sensushhealthcare.com/role/DebtDetails"], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth ref": ["r33", "r37", "r746", "r773", "r774"] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": ["http://sensushhealthcare.com/role/DebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Borrowing facility amount", "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth ref": ["r33", "r37"] }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "presentation": ["http://sensushhealthcare.com/role/DebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Borrowing interest", "label": "Line of Credit Facility, Interest Rate During Period", "documentation": "The effective interest rate during the reporting period." } } }, "auth ref": ["r33", "r37"] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLenderDomain", "presentation": ["http://sensushhealthcare.com/role/DebtDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth ref": ["r33", "r37", "r746", "r773"] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://sensushhealthcare.com/role/DebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowings amount", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth ref": ["r33", "r37"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": ["http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth ref": ["r175", "r575", "r599", "r603", "r779", "r832", "r833", "r834", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://sensushhealthcare.com/role/ScheduleofPropertyandEquipmentTable"], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth ref": ["r194", "r195", "r196", "r197", "r276", "r313", "r361", "r393", "r452", "r453", "r459", "r471", "r472", "r524", "r526", "r528", "r529", "r535", "r550", "r551", "r566", "r572", "r580", "r583", "r584", "r585", "r586", "r600", "r777", "r825", "r826", "r827", "r828", "r829", "r830"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure." } } }, "auth ref": ["r685"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth ref": ["r685"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://sensushhealthcare.com/role/ScheduleofPropertyandEquipmentTable"], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth ref": ["r194", "r195", "r196", "r197", "r276", "r313", "r361", "r393", "r452", "r453", "r459", "r471", "r472", "r524", "r526", "r528", "r529", "r535", "r550", "r551", "r566", "r572", "r580", "r583", "r584", "r585", "r600", "r777", "r825", "r826", "r827", "r828", "r829", "r830"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth ref": ["r705"] }, "ecd_MtrlTermsOffTrdArTxBk": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOffTrdArTxBk", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth ref": ["r713"] }, "dei_NameChangeEventDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventDateAxis", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event Date [Axis]", "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type." } } }, "auth ref": [] }, "dei_NameChangeEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventLineItems", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event [Line Items]", "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table." } } }, "auth ref": [] }, "dei_NameChangeEventTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NameChangeEventTable", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Name Change Event [Table]", "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period." } } }, "auth ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth ref": ["r175", "r575", "r599", "r603", "r779", "r832", "r833", "r834", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860"] }, "ecd_NamedExecutiveOfficersFnTxBk": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTxBk", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth ref": ["r686"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth ref": ["r127"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth ref": ["r127"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth ref": ["r56", "r57", "r58"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement", "http://sensushhealthcare.com/role/ScheduleofEarningsPerShareComputationTable"], "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)", "netLabel": "Net income (loss) (in Dollars)", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth ref": ["r52", "r58", "r80", "r102", "r116", "r117", "r121", "r134", "r140", "r142", "r143", "r144", "r145", "r146", "r149", "r150", "r154", "r177", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r342", "r345", "r360", "r362", "r441", "r501", "r516", "r517", "r614", "r775"] }, "us-gaap_NetIncomeLossAttributableToParentDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToParentDilutedAbstract", "presentation": ["http://sensushhealthcare.com/role/ScheduleofEarningsPerShareComputationTable"], "lang": { "en-us": { "role": { "terseLabel": "Diluted", "label": "Net Income (Loss) Attributable to Parent, Diluted [Abstract]" } } }, "auth ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": ["http://sensushhealthcare.com/role/ScheduleofEarningsPerShareComputationTable"], "lang": { "en-us": { "role": { "terseLabel": "Basic", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyTextBlock", "presentation": ["http://sensushhealthcare.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth ref": [] }, "dei_NewEffectiveDateForPreviousFiling": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NewEffectiveDateForPreviousFiling", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "auth ref": ["r656", "r657", "r658", "r659"] }, "dei_NoSubstantiveChanges462c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462c", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "auth ref": ["r730"] }, "dei_NoSubstantiveChanges462cFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "auth ref": ["r730"] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth ref": ["r685"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth ref": ["r640", "r651", "r667", "r693", "r702"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt"] }

"NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } }, "auth_ref": ["r676"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } }, "auth_ref": ["r675"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } }, "auth_ref": ["r693"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } }, "auth_ref": ["r713"] }, "ecd_NonRule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } }, "auth_ref": ["r713"] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } }, "auth_ref": ["r83", "r563", "r754", "r755", "r756", "r757", "r758"] }, "srts_OperatingLeaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "OperatingLeaseAgreementsMember", "presentation": ["http://sensushhealthcare.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease Agreements [Member]", "label": "Operating Lease Agreements Member" } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://sensushhealthcare.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } }, "auth_ref": ["r377", "r588"] }, "us-gaap_OperatingLeaseLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLeaseIncome", "crdr": "credit", "presentation": ["http://sensushhealthcare.com/role/ScheduleOfOperatingLeaseIncomeTable"], "lang": { "en-us": { "role": { "terseLabel": "Lease income - operating leases", "label": "Operating Lease, Lease Income", "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable." } }, "auth_ref": ["r162", "r383", "r385"] }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "presentation": ["http://sensushhealthcare.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Lease Income", "label": "Operating Lease, Lease Income [Table Text Block]", "documentation": "Tabular disclosure of components of income from operating lease." } }, "auth_ref": ["r162", "r385"] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Operating Leases [Abstract]" } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ScheduleOfMaturityNoncancellableLeasesTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": null, "order": null, "root": true }, "presentation": ["http://sensushhealthcare.com/role/ScheduleOfMaturityNoncancellableLeasesTable"], "lang": { "en-us": { "role": { "totalLabel": "Present Value of Operating Lease Liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } }, "auth_ref": ["r374"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ScheduleOfMaturityNoncancellableLeasesTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet", "http://sensushhealthcare.com/role/ScheduleOfMaturityNoncancellableLeasesTable"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability, current portion", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } }, "auth_ref": ["r374"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://sensushhealthcare.com/role/ScheduleOfMaturityNoncancellableLeasesTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet", "http://sensushhealthcare.com/role/ScheduleOfMaturityNoncancellableLeasesTable"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "verboseLabel": "Operating lease liability, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } }, "auth_ref": ["r374"] }, "us-gaap_OperatingLeasePaymentsUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePaymentsUse", "crdr": "credit", "presentation": ["http://sensushhealthcare.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Operating Lease, Payments, Use", "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use." } }, "auth_ref": ["r375", "r378"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use asset, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } }, "auth_ref": ["r373"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow", "http://sensushhealthcare.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of right-of-use asset", "verboseLabel": "Amortization of the ROU asset", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } }, "auth_ref": ["r744"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://sensushhealthcare.com/role/ScheduleOfMaturityNoncancellableLeasesTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } }, "auth_ref": ["r380", "r588"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://sensushhealthcare.com/role/ScheduleOfMaturityNoncancellableLeasesTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } }, "auth_ref": ["r379", "r588"] }, "us-gaap_OperatingLeasedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasedAssetsLineItems", "presentation": ["http://sensushhealthcare.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "label": "Leases [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }, "auth_ref": [] }, "us-gaap_OperatingLeasesLeaseIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasesLeaseIncomeAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Operating Lease Income [Abstract]" } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": ["http://sensushhealthcare.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } }, "auth_ref": ["r59", "r60", "r61", "r73"] }, "srts_OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsScheduleOfDeferredRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsScheduleOfDeferredRevenueTable", "presentation": ["http://sensushhealthcare.com/role/ScheduleOfDeferredRevenueTable"], "lang": { "en-us": { "role": { "label": "Organization and Summary of Significant Accounting Policies (Details) - Schedule of Deferred Revenue [Table]" } }, "auth_ref": [] }, "srts_OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsScheduleOfEarningsPerShareComputationTable": { "xbrltype": "stringItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsScheduleOfEarningsPerShareComputationTable", "presentation": ["http://sensushhealthcare.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Organization and Summary of Significant Accounting Policies (Details) - Schedule of Earnings Per Share Computation [Table]" } }, "auth_ref": [] }, "srts_OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsScheduleOfTotalRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsScheduleOfTotalRevenueTable", "presentation": ["http://sensushhealthcare.com/role/ScheduleOfTotalRevenueTable"], "lang": { "en-us": { "role": { "label": "Organization and Summary of Significant Accounting Policies (Details) - Schedule of Total Revenue [Table]" } }, "auth_ref": [] }, "srts_OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsTable", "presentation": ["http://sensushhealthcare.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Organization and Summary of Significant Accounting Policies (Details) [Table]" } }, "auth_ref": [] }, "dei_OtherAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherAddressMember", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Other Address [Member]", "documentation": "Other address for entity" } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } }, "auth_ref": ["r114", "r589"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } }, "auth_ref": ["r109"] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Other Income and Expenses [Abstract]" } }, "auth_ref": [] }, "srts_OtherInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "OtherInformationAbstract", "presentation": ["http://sensushhealthcare.com/role/ScheduleOfMaturityNoncancellableLeasesTable"], "lang": { "en-us": { "role": { "terseLabel": "Other Information", "label": "Other Information Abstract" } }, "auth_ref": [] }, "srts_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "OtherMember", "presentation": ["http://sensushhealthcare.com/role/ScheduleOfTotalRevenueTable"], "lang": { "en-us": { "role": { "terseLabel": "Other [Member]", "label": "Other Member" } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "totalLabel": "Other income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } }, "auth_ref": ["r54"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } }, "auth_ref": ["r685"] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "Item 171 or Item 181 specified when the basis of accounting is neither US GAAP nor IFRS." } }, "auth_ref": ["r631"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } }, "auth_ref": ["r638", "r649", "r655", "r700"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } }, "auth_ref": ["r641", "r652", "r668", "r703"] },

"ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth ref": ["r641", "r652", "r668", "r703"] }, "dei_ParentEntityLegalName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ParentEntityLegalName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Parent Entity Legal Name", "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity" } } }, "auth ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth ref": ["r674"] }, "srts_PaymentofInventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "PaymentofInventoryFinishedGoods", "crdr": "credit", "presentation": ["http://sensushhealthcare.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Inventory finished goods", "documentation": "Represent the amount of payment of inventory finished goods." }, "label": "Paymentof Inventory Finished Goods" } } }, "auth ref": [] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "Withholding taxes on stock-based compensation", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth ref": ["r125"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "negatedLabel": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth ref": ["r55"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth ref": ["r684"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth ref": ["r684"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth ref": ["r676"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth ref": ["r693"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth ref": ["r686"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth ref": ["r675"] }, "srts_PerShareBecauseToDoSoWouldHaveBeenAntidilutiveForThePeriodsPresentedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "PerShareBecauseToDoSoWouldHaveBeenAntidilutiveForThePeriodsPresentedAbstract", "presentation": ["http://sensushhealthcare.com/role/ScheduleofEarningsPerShareComputationTable"], "lang": { "en-us": { "role": { "terseLabel": "per share because to do so would have been antidilutive for the periods presented.", "label": "Per Share Because To Do So Would Have Been Antidilutive For The Periods Presented Abstract" } } }, "auth ref": [] }, "dei_PhoneFaxNumberDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PhoneFaxNumberDescription", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Phone Fax Number Description", "documentation": "Description of Phone or Fax Number" } } }, "auth ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://sensushhealthcare.com/role/EquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth ref": ["r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://sensushhealthcare.com/role/EquityBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth ref": ["r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth ref": ["r677"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth ref": ["r722"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth ref": ["r676"] }, "dei_PostEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "auth ref": ["r617"] }, "dei_PostEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PostEffectiveAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }, "auth ref": ["r617"] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth ref": ["r624"] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth ref": ["r626"] }, "dei_PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendment", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "auth ref": ["r617"] }, "dei_PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreEffectiveAmendmentNumber", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } }, "auth ref": ["r617"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://sensushhealthcare.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth ref": ["r42", "r481"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth ref": ["r42", "r248"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth ref": ["r42", "r481", "r499", "r863", "r864"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth ref": ["r42", "r433", "r589"] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "presentation": ["http://sensushhealthcare.com/role/CommitmentsandContingenciesDetails", "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid inventory", "verboseLabel": "Prepayment related to these finished goods", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth ref": ["r113", "r184", "r185", "r558"] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": ["http://sensushhealthcare.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of Prior Year Presentation", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth ref": ["r741"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth ref": ["r1", "r9"] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductInformationLineItems", "presentation": ["http://sensushhealthcare.com/role/ScheduleofTotalRevenueTable"], "lang": { "en-us": { "role": { "label": "Schedule of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": ["http://sensushhealthcare.com/role/ScheduleofDeferredRevenueTable", "http://sensushhealthcare.com/role/ScheduleofDisaggregatedRevenueTable"], "lang": { "en-us": { "role": { "terseLabel": "Product Revenue - recognized at a point in time [Member]", "verboseLabel": "Product [Member]", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth ref": ["r573"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://sensushhealthcare.com/role/ScheduleofDeferredRevenueTable", "http://sensushhealthcare.com/role/ScheduleofDisaggregatedRevenueTable", "http://sensushhealthcare.com/role/ScheduleofRemainingPerformanceObligationsTable"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth ref": ["r172", "r396", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r554", "r573", "r598", "r600", "r601", "r604", "r605", "r769", "r770", "r779", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860"] }, "us-gaap_ProductWarrantiesDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantiesDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Product Warranties [Abstract]" } } }, "auth ref": [] }, "us-gaap_ProductWarrantyAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyAccrual", "crdr": "credit", "presentation": ["http://sensushhealthcare.com/role/ScheduleofChangesinProductWarrantyLiabilityTable"], "lang": { "en-us": { "role": { "terseLabel": "Warranties accrued during the period", "label": "Standard and Extended Product Warranty Accrual", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers." } } }, "auth ref": ["r76", "r202", "r206", "r208"] }, "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyAccrualClassifiedCurrent", "crdr": "debit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet", "http://sensushhealthcare.com/role/ScheduleofChangesinProductWarrantyLiabilityTable"], "lang": { "en-us": { "role": { "negatedLabel": "Payments on warranty claims", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty." } } }, "auth ref": ["r207"] }, "us-gaap_ProductWarrantyDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyDisclosureTextBlock", "presentation": [

```

url: "http://sensushhealthcare.com/role/ProductWarranties", "lang": { "en-us": { "role": { "terseLabel": "Product Warranties", "label": "Product Warranty Disclosure [Text Block]", "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period." } } }, "auth_ref": [ "r198", "r199", "r200", "r201", "r203", "r204" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://sensushhealthcare.com/role/ScheduleOfDeferredRevenueTable", "http://sensushhealthcare.com/role/ScheduleOfDisaggregatedRevenueTable" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r172", "r396", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r554", "r598", "r600", "r601", "r604", "r605", "r769", "r770", "r779", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property and Equipment [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://sensushhealthcare.com/role/ScheduleOfPropertyandEquipmentTable" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r4", "r382" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://sensushhealthcare.com/role/PropertyandEquipment" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r65", "r93", "r96", "r97" ] }, "us-gaap_PropertyPlantAndEquipmentCross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentCross", "crdr": "debit", "calculation": { "http://sensushhealthcare.com/role/ScheduleOfPropertyandEquipmentTable": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 }, "presentation": [ "http://sensushhealthcare.com/role/ScheduleOfPropertyandEquipmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r66", "r107", "r439" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://sensushhealthcare.com/role/ScheduleOfPropertyandEquipmentTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Property and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r382" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "presentation": [ "http://sensushhealthcare.com/role/ScheduleOfPropertyandEquipmentTable": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet", "http://sensushhealthcare.com/role/ScheduleOfPropertyandEquipmentTable" ], "lang": { "en-us": { "role": { "totalLabel": "Property and Equipment, Net", "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r4", "r382", "r429", "r439", "r589" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://sensushhealthcare.com/role/PropertyandEquipmentTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": [ "r4" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://sensushhealthcare.com/role/ScheduleOfPropertyandEquipmentTable" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r66", "r382" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://sensushhealthcare.com/role/ScheduleOfPropertyandEquipmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, estimated useful life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [ ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "presentation": [ "http://sensushhealthcare.com/role/ConsolidatedCashFlow", "http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit loss expense", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r124", "r180" ] }, "srts_ProvisionForProductWarranties": { "xbrltype": "monetaryItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "ProvisionForProductWarranties", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 }, "presentation": [ "http://sensushhealthcare.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Provision for product warranties", "documentation": "Amount of provision for product warranties." }, "label": "Provision For Product Warranties" } } }, "auth_ref": [ ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r674" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r674" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://sensushhealthcare.com/role/ScheduleOfPropertyandEquipmentTable" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r194", "r195", "r196", "r197", "r274", "r276", "r303", "r304", "r305", "r313", "r361", "r391", "r392", "r393", "r452", "r453", "r459", "r471", "r472", "r524", "r526", "r528", "r529", "r535", "r550", "r551", "r566", "r572", "r472", "r524", "r526", "r528", "r529", "r535", "r550", "r551", "r566", "r572", "r580", "r583", "r584", "r585", "r586", "r600", "r608", "r767", "r777", "r808", "r826", "r827", "r828", "r829", "r830" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://sensushhealthcare.com/role/ScheduleOfPropertyandEquipmentTable" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r194", "r195", "r196", "r197", "r274", "r276", "r303", "r304", "r305", "r313", "r361", "r391", "r392", "r393", "r452", "r453", "r459", "r471", "r472", "r524", "r526", "r528", "r529", "r535", "r550", "r551", "r566", "r572", "r472", "r524", "r526", "r528", "r529", "r535", "r550", "r551", "r566", "r572", "r580", "r583", "r584", "r585", "r586", "r600", "r608", "r767", "r777", "r808", "r826", "r827", "r828", "r829", "r830" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r633", "r644", "r660", "r695" ] }, "dei_RegistrationStatementAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "RegistrationStatementAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/dei/role/document/Cover" ], "lang": { "en-us": { "role":
```

"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "presentation": ["http://sensushhealthcare.com/role/ScheduleofRemainingPerformanceObligationsTable"], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [] }, "us-gaap RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "presentation": ["http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Remaining Performance Obligations", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]", "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation." } } }, "auth_ref": ["r737"] }, "srts RevenueRemainingPerformanceObligationNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "RevenueRemainingPerformanceObligationNextTwelveMonths", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ScheduleofRemainingPerformanceObligationsTable": { "parentTag": "us-gaap ContractWithCustomerLiability", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://sensushhealthcare.com/role/ScheduleofRemainingPerformanceObligationsTable"], "lang": { "en-us": { "role": { "terseLabel": "2025", "documentation": "Represent the amount of revenue remaining performance obligation next twelve months." }, "label": "Revenue Remaining Performance Obligation Next Twelve Months" } } }, "auth_ref": [] }, "srts RevenueRemainingPerformanceObligationRemainderofFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "RevenueRemainingPerformanceObligationRemainderofFiscalYear", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ScheduleofRemainingPerformanceObligationsTable": { "parentTag": "us-gaap ContractWithCustomerLiability", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://sensushhealthcare.com/role/ScheduleofRemainingPerformanceObligationsTable"], "lang": { "en-us": { "role": { "terseLabel": "2024 (July 1 - December 31, 2024)", "documentation": "Represent the amount of revenue remaining performance obligation fiscal year." }, "label": "Revenue Remaining Performance Obligation Remainder of Fiscal Year" } } }, "auth_ref": [] }, "srts RevenueRemainingPerformanceObligationYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "RevenueRemainingPerformanceObligationYearThree", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ScheduleofRemainingPerformanceObligationsTable": { "parentTag": "us-gaap ContractWithCustomerLiability", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://sensushhealthcare.com/role/ScheduleofRemainingPerformanceObligationsTable"], "lang": { "en-us": { "role": { "terseLabel": "2027", "documentation": "Represent the amount of revenue remaining performance obligation year three." }, "label": "Revenue Remaining Performance Obligation Year Three" } } }, "auth_ref": [] }, "srts RevenueRemainingPerformanceObligationYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "RevenueRemainingPerformanceObligationYearTwo", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ScheduleofRemainingPerformanceObligationsTable": { "parentTag": "us-gaap ContractWithCustomerLiability", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://sensushhealthcare.com/role/ScheduleofRemainingPerformanceObligationsTable"], "lang": { "en-us": { "role": { "terseLabel": "2026", "documentation": "Represent the amount of revenue remaining performance obligation year two." }, "label": "Revenue Remaining Performance Obligation Year Two" } } }, "auth_ref": [] }, "us-gaap Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement", "http://sensushhealthcare.com/role/ScheduleofDisaggregatedRevenueTable"], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "verboseLabel": "Revenue", "netLabel": "Total Revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r81", "r82", "r122", "r134", "r161", "r165", "r166", "r169", "r171", "r172", "r173", "r175", "r177", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r362", "r428", "r564", "r775"] }, "srts RevenuesFromNonLeaseComponents": { "xbrltype": "monetaryItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "RevenuesFromNonLeaseComponents", "crdr": "credit", "presentation": ["http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenues from non-lease components", "documentation": "Represent the amount of revenue from non lease components." }, "label": "Revenues From Non Lease Components" } } }, "auth_ref": [] }, "ecd Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r713"] }, "ecd Rule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmtdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r713"] }, "us-gaap SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": ["http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "http://sensushhealthcare.com/role/ScheduleofTotalRevenueTable"], "lang": { "en-us": { "role": { "terseLabel": "Revenue [Member]", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r175", "r738"] }, "srts ScheduleOfDeferredRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "ScheduleOfDeferredRevenueAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Deferred Revenue Abstract" } }, "auth_ref": [] }, "srts ScheduleOfDisaggregatedRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "ScheduleOfDisaggregatedRevenueAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Disaggregated Revenue Abstract" } } }, "auth_ref": [] }, "us-gaap ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share Computation", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r753"] }, "srts ScheduleOfEarningsPerShareComputationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "ScheduleOfEarningsPerShareComputationAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Earnings Per Share Computation Abstract" } } }, "auth_ref": [] }, "us-gaap ScheduleOfProductWarrantyLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "presentation": ["http://sensushhealthcare.com/role/ProductWarrantiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Product Warranty Liability", "label": "Schedule of Product Warranty Liability [Table Text Block]", "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability." } } }, "auth_ref": ["r205"] }, "srts ScheduleOfPropertyAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "ScheduleOfPropertyAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Property And Equipment Abstract" } } }, "auth_ref": [] }, "us-gaap ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://sensushhealthcare.com/role/ScheduleOfPropertyandEquipmentTable"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r4", "r382"] }, "srts ScheduleOfReceivedLeaseAgreementsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "ScheduleOfReceivedLeaseAgreementsTableTextBlock", "presentation": ["http://sensushhealthcare.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Received Lease Agreements", "documentation": "Tabular disclosure of schedule of received lease agreements." }, "label": "Schedule Of Received Lease Agreements Table Text Block" } } }, "auth_ref": [] }, "srts ScheduleOfRemainingPerformanceObligationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "ScheduleOfRemainingPerformanceObligationsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Remaining Performance Obligations Abstract" } } }, "auth_ref": [] }, "srts ScheduleOfRestrictedStockActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "ScheduleOfRestrictedStockActivityAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Restricted Stock Activity Abstract" } } }, "auth_ref": [] }, "us-gaap ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "presentation": ["http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Revenue", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": ["r49", "r63"] }, "us-gaap ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": ["http://sensushhealthcare.com/role/EquityBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Activity", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": ["r71"] }, "us-gaap ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://sensushhealthcare.com/role/EquityBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r7", "r8", "r71"] }, "srts ScheduleOfStockOptionActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "ScheduleOfStockOptionActivityAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Stock Option Activity Abstract" } } }, "auth_ref": [] }, "srts ScheduleOfTotalRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "ScheduleOfTotalRevenueAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Total Revenue Abstract" } } }, "auth_ref": [] }, "us-gaap SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSoftOvernightIndexSwapRateMember", "presentation": ["http://sensushhealthcare.com/role/DebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate [Member]", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": ["r806"] }, "dei Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r618"] }, "dei Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": ["r622"] }, "dei SecurityExchangeName": { "xbrltype": "edgeExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r621"] }, "dei SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": ["r627"] }, "srt SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://sensushhealthcare.com/role/ScheduleofTotalRevenueTable"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "documentation": "Geographical domain of the segment." } } }, "auth_ref": ["r173", "r174", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r467", "r468", "r469", "r525", "r527", "r530", "r536", "r538", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r559", "r574", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r602", "r608", "r779", "r832", "r833", "r834", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860"] }, "us-gaap SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Selling and marketing", "label": "Selling and Marketing Expense", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceMember", "presentation": ["http://sensushhealthcare.com/role/ScheduleofDeferredRevenueTable"], "lang": { "en-us": { "role": { "label": "Service Revenue - recognized at a point in time [Member]", "verboseLabel": "Service [Member]", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": ["r573"] }, "srts ServiceRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "ServiceRevenueMember", "presentation": ["http://sensushhealthcare.com/role/ScheduleofDisaggregatedRevenueTable"], "lang": { "en-us": { "role": { "terseLabel": "Service Revenue - recognized over time [Member]", "verboseLabel": "Service Revenue [Member]", "label": "Service Revenue Member" } } }, "auth_ref": [] }, "us-gaap ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": {

```
"verboseLabel": "Stock-based compensation, \"label\": \"Share-Based Payment Arrangement By Share-Based Payment Award Equity Instruments Other Than Options Forfeited In Period\", \"documentation\": \"Amount of non-vested equity-based payment arrangement.\" } } }, \"auth ref\": [ \"r2\" ] }, \"us-gaap.ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod\": { \"xbrltype\": \"sharesItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod\", \"presentation\": [ \"http://sensushhealthcare.com/role/ScheduleofRestrictedStockActivityTable\" ], \"lang\": { \"en-us\": { \"role\": { \"negatedLabel\": \"Restricted Stock, Forfeited\", \"label\": \"Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period\", \"documentation\": \"The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.\" } } }, \"auth ref\": [ \"r297\" ] }, \"us-gaap.ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue\": { \"xbrltype\": \"perShareItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue\", \"presentation\": [ \"http://sensushhealthcare.com/role/ScheduleofRestrictedStockActivityTable\" ], \"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Weighted-Average Grant Date Fair Value, Forfeited\", \"label\": \"Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value\", \"documentation\": \"Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.\" } } }, \"auth ref\": [ \"r297\" ] }, \"us-gaap.ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod\": { \"xbrltype\": \"sharesItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod\", \"presentation\": [ \"http://sensushhealthcare.com/role/ScheduleofRestrictedStockActivityTable\" ], \"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Restricted Stock, Granted\", \"label\": \"Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period\", \"documentation\": \"The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).\" } } }, \"auth ref\": [ \"r295\" ] }, \"us-gaap.ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber\": { \"xbrltype\": \"sharesItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber\", \"presentation\": [ \"http://sensushhealthcare.com/role/ScheduleofRestrictedStockActivityTable\" ], \"lang\": { \"en-us\": { \"role\": { \"periodStartLabel\": \"Restricted Stock, balance at beginning\", \"periodEndLabel\": \"Restricted Stock, balance at ending\", \"label\": \"Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number\", \"documentation\": \"The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.\" } } }, \"auth ref\": [ \"r292\", \"r293\" ] }, \"us-gaap.ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue\": { \"xbrltype\": \"perShareItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue\", \"presentation\": [ \"http://sensushhealthcare.com/role/ScheduleofRestrictedStockActivityTable\" ], \"lang\": { \"en-us\": { \"role\": { \"periodStartLabel\": \"Weighted-Average Grant Date Fair Value, balance at beginning\", \"periodEndLabel\": \"Weighted-Average Grant Date Fair Value, balance at ending\", \"label\": \"Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value\", \"documentation\": \"Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.\" } } }, \"auth ref\": [ \"r292\", \"r293\" ] }, \"us-gaap.ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod\": { \"xbrltype\": \"sharesItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod\", \"presentation\": [ \"http://sensushhealthcare.com/role/ScheduleofRestrictedStockActivityTable\" ], \"lang\": { \"en-us\": { \"role\": { \"negatedLabel\": \"Restricted Stock, Vested\", \"label\": \"Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period\", \"documentation\": \"The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.\" } } }, \"auth ref\": [ \"r296\" ] }, \"us-gaap.ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue\": { \"xbrltype\": \"perShareItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue\", \"presentation\": [ \"http://sensushhealthcare.com/role/EquityBasedCompensationDetails\", \"http://sensushhealthcare.com/role/ScheduleofRestrictedStockActivityTable\" ], \"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Weighted-Average Grant Date Fair Value, Vested\", \"verboseLabel\": \"Grant date fair value (in Dollars per share)\", \"label\": \"Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value\", \"documentation\": \"The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.\" } } }, \"auth ref\": [ \"r296\" ] }, \"us-gaap.ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems\": { \"xbrltype\": \"stringItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems\", \"presentation\": [ \"http://sensushhealthcare.com/role/EquityBasedCompensationDetails\", \"http://sensushhealthcare.com/role/ScheduleofRestrictedStockOptionActivityTable\" ], \"lang\": { \"en-us\": { \"role\": { \"label\": \"Schedule of Restricted Stock Activity [Line Items]\", \"terseLabel\": \"Schedule of Stock Option Activity [Line Items]\", \"verboseLabel\": \"Equity-Based Compensation [Line Items]\", \"documentation\": \"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.\" } } }, \"auth ref\": [ \"r278\", \"r279\", \"r281\", \"r282\", \"r283\", \"r284\", \"r285\", \"r286\", \"r287\", \"r288\", \"r289\", \"r290\", \"r291\", \"r292\", \"r293\", \"r294\", \"r295\", \"r296\", \"r297\", \"r298\", \"r299\", \"r300\", \"r301\", \"r302\", \"r303\", \"r304\", \"r305\", \"r306\" ] }, \"us-gaap.ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant\": { \"xbrltype\": \"sharesItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant\", \"presentation\": [ \"http://sensushhealthcare.com/role/EquityBasedCompensationDetails\", \"http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable\" ], \"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Shares available, grant\", \"label\": \"Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant\", \"documentation\": \"The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.\" } } }, \"auth ref\": [ \"r26\" ] }, \"us-gaap.ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber\": { \"xbrltype\": \"sharesItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber\", \"presentation\": [ \"http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable\" ], \"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Number of Options, Exercisable\", \"label\": \"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number\", \"documentation\": \"The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.\" } } }, \"auth ref\": [ \"r286\" ] }, \"us-gaap.ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice\": { \"xbrltype\": \"perShareItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice\", \"presentation\": [ \"http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable\" ], \"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Weighted-Average Exercise Price, Exercisable\", \"label\": \"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price\", \"documentation\": \"The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.\" } } }, \"auth ref\": [ \"r286\" ] }, \"us-gaap.ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod\": { \"xbrltype\": \"sharesItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod\", \"presentation\": [ \"http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable\" ], \"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Number of Options, Expired\", \"label\": \"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period\", \"documentation\": \"Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.\" } } }, \"auth ref\": [ \"r291\" ] }, \"us-gaap.ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross\": { \"xbrltype\": \"sharesItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross\", \"presentation\": [ \"http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable\" ], \"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Number of Options, Granted\", \"label\": \"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross\", \"documentation\": \"Gross number of share options (or share units) granted during the period.\" } } }, \"auth ref\": [ \"r288\" ] }, \"us-gaap.ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue\": { \"xbrltype\": \"monetaryItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue\", \"crdr\": \"debit\", \"presentation\": [ \"http://sensushhealthcare.com/role/EquityBasedCompensationDetails\", \"http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable\" ], \"lang\": { \"en-us\": { \"role\": { \"terseLabel\": \"Stock options outstanding intrinsic value (in Dollars)\", \"label\": \"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value\", \"documentation\": \"Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.\" } } }, \"auth ref\": [ \"r26\" ] }, \"us-gaap.ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber\": { \"xbrltype\": \"sharesItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber\", \"presentation\": [ \"http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable\" ], \"lang\": { \"en-us\": { \"role\": { \"periodEndLabel\": \"Number of Options, Outstanding\", \"label\": \"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number\", \"documentation\": \"Number of options outstanding, including both vested and non-vested options.\" } } }, \"auth ref\": [ \"r284\", \"r285\" ] }, \"us-gaap.ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice\": { \"xbrltype\": \"perShareItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice\", \"presentation\": [ \"http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable\" ], \"lang\": { \"en-us\": { \"role\": { \"periodEndLabel\": \"Weighted-Average Exercise Price, Outstanding\", \"label\": \"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price\", \"documentation\": \"Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.\" } } }, \"auth ref\": [ \"r284\", \"r285\" ] }, \"us-gaap.ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber\": { \"xbrltype\": \"sharesItem\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber\", \"presentation\": [ \"http://sensushhealthcare.com/role/EquityBasedCompensationDetails\", \"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure\" ], \"lang\": { \"en-us\": { \"role\": { \"label\": \"All Award Types\", \"terseLabel\": \"All Award Types\", \"documentation\": \"Award under the share-based payment arrangement.\" } } }, \"auth ref\": [ \"r281\", \"r282\", \"r283\", \"r284\", \"r285\", \"r286\", \"r287\", \"r288\", \"r289\", \"r290\", \"r291\", \"r292\", \"r293\", \"r294\", \"r2
```

"http://sensushhealthcare.com/role/EquityBasedCompensationDetails", "http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Exercise Price, Exercised", "verboseLabel": "Exercise price (in Dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r289"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Exercise Price, Expired", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": ["r291"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Exercise Price, Granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } } }, "auth_ref": ["r288"] }, "srts_SharebasedArrangementbyReamainingShares": { "xbrltype": "sharesItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "SharebasedArrangementbyReamainingShares", "presentation": ["http://sensushhealthcare.com/role/EquityBasedCompensationDetails", "lang": { "en-us": { "role": { "terseLabel": "Remaining vested shares", "documentation": "Number of shares vested remaining shares." }, "label": "Sharebased Arrangementby Reamaining Shares" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Remaining Contractual Term (In Years), Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r26"] }, "srts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm", "presentation": ["http://sensushhealthcare.com/20240630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm", "presentation": ["http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Remaining Contractual Term (In Years), Exercised", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." }, "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "srts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm", "presentation": ["http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Remaining Contractual Term (In Years), Expired", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." }, "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Expired Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "srts_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm", "presentation": ["http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Remaining Contractual Term (In Years), Granted", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." }, "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": ["http://sensushhealthcare.com/role/EquityBasedCompensationDetails", "lang": { "en-us": { "role": { "terseLabel": "Shares vested expense", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Remaining Contractual Term (In Years), Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r72"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": ["http://sensushhealthcare.com/role/EquityBasedCompensationDetails", "lang": { "en-us": { "role": { "terseLabel": "Grant date term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, vested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r300"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": ["http://sensushhealthcare.com/role/EquityBasedCompensationDetails", "lang": { "en-us": { "role": { "terseLabel": "Grant date fair value (in Dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://sensushhealthcare.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "srts_SiliconValleyBankMember": { "xbrltype": "domainItemType", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "SiliconValleyBankMember", "presentation": ["http://sensushhealthcare.com/role/DebtDetails", "lang": { "en-us": { "role": { "terseLabel": "Silicon Valley Bank [Member]", "label": "Silicon Valley Bank Member" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover", "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": ["r625"] }, "us-gaap_StandardProductWarrantyDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Changes in Product Warranty Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://sensushhealthcare.com/role/EquityBasedCompensationDetails", "http://sensushhealthcare.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r6", "r43", "r46", "r47", "r101", "r119", "r120", "r121", "r137", "r138", "r139", "r141", "r146", "r148", "r150", "r163", "r178", "r179", "r186", "r260", "r332", "r333", "r339", "r340", "r341", "r343", "r344", "r345", "r351", "r352", "r353", "r354", "r355", "r356", "r358", "r363", "r364", "r365", "r366", "r367", "r368", "r370", "r372", "r386", "r442", "r454", "r455", "r456", "r465", "r518"] }, "srts_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://sensushhealthcare.com/role/ScheduleofTotalRevenueTable", "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": ["r173", "r174", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r467", "r468", "r469", "r525", "r527", "r530", "r536", "r538", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r555", "r574", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r602", "r608", "r779", "r832", "r833", "r834", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://sensushhealthcare.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r137", "r138", "r139", "r163", "r372", "r396", "r461", "r466", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r494", "r495", "r496", "r497", "r498", "r500", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r518", "r609"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://sensushhealthcare.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r137", "r138", "r139", "r163", "r176", "r372", "r396", "r461", "r466", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r518", "r609"] }, "ecd_StkPrCOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrCOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r637", "r648", "r664", "r699"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "presentation": ["http://sensushhealthcare.com/role/EquityBasedCompensationDetails", "lang": { "en-us": { "role": { "terseLabel": "Restricted stock issued", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://sensushhealthcare.com/role/EquityBasedCompensationDetails", "lang": { "en-us": { "role": { "terseLabel": "Common stock shares issued for employee", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r6", "r42", "r43", "r70"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "calculation": ["http://sensushhealthcare.com/role/ScheduleofEarningsPerShareComputationTable", "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0], "presentation": ["http://sensushhealthcare.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "http://sensushhealthcare.com/role/ScheduleofEarningsPerShareComputationTable", "lang": { "en-us": { "role": { "terseLabel": "Restricted stock awards", "verboseLabel": "Restricted shares issued (in Shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": ["r6", "r70"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": ["http://sensushhealthcare.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Forfeiture of restricted stock units (in Shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": ["r6", "r42", "r43", "r70"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://sensushhealthcare.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation (in Shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units

issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r6", "r42", "r43", "r70"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable", "http://sensushhealthcare.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options (in Shares)", "negatedLabel": "Number of Options, Exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r6", "r42", "r43", "r70", "r289"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": ["http://sensushhealthcare.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "negatedLabel": "Forfeiture of restricted stock units", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": ["r6", "r70"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://sensushhealthcare.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r6", "r43", "r46", "r47", "r70"] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": ["http://sensushhealthcare.com/role/EquityBasedCompensationDetails", "http://sensushhealthcare.com/role/ScheduleofEarningsPerShareComputationTable", "http://sensushhealthcare.com/role/ScheduleofStockOptionActivityTable"], "lang": { "en-us": { "role": { "terseLabel": "Stock Options [Member]", "verboseLabel": "Stock Option [Member]", "netLabel": "Equity Option [Member]", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": ["r608"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": "1.0", "order": "2.0" }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet", "http://sensushhealthcare.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders'2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r43", "r46", "r47", "r64", "r483", "r499", "r519", "r520", "r599", "r615", "r747", "r764", "r817", "r863"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders'2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders'2019 Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://sensushhealthcare.com/role/StockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r69", "r133", "r247", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r357", "r521", "r522", "r537"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://sensushhealthcare.com/role/SubsequentEvents"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r389", "r390"] }, "us-gaap_SubsidarySaleOfStockAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://sensushhealthcare.com/role/ScheduleofEarningsPerShareComputationTable"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" }, "auth_ref": ["r692"] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": "1.0", "order": "4.0" }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "terseLabel": "Income tax payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r34", "r35"] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r684"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r691"] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": ["http://sensushhealthcare.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": ["r85", "r86", "r87", "r761", "r762", "r763"] }, "srts_TradeshowsAndDemoEquipmentMember": { "xbrltype": "domainItem", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "TradeshowsAndDemoEquipmentMember", "presentation": ["http://sensushhealthcare.com/role/ScheduleofPropertyAndEquipmentTable"], "lang": { "en-us": { "role": { "terseLabel": "Tradeshows and demo equipment [Member]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement" } } }, "auth_ref": ["r712"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r714"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "srts_TransferOfInventoryToPropertyAndEquipment": { "xbrltype": "monetaryItem", "nsuri": "http://sensushhealthcare.com/20240630", "localname": "TransferOfInventoryToPropertyAndEquipment", "crdr": "credit", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Transfer of inventory to property and equipment", "documentation": "Represent the amount of transfer of inventory to property and equipment." } } }, "auth_ref": [] }, "ecd_TrdrArrAdoptionDate": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r715"] }, "ecd_TrdrArrDuration": { "xbrltype": "durationItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r716"] }, "ecd_TrdrArrExpirationDate": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r716"] }, "ecd_TrdrArrIndName": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r714"] }, "ecd_TrdrArrIndTitle": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r714"] }, "ecd_TrdrArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r717"] }, "ecd_TrdrArrTerminationDate": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdrArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r715"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://sensushhealthcare.com/role/ShareholdersEquityType2or3"], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r24"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet_Parentheticals"], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r24"] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://sensushhealthcare.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": "-1.0", "order": "6.0" }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedBalanceSheet"], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, 532,924 shares at cost, at June 30, 2024 and December 31, 2023", "label": "Treasury Stock Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": ["r24", "r25", "r43", "r46"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://sensushhealthcare.com/role/LeasesDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r346"] }, "country_US": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": ["http://sensushhealthcare.com/role/ScheduleofTotalRevenueTable"], "lang": { "en-us": { "role": { "terseLabel": "United States [Member]", "label": "UNITED STATES" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r711"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://sensushhealthcare.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r19", "r20", "r21", "r90", "r91", "r94", "r95"] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": ["http://sensushhealthcare.com/role/DebtDetails"], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": ["http://sensushhealthcare.com/role/DebtDetails"], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "ecd_VstngDtrFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtrFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r680"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://sensushhealthcare.com/role/ScheduleofEarningsPerShareComputationTable": { "parentTag": null, "weight": null, "order": null, "root": true } } }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement", "http://sensushhealthcare.com/role/ScheduleofEarningsPerShareComputationTable"], "lang": { "en-us": { "role": { "totalLabel": "Weighted average number of shares used in computing net income (loss) per share '2013 diluted", "terseLabel": "Weighted average number of shares used in computing net income (loss) per share '2013 diluted (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r152", "r157"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://sensushhealthcare.com/role/ScheduleofEarningsPerShareComputationTable": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": "1.0", "order": "1.0" } } }, "presentation": ["http://sensushhealthcare.com/role/ConsolidatedIncomeStatement", "http://sensushhealthcare.com/role/ScheduleofEarningsPerShareComputationTable"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares used in computing net income (loss) per share '2013 basic (in Shares)", "verboseLabel": "Weighted average number of shares used in computing net income (loss) per share '2013 basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r151", "r157"] }, "dei_WrittenCommunications": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": ["http://xbrl.sec.gov/dei/role/document/Cover"], "lang": { "en-us": { "role": { "label": "Written

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[http://www.xbrl.org/2003/role/disclosureRef](#), "Topic": "850", "SubParagraph": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "50", "SubParagraph": "(c)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147483326/850-10-50-1](\"https://asc.fasb.org/1943274/2147483326/850-10-50-1\")", "r388": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147483326/850-10-50-1](\"https://asc.fasb.org/1943274/2147483326/850-10-50-1\")", "r389": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "[https://asc.fasb.org/855/tableOfContent](\"https://asc.fasb.org/855/tableOfContent\")", "r390": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147483399/855-10-50-2](\"https://asc.fasb.org/1943274/2147483399/855-10-50-2\")", "r391": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481326/860-20-50-3](\"https://asc.fasb.org/1943274/2147481326/860-20-50-3\")", "r392": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481420/860-30-50-7](\"https://asc.fasb.org/1943274/2147481420/860-30-50-7\")", "r393": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482546/910-10-50-6](\"https://asc.fasb.org/1943274/2147482546/910-10-50-6\")", "r394": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478345/912-310-45-11](\"https://asc.fasb.org/1943274/2147478345/912-310-45-11\")", "r395": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478411/912-330-50-1](\"https://asc.fasb.org/1943274/2147478411/912-330-50-1\")", "r396": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147479941/924-10-S99-1](\"https://asc.fasb.org/1943274/2147479941/924-10-S99-1\")", "r397": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478934/932-220-50-1](\"https://asc.fasb.org/1943274/2147478934/932-220-50-1\")", "r398": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477215/932-235-50-18](\"https://asc.fasb.org/1943274/2147477215/932-235-50-18\")", "r399": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477215/932-235-50-18](\"https://asc.fasb.org/1943274/2147477215/932-235-50-18\")", "r400": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477215/932-235-50-18](\"https://asc.fasb.org/1943274/2147477215/932-235-50-18\")", "r401": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477215/932-235-50-19](\"https://asc.fasb.org/1943274/2147477215/932-235-50-19\")", "r402": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477215/932-235-50-23](\"https://asc.fasb.org/1943274/2147477215/932-235-50-23\")", "r403": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477215/932-235-50-23](\"https://asc.fasb.org/1943274/2147477215/932-235-50-23\")", "r404": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477215/932-235-50-23](\"https://asc.fasb.org/1943274/2147477215/932-235-50-23\")", "r405": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477215/932-235-50-23](\"https://asc.fasb.org/1943274/2147477215/932-235-50-23\")", "r406": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477215/932-235-50-23](\"https://asc.fasb.org/1943274/2147477215/932-235-50-23\")", "r407": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147477215/932-235-50-31](\"https://asc.fasb.org/1943274/2147477215/932-235-50-31\")", "r4

[illegible]

[illegible]

[illegible]

[illegible]

Q~<8>:SUVJ4H,-.836K:CF*FC7710QJQDS(XK(M*2SXJM*517-LX74/+7# MY*4/Q:9LNI*#PR+U*CYTNCN.%0J4S4<T=T4WU06@-YSJIDA7BA#X^M:M,"G/5L&-
=TM6.213K41-AL "93%7G9U@<+>J\$=B0-7P=>48J):D: MUGOB L-7P=U608CH.6(-XAAJ)-U5DX5?QYJMLXJ1H-1P. 41NZW+ME#71U5) &JL 8BEE A^V%
=39.25:3SVBVI/QJK L C)IEAF4<Y^&5&J!M!3GV.R/Z@L4J(DZUJ)%!G<+>^!Q^Q(Z78H)+U5Y5:M H8^Y+CB^FHS&KS3) MJ.:@%0\$H=NS,&
I QLM+M&M%PNV:ASZ5D1R+4M->^!U2EJ5G6?J9G MO:BHF AN690QJY8<@>@UJPL69@Q5G:PNV+\$\$4(LDWAQJ. M!M^HLHJ M^Y:YJ. 7H)0KB2P)T !^QY.+3*^Y E15Z24Q*P
IHQ^N B MTK% 109U0U+4M->^!06*(K^ZBK6D&B:U@<+>1. @>5CPRB81GX^?>@> 19N^: MB7^L2BRU V \$., 03Q8XBB9M2D&7Y) 1R. %Y@.LL.59 MB8T34.D&H(S4)5ZD-POA\$>HPE/QJT?>
=SPK^74G(ZBBLL 2T^9JNLHMK^TD6R30H+7 M .D-T4.KSA3,8J@?> Y8YU-5YL6L@EX.CSF&B7FASV:NX+I;2,6&R&K M V3U2+>^!5#ZJ(QVOOL\$W IE,<+>^!11G51^5L0#G 7-
P^V^TB7N40J:M.PBH>+>6U^(<?%6 81,"58^J?>QHS(S4)48ETO L M^ 8B8Y2P4^DVKKHJ^T8M.R77AS9U^P^OBKRJ=DX:=- S5:@(M&E)>
@QJRD3,TBQPI:KZMX.Y^JN:ND "EVEJQ">Q"E.MGWS M^8W+V +J5J0 3>2W:G3?>@>T@H3.3+?>Z^E?K^P^KK @X|>S=7+K&K M!QHU! XJ
QAKM&X&L&V^&M^WKVY:MPJY^7WP^O^U^S^AM^OKG\$^XJ|>@> H M^M^W&C.O*5=| 88RT^ZXKH06(W\$)P4>5NHB=D7EJ>HV OVE?NLF6^AEJ M6^8R<Z+T^JZE65^X^J^T
=<^!LT3%WW,% 07&I>= <^!MX09T[Y+>E63N=2D?>4L)STLNJ.:!H=H=A@5?>@>4DL\$WP4@>J|U4|%= .7V M|^962JL:F+I>V+^H?>0W2E!^>3 BOU5F) \$(/ M^?M3KRIZACB\$4E<-.P=^L.).
T7V^M&B*2^90^W&ZE.#K@Z@J42K79^?>6C8 8WD8B+9NN01PG=7M; MF^F8J8D 2A15+I= INCYL2@>@>H2I5>9J5L9%4&T<^!>ZP5\$>F=8R5=5
N^9KURG6ET@B5EKE0L+>XJ@>PIR-1@>E320XAI?>Z&N>+>0.&O=S72==H8 M^AC@>A^>J%LI^P^C.E^XDJ. |5|5U1|35)I03Q@>Q@G1-BTK\$WCHCJF@>=J
=JH^WC9 8J|BP> <^!>K>=> Q0^19Y1<0>WFT M5A\$ =YX MJ|TCG[VQ?>0BRR\$>K^C@>O WLM F|S(OHND2^>SPKXJ^UC3PXON^QVL7BH^7F&9Y MOX^B9.-8&888M/Q@>QZEWMD>#XB
JYJL2I0H21J|B|B|GJ^D6>G6QM.M.ZID.RP=CVWT <^!>?%6K3?>^!D34>=>74XG%>L^K4OJ) S^M F|^9#9G>0^!15913 3P305~7V.N.X.1+>=>63RDK900^4K^Q7.8N
>U2^HDA+SR.M.S@>J2Z.4+ATH-PWUD^NT+AG6,2753IWSM. <^!>+E65%>J76 MDA5\$4>J2>JWL9544HQK@QP^*4A4<+> <^!>PP80.RS.M\$O^M\$%9CM=7X MJZ^X9Y7@>IGO
UWSU/DDL5H.R9 JDDPVRHJZOVTV?>QQOQ^P.LWJ3B7J MRG 92P9WU^0E#%>J^=JXJ80D7^>SF4H.F5GZTD6D77J^V.Y.18^O^E92G M2D=0T^<^!>K^H 7W?
>K^K^T^DZSIE@>=>^F9YQJ^OFIS^M^Q3R4V2XICB\$ M^+K 1V;N^OAWEE4@J04C10-07@WAU4B=0548?>%8R7V.D90LM+7J|^1^<^!>M^J0.2<+>P|J|^14%7_1 D5/GS.WMPVA(2#=-S/
^W^N^N^L<^!>Z@>ZSVI^?>M1J|KD&6\$J1IB(ITEK^S^8)3%3&U1|^19.DV=I<^!>S=Y&8;J@>O^>K^L M^*R|Z.XK8Q^O5U^U=^N^JCFX>J^>B56J|U7JM3K68W#<+>^!>E9 KH9G\$5%JLX(8
=>#45%677^>S^H. <^!>+>X9R6J263T1|^1|(R9256J&?>XLOWMDV?>#4%>GEW?>X^T MF=LD15+>^!>DV+M^&P&P. \$M@2^>QK?>I\$>#?>QY-XL6R^RJT^B^>W3M H
=ZH+>C@>J.1|J@>J47UDU=U=0^>6S;G=CPIJ9Q/K83M8IB^C. ^>@>H&M J|P&N+U^XJ|9J|HJ:G^WG-K%> <^!>1W!^>X^H.N.Q^>V^U^Y^J435F ME@>745.%&5C 1-
=JYJSEJBI^FQJ1^>K^V6F^P. W>U+JAKA1R^H-2>J>J6J19U^OJ&M^+J|87%?FX:NJOKE|B|^>SNFOT6|&25J|>BREN4#>7^9N9 MPG<900Q^OJQ9KRS4|SVV M4^80Z&
=>QW\$59Q^>K^K3KJ^90-6>RZ^I.O08\$ M^Q10K47K543J16H9V9J1UJ17^H^("ESG778UQV:7&=I45X4J.<+>S5YK0J).X^ M^<^!>QZV.&46V05+1|^1@J15J1KJ|895+J^D^JURV(6^>6^>K^O=>^!>F&DKM
=>#ZHK6B+E75F 72.YJX=A. |X9= 6%F678U2QJ|JHFH^JOXYKJ|JZ<X M^W=120>|^1?>2J^N&E51GAPIMK@E4LO@>M0V62V3<12PB.A5.V1^<^!>6KJ|K
990ADJ^>P<PZ.4.B^>CKMGJ4I4ZSLER9T:6H|DE. 7&T7XRC9G95%<^!>51A^8 M^V=1.TNPWFT.DPHZ:~M^!RMRZJ^XJW U^S=YJNWJM M>JSLJ|V^+1+9S|P5AT7
9J3JUPQ.ZJGJ@>V^M^K:4V5QZP98Y-S^CZ M7RW9:Q64HOC<+>Y. |@>C#%VQ=>K^T)?>FJY^XJ:SK1M.NE41+ 8EN.PJ6V=I>^T2ZF|B0H?2<@>Q:(F3#6H MM|KGC.3<-
=>#45%677^>SR. <^!>(RAV>G-I|B|>V73J1ZYRPYJ.8^|B8T58C MAL=80^>RQ<^!>W. |>U4WDXWJF^BBE^9HCQXXJ91EX^5.4FG(WA|F69E72HO<+> PPHF/EAL. <^!>7RL; <^!>Z#*3J|^1.LOI^*J4H/O:(<
=>0H83-MU7|^1|B8ZADL|>N6<+>0K^>..0025J|2.B+J.X96\$>NKE02^>M97. N.PMD20MQAJ L<Y<^!>.2JL.8.Y^Y5N XRS^+>@>TN^>2^>5^>X^<^!>Q@>UF4 M<^!>61D%>DY+2->@>8BRJ|U9B59R.^19A^
=UMGJRTJ|^1|MX8GR<1GK3+3>A.N>J.5IUIUC+4W\$S:3FGXG>+Y3CVDJ3T3ASXR7C~.NAJ)<^!>CE:G7F34XKT^R M=U6F^H93T^N^E6J^>
Q@>14=-N^%>U9M81+> @0E1=E4J7N;N#G:SWF.EP/C74+GH ETKJRG(96UHNW M^7J^N2FWU^7KGB3J5|LEJ|U^PHEOLGE+J|V|1H^QFES; H22J:
>QO>106.QLYJM^C8R4QJ7;3JVQ3.2Z|PWR91M^&4^MFE02BMN5^O=(R3>7+9BIX+J^P^W^H^MUU+R.KNX6^EPA|>2H-U4B5J3|^1|W=N4S W7W\$;D3W=
=M^P&T&GJ|T5Z^A=Q&B^UM^>831R@>=>X9>J#>=>@Z^Q MX(OAE>TMSB;W&H^J).QD61^>S^WEL6BN17L>+>17+>6C^>H M^B>B6IV^>GQJ^C@>@>N^Y8^>(9@>V\$>W#>.
=>T&L.N.OJ|9J.G.T=1. <^!>FPDIV<~MHPH599R7 8Y\$S=W7Q^>Y^C+P5+WQJ^W^XU=CEWGNJNHBGFU7J TL82GM M3J71U5|>J2LH7^

007:=-E3VQTJH^H^X7S/VEH^QH^K^E.ID^Y=PZL^1.T11B#1,1BR69M^M^S&Y?2^DOJCT2+4%Y1:DB,LE:4^S8+2A5+\$C,H.W(./:31%:*@|72I|=8#(MC)I&W\$Q3^I5%A^=GBXN0^)+H5
@0N^T4N8^HD16?|S|T^1CD&T6+?/MS(C,H,U)96,10W;833?I7J9P|=+&Q06Q^+B U3700^:Q9,@H2B^SIXAR: M5 R^,DX\$@=-SY%A=W=L0^0,N%A\$S^PN^M^+&S3131?
^1WJAE@/MDNQK|:/=-^A2C M027^YO&|;P29=-(WC#I^BG/Al^JZK^H3QZ4Q0&^*,6G(+,V+RWA1^7:PF52T MN027^6-GR0UC^TIUY1@2K^J9VHT^P^2^,+&OS&N6F
YMT^fKJ924+^F3H+QY M^+^ATTYA(RWUJ)D1@^0^ 56&S+;|V^1^AN:3(51|T^7-B0 1VA^XRF 7|8 M1U5W1^F>F>?^21+2^WOM06L.S|D|10^:9^L^7^XKJ3B42^G&K&K|AN^8
M;YC0^W1+>^R1TEL+HK,38>QKF3;WW=FK4;FRE^7KYD16U5E^GZ^*;?^AT=C M^-^"/^BGMW11UWW^M&S&AGZ0(?^U^J0FNJ^QR^LF1V,6)0TWV^X37^K,3|J|U MAK;UDS1G
<>MZF95?S^S6IQD^|*^#1|LJUE^6UN^7KSG^|K0V1^9^2^<^3Q3QNDPEIUTMRK827Y^X5VX0|^7^1^L8^W^4LUN&^;O^YCI,9?>A;OTU^MEV^1C^9=7^V|&|^1^R|QD9P91#(55^*NN@E^F:V-
WZ^~9U^08-KPE|^|(GQ M^+>#&D,B^B^KG^JJK0V1^9^2^<^M:KRS&T4^F^".WUE/@(P+GJK8EB^MAO)MYBEQ^%#=[MIT6#2W0-WI|XOX>^,6L9J^%K0+&|^)#6
STD0B@OBT^#@3D7 M|(MN8+>^=K9L\$F123639/MW>XZ,1F:~4AY<8;&|Y>^P%>DG^350+0|RAA7^F| M^KT=W-;?^TV\$|^U/O^FAZK,1283QJ03731J|^#4^42UIY1|LSL;#^I=NLD;A\$
MWDK^%&^U|U:GO|^M8VWQ|^#^1+&P^%Q^3^1B4M^WJ4=5|J|,P^M|@;7B?V^MMJ&S^WJYPB,|J^K=-V^0|^X^J758|GL^VR>69@8J8+&|B=&~R,53U^F^"V^M^L7^<9M^YK^="|
|W5/GM2^9|1FWN4@HXX-ENQ+>^L26(BG/K^YN^QUSX\$|,Y|^>^PF#=#=@Q|3|NJV^E91L^B-91K&X&H|N|JHX>^L^2;1HCW>GD754^<^%Z|T^=6E61^RV|Y^|W&?^|D
M^JRK^6&60XVU@B3H91V4W18\$JRK^~Y^VD<+&P^V^XRTSOZBG:HDH7T|J0|+|^4^|,M^D1A^+^N^=(GTRV^%V^J(4 5Z^FBU^9J^LAVGT^>^=^USXXV^76,7/0^@^G
M^MC2(KC=FCZ;N|BB^7E4W44AC^E.12^+&^JVM^M^TUR^;H|I|D^L2SNP^PA;LVD^F2NT5^>^0^_I0^F^M^V(SRO)A|J^HMD Q^_64;5&S^6XXN^AR|S^Q7R^XKLACHQT|E^A>^!8L^-CH
MQ X^%A>^!80^;|^JQXW^%K|C^I^FEBKGQ1S^6M^8^M01\$S&J=|M^R N^%Z8<24%|76G%,_ODAA^CT(F&X^J|;P|L/R@^|J^3^ M^F98^E^N^UA2+K^=R^I^T^U
MIF21|180^G^+>^S^F0^7^9^E^8V^|B^4X4|3ULB^W^E=^0P6\$^WDQ1|K&8?^,12IEF M|AH:N^D^I^X^C5PT^Q^P^=^F+Y1F:|^Y^Y-RD^U^@|^I^E^H^BCX>^JBG+M^?|^1^7DP1^M^,M|JR^V8?^|
^I|E&ARQ|3@|1P|^J^A9;|^E^N3|^J^F&6RT|^J|^M^J=|^1^KQY^UCD2^7^+&W^J^H^4XZ=|^|^|Q^P^H5NVN^|,I^W|^|N^XN^>W^8T0;B^M^RGC+P^S^8E^+&ZIT|(C?
^*U^ZFTCS6^N5D|S&J^M^>^<|J^X9SD2\$7^~>^G|J23^E MD^N0|U9^&^M^@^7S2^+B^S^C^U^J1K<^G^EG^| MT,ZAM|3J^R^,YBUW|3|^1^3RNN^+TIU^F@|^J^_NH9,QRU3ET5^JH^Y.R92^"SH
M6LSR^;C^YE2M0@CCW25X8R^?>^J9&M,^U|A|PEM+^M+2&^7404^AJORES=M^7 MT|^976&S&SN4LM0D^4+&2Z5Y30^5^&W^X^3^J^NVN|J|21,^D2+&^E^INLH^@&T^M^Z^T^|&E^&^
^X@NPJ^V04B^UP6DE^8@^!3ME8G-K04G^>^X)^&S^JF?^J_N>AXQDU^ M2^W987.Q-0GUWMS^J^****TNHKE(%|0|@5..Z^H^JHS40CB7^04|&D11?
M^@E^JECU|U^N^="SX@+7S1U^LQ0|^9I9H^M^V&@&^+&M^6|9CYB^8;8|N|^(-2)^7\$;JAK<D^3^&HVM3^3C,^>HUI>D518NY6^FQ^M|^&J^R^_AU019,2XURV>+<<>UMA|Z\$E^J|>20B8^-P&^
^D^OLY|^|^QV^GH8^M1&R;|^M^"V|J0|JPH^PCRN0^HEH=^7&^&X^#&S^U>8Y^"^^7^S|^1|N>+&F\$>+9^E^MX&D23HP9^62B,0^|(^%EOGCQ\$J^T^="5H6|H|FP^J|^1^JYS4\$S^FLM03Y^<^
M^E2928^8.06W0K^5^N^~^@|^J^,W1XDKX^6;D6^0.9ST1+|M^&^<^,CPG|J0@|^(\$ M^+0^+H5;JLH^M2SRWHEEH^%XK7&^&|^@^ARLP^;^#CE26|G^J|C|S|^1^@^W
MWJ|J^>^EK843^H^#4B4Y0SP0B633^I^Y:V^%1^*^\$|^#&^0^7^L82|>+&J|^60|Y^D^MB8Z^>^0.02M^UGOHS^".W3<^#002W\$2817\$>^7^<^=^@J48&AFO+D=^
^I^VH^_H9S\$5\$=5@^9YH^X^KL0DX^MBH^%>^VWK^7=^@BR4L^TV^DJ+^_ZX;W@7;AUK^LY&^B^*8N0K^X&S\$&@6^!#^0S^M12R^B6XH8O2\$/_^"F@^_M^7T
^QSWHYS\$1Q^GJ\$W^_O=DR&K^|,^Y@|H\$O^M8UT=^>^T@^HR9^Q^QZQ5L\$7M^R^C^XTFNSOH-T2/>V^E^KHU^A^XM^OSR^?>^7^60P^M^?>J
82KR/LAT7AX12F5W,6XCZYUQV4Z=2V^B^L^X^%>^F0^P^W^6Q^PP(6^G^?|^2|^W0^?X85=^..DX3^DDBP^6X^X^GP9\$|^_MAO^M^7^UMP<R>^<R@|0Q/A8^M^@;5^1&N
(9W5<4@,73306>WT-4;HG&WA9P^#@^@|A|J^P=0\$1>8^X^TV=(K@A|J^+7H1;L3M3EP07KM1H5P^|,N2Z>S918^YZV9^P^M^#(7?7Z^A^"ILQO^HELW9.5>^86%C+&E&AS186^?
6j8;W@,^T^Q^KN^&R^Y^A^MNV-V|Q^&P|^>^KY0%6#>=NOSQGA^+76U;K,K2^K=|^1^=8R^?17P=1Q2ER^MNN5^Q^,^%IT(T^ZF^>^@&8)U
R8KWT\$S(Q4V+ZTZ^:15.UN^O^3^D;2Q>81>^M+D^F|O^|3P&1^9^A,R|^(-0X^J|BOCR=QS^S4\$E^QR^A3^P^8^,8L^+>W^OQ|OJS+^M^AXNR1,4H4E^%=\$6\$>((@&J/HU&C).
|Q@WWP=C4^%X^Y^_I>P>8^"^^.50%0^MLE^MD1S^T^CUL>I27R,ORQ^,^G^5ORY^|10I2^*J|F^B^O^%#D^?>V^KTS@/R1P5P8
MHH^?P,00P+I3^<^C^PBI|^J^&^ANV&^R^RPM^|2|J^OBSF58^+83%G^GM319^E^H^7^PUM^6^H^E=Y77=6^KOK\$;M&^8CS^70KH%7D,ME^<U8FR24=^"02^|BVAL^+
(W2+01H^?Z^+ICEL^M^90E^>^MD&|^1^1.R56^M^P15\$^53^S^N^S^5^%+GW(W1B^8^=E^%6L1^63;PA:C^I^Y^M^@^G;U3DL8X|7GM^3^CY^8B31P^V3|4QD=HV^3FG&7^7L1L^+>+&XH0^:5
^M^L^N^P27R,82^S1,6CSD0I|>^<^(\$7=62M0)PL|F^T&F^7P^,ME^E/25B&^BFZ0^M^N/(%&1^2^P5X2^Y,3R|9C2J^9^#3C&GWTA^MSI<^<E^UGI^LMR|^>|
|8&EP9^#5@|^38&Q&#^RV1|^%&P1K2U\$^P@|^+&Q|^,MA^Z=VYL=A^KB^J^T^+^,5K0A8^10IMRT3^7HKL^&S8|VA|U|^TW;2^T^>^?^J|^,M^O^&

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~630<8/G/E#Y(1%R&R@69VBI30MZ2W0ZBH8 MXM[KZJ]^E\$J;=2&NZJ;CG+UCG^FG+J^C.&1#47P\$12.7 V/2E\$ 9J:K8M\$ MJYEZ QI S0&W>YA5P I>E>E;~<7Y>/GE/OI!^W;WLT>K^X^NOI =7-JR?P?5' M^1[X_?J]U;UPTG^=5?JGUQ?2Y90KBY GCUOZ1R|OOWY^H\$=N;B_OSO&+ M^X4700?1G|C^OQAAMLE3+^M#R0,3%3X9(1+3QHQ83,VW<~<3%I@|O#|1_#J,6EV#BFBA"FU"XJ-JU MPV0\$%030G>Y,B_>JH+> J15VAB6P1=VMA2.9.HX1T2.A2)2Y0Z&7XYRZ B&JCO&:D.A MM@5:OWG&#HOLIOA?#="JNP>J?P,5Pj7?(SIN^T I&L>E-QS BH7 /I=(F_ M0N^1>TH>U) ^&O/F!5Q1; 14-Y3LUVB,KHLQ5F9.EPLU/U^5 A, WU1U3 MG.RL06?X&MB^SK?~7GE|93<0&8|QRJ|>|6CS53(1L.6 E+ED)P3C0ADG|PI(>OG< -P6H\$=@T6C.U+Q6E#WON5Y7|E|X|- F|DGC26_Y)@UB, 3JJR&W&X.O^R=D; MLIAX1H5\$,SX80H^V\$1Z|G1>_QYO,2_SG<J["H6.6TKKJG8<L.TPYGMC|>ZLR\$B MQPS%Y!FBBF5Q3TX1&J.0|FL5?22.RLH| M7V^<+>VC@M.M^*D:BIO6.G&BCF>A Z E)C>H0&A M4>E>Q|,-J;J;ZA3QI\$Y H_VEB0_K^X^M^>Z6^F&M2C.I IX:U=8K;26A91T; M\$N1ZI=9M^3H4@&DD=+&A^I.GD|^8(?? FY7P_KQ3+>LFVQJ(L?7?>?>B9 M@FXXF7V;7/N>@>0:53V.G M^7Q^J;C:7Z2B48J8[V4J_4Vt6I M2Z2|LUUQ6V6RR;?>_5Z_1D\$54;Z;M\$N,ACGM3@&-%%:" [HYI>B0&A1:51H MY&G&WJ&F+D5HWP59G6BQWS&JW12760LFI1G6&]-32J^M 7N&Z4J 4UFUXJ;H M HE4JO1(1^K|YMS|MG_P 2HT^CR2 =M=MU906-BU^+N5.K^ M1\$>ATJ&M|C%1I&+5CMOL6W46UXQJ.D4R5DN.09 UW8,7L&^4BI?<~<8&O&M+M M^K0:9J(7B,WFKJ|5FKMQU;WF;?P2E?>=KQAQO/L^+A^/FRG%9@KBS|CRF|5R M6BX|SGZ?H2|UO1T,Q_<L-B;~<3%-%I^>=9L+6%>F^16VLO^N;G3B9I% M_J,17IAKKI,IQZZD-EVUW(F.83W_5^0;P^/OBC/LR1^#RGO&J^9JC@_F M#- USMM14ZF/L4)XFN1+J] TBG^H(G^7H09)O^RY^N^ +JX+J1;IU:0; MAJJ|F9YHTRX.R?P? JUEMR4N^H5W(=>BW|OB6CK^H^K;V56K^U,|WCXP\$="J MJ;^MPU^DQXFL4N,Z9LFFS3%~+T @=U^8TW C<8\$SN UA-M^N^9^Y12 M3YKE8,>679,EFQ/7:1?FQ#;\$.SW>.S8GWX3X|QJO2.2..2231^*Y&M;LL^YUB MQDJUMQXSEI 91|XBFB^M6|MFOM3W,?W\$*X^MNV@1(1 MRRBJV+4)QFZ25OS.YM^K J1.NI21V>GUVBQ,R7Z?>~+^E?K6G163|PM5|MK MPX20^4J1V=;>@HJ^<B4G0&PAY#?HKN(D)2?2% (T2+J/U5?7;G7A#4L3<+JH MK4ZUO RR;JDX,FBF^>1>9J2@L1+ADD; <~\$P?12?>_7,J51KVL;S#0H M16|PG?2%#1,60H1(L-&IM&Z;FG|59X^J|ZKZH|&A;2H#;~+P#>+5 IE 8F M1\$>K^*Y2T.F.COB613W1(95V;J6P2)7B^UG^*Y1&^OVN9V1#2^0931QK MEN^989^81K9^B#M,|JH5JO(9^CJ|(D.CY\$&B^91X1+>+3&)BDMM; |^8-32 M^MXQ8^%:(AX)?JH&4|>- #:SLX2?1|JW1T3W;J|I^C=<#7|5,6N1B^E+B M4K7,61K;S;J5Y5V0&K^?28^BBDY_D\$@1 3F1T3_?K^1H3V1GXN^D^MRR MRASBNZOW9<_19MC19^URJ;+.0%(N%5M M5|ZJR4I^C7<#7^T^CM@8|667G\$|S8H3C|I|VS|J\$XO1/8U7_8DP|@W/-;1^% MZG MNH_&LZL&G^3NQNSP9J^Z:G+4#J|D4)5KB%(N\$FP&EI@4JPTQP9 MCXS20&- RH:#D| |IJM#E(K2|S,UHGHV,B<5R1^34^I^FSOODK7!> /89P1#<= M^A^TD?B+>J&HQ1W^7H&=;~+J(3FNQ^J\$+F&Q.Z.CMP4W<64^ T L6V=; M.LC\$ M17+>IKM^#H9YPE\$34@G: (62&?)JL6VKH96V(6@S357<56-ONGA1=)1DPC0 M64IXV<#&H^TRB+>J U|U62A 12|>D^>K=PB|>=I|JUD X H^EQY MUC<+|T3,& M.TC^Y^BT4S^88\$Q?;#1^QY 9)703@J15DHWYBL0J^R-U OQZUN^?>+>S M, (<5AK&8^&EETP;18QH>D<;<-4^>Y11=|HA|G0&#>+|STGMA|YVX^#W^E.L M.U|G^6^M1|J|ORN|HXS0^XP9\$ZJIOZ MID,+>L1J,1,8F8QH^L^S+4, (<@FG\$ M.M^3^YJVBV NZ4^4^U VU&L^H|LE10KIA\$7<OSBE2,3J1V36AT|(H4R M@PQ5,M1^O=0^#WH,X3L&X|M_1\$-A, J,DS5-N82.Q9-4!C@<@V0WS=F6^& MN_9-OXB^UOP52,D>[2,Q6?B|= B7AZJ|ST&#@QA+DV86Q1B_B-WN^@9MO M6|MJSIHZ7A#7%&IY9F:XT\$X MUY;V|V)50_U9 9,R,D,H)0<#%R^1^JYF@O3XK^1U%>6_~>1^>N^K8@>J1B M_RNFT7TO9SW0V4@>D67\$3R|GMJ|I(|=<J^<V%F,5WBR7P^MDSOUS^>>>6_1)^+M M89\$?>~>CYSL^4V1;_>7/8Y,SO&G^Q8U^4_4 A8BP9_X7,1|1^|(H|B|J M7D91?T768F|A007RTRV TTLV=TOT.O+D576R6;L;S,0+|EILW:BS9>^XB &M)KJDE AJO)&=-QZ/A|^<^/I JY3X<77_6^W7<^E^<^>TOTSNI6^"W9W H T C MT)>3WUUM,|HIE:FUJ^BZ_5TVJ|JUTJ51^JH(KH|+433^>K0>|&AV3=Q M9N TKU|J4:BW>T<^6V^R^1|2M|+Q>W-L;,&F1Z30W L^N|FR^K^#>G+> MONVIK9FZKJZVD^99T7JW-MVL^Y^VL-Z_N:|KMA9>LU^V5U2>EL^K|Q8^ MM\$A&S^B^2\$S^YM6%5:5|J3|GHXC^M^O%>Y7Z136 2/XF90Q8YBGM13^>G\$7.L MN^IL8+>POV\$>F|1\$1^8@2^|SW_03L X2;M6Y|_RAJ|JWY500:A MH;MLY 3=);4P5U#&+&1!18;>DL0\$3|PXVU2_+S^M^J^E1=NA(6W847X.#8E M1_20#ZV.;1M\$1%>Z=C^ CLT+6+V6|4VMPZFR@>:S\$MDAC 1^C_>Z^G? M^P1|B^#^R;0, 157H^6(MP2SXLTM^B:866G+|6T|V,|BEFOX+S?>P45|P|AACG|3BUB(1+1/%?> 3^JZ4@30^Q1 M^8ZC&^U^T^1^J|S&8+R-W|J|NTRFS@&E MJP<=>J|PB>+>N^W|J@F#&K^%W4&=<=<M^PZC@WL,9Z,Q14^W13;_8E_MJ^>P^5;#8MX:HG(78E@4 LACM1C|T^Y^Q^GS

[illegible]

```

1)MAX(=M5.0+E0K8J.WM'KJ;@#5K1AQUUBJFFI05=3&N.H.PP^H+UYQ"TI]-ELX'Z@F8JNKKOVJK5.7C.0U#)KP MBZHJWJS>I/J/SX6J0UWBG)&JO_VW^?R4 MI;
2)C=|B|L4+3GC5W-2CWQ^A^ICX9N1M^M^JVV<0459>@8J'O-..R?H.G.111^64GVZ8Z!Y?TOBLJ1Q(OY68A)Y.760. M6;*&1;I=0. W: I?
3)C=IPGK073^38<=>=7C6X>P+V6S+SUP166^N9>4P0 MC OY2H;8:CKD)9DWVV+M..C0?B3J)1@Q4J,IS17. Y80. M2;I:CSG$X1[K'XY;K:B(JT)V=C&60ER>I/T%=D#&#
4)MH3EJ(223T)GHXX7? 2#H-CIVPH@1V..=+M8J|H=2E@+35&Z?M6#M&=D(1XO ME7YRN..IPN@>..(NEBB08KKK1T)U6Z^?0I..^<417 L^ Y_ =8TC.(57 M01G.[P]J2N
5)JR<=>5%I[=QVZ ]J6KEK7%>H..&=[^<3JW0+H(RB=O@V^?DTHVR ES17N8O+V4XJN$M/VZYL+.4; ?E MR9?5Y0Y3.ME4? 6?M9J)IT66?F1I= M=>S^I5+ P04 ^IC=PU9D%)
6)J4 T IU0@. %0 ^R=,M C R= V M,S129&5F+GAM;U1J7^|K-OJ-.7-..I^N79>?Q7-J9J, 6633V87A|JWV#Y.PX.#Q9AN/KUZ.CN|NY^FWZ^ MV^Y&)(BPC0C|X.#PD Z8#3G&B
7)WXZ|S0@>C:|P|,7LJY^>G9KTI?KR? MC@>@/WW^4^ *3_C< TOMQ9?IYOG|QYD?J^XN?J^V,WK^H^I.F+H^R+3Y)O
8)M_GK/BA\ ^Y% _UGKU ^_JHK NOTJ<@>N^2(=I=03W^L^ *3_X&6UJ|K0|NR;4: MN+>+>2^..W@6V%9^M?IUP0@>Z$#|VB^|Z#9|,7SWZ|JZ61?H=)JR2R0_P
9)MBCYJL@1V;SCPT#6<^13_#72S9J_9_0R^Y>| 73G M%T9K?> /OE,|X|GP2>ZS A^5L^F_ J^PJR0; ^OWUV98->GP2D06BRO^IA M6Q@Q61^Q+QUQQA^M
10)&2XJ|7E14_?#0M2V/Z^|J^30+;|J2HERBFY>| TCG M7J>|B^A5@>|P-M^A=X^X#C4A|U|C-JQ,Z#? _Q^AMN&46)FM2,MLCBO^ON
11)M5^= IZRIXY62SRW?|=;#|TLWJF|EDL+X+9C30WV1G5,C14 M^=M^M^4J|L1N|(EQ&YPL$^X7I^#23,IKV3UN?WNL^?2H%L19N+O:USS=).9(&^4AM=8R|&S&T,9CLE=-
12)KLYX>9_ID.S MI^>@.KX&5&5.UDQOI 19_JT^MJIV^G@>3_TM^TQI&T<>J|JXSM6ZJ|C:WE(Q> M_U.1910GTS^%LJ^4@>|TE/FN^T&+DIU$GK^?W=H|UD^>P>2^>.&L.G.JD|D MH6
13)V<8DUGV,T9^|K:-(V^4|Q2FC)C^<+J>N|XIEC+I, &AD35N@6O^TR^TO.X^J^ ZCU?7:TCFQ,5|4|CJCB ML9S;95&X6V1JW+>,"C,9|H;@>+M^?N^Q|J|B|;|
14|,5Z^F,DK?>=M0FU^X1LP^PNR5R>214ZWC4S|UIY M#OSA,RLC=PU&M:N:U840 |1^I^%KTRTJ?>I-!-u=U4C2^| M^S^?F^?0HMS5RYVW(F.KL529^L5YM(TC,X)CXP6%-C+ M TR?
15)I_<(Q38?Y0VZ2)K^& I,"DPFLY32^6LI< R?QI<-RX5&+E@M64D70SG MEXE3^J^,INKNV3J@(|J8FHUHK;"E6X,K^?CDXLJ+^QGSJ|; MRBPYG9I5&3FN MJ64|I>EE&E^*
16)^!,RORPB<^?D|J|J?>|H|C|Y2K|55|UY^F|@7@-V.1F M-2GU;M^X^>+N@OV |ND6^6|R-8^*-T,3^?2|215@2W<|/MUL3|>6YIGQ MQGZPY8CJ|>N|&F|H|13#MC7NN3V^Y-
17)^JR^>2D90F4I?8A6|XK^@BP.G/ MZ.^5>6>+1.1P,EFKS|OT?>7LU^4^E:UW5 8IY^M|3IM>RP^A^M^?A)A9Y&#& M& I(WOB^FL(^2%)LDMF(QE%
18)(DDY4M,9T1(2@DXPB$.@>N^M|J;G^R7BZBQZ M^?#*4 B1>^L^:7D^WV5=OASE052 MLF^?>KKL|JCV_C|IB7^ K^L8;ZB5J+RH9IEVDI48S6R|FI|>H^;FQ24(
19)M7XO&95^I?T04)CRK^M^U-9$J; _^BHJ9KE1^I_>+3&5$9S|<AP9X M^?K^ M|,D|P@%N^..LB1H^I| %%=>"DC,E(OEZD,3; MKM^WY(FK5>J)BPKK^WE49:NQGL09A:0&M?2=U?P?E;I
20)A=[V:U;DNSB$*(RS4^J2BNE;WMB$>G^+G^>@-B5 TZ$^?2%I91 MP|H|O-M2VJ @>G-Q-4:IPOT76QML(MN>BKCWBWJZ6YD5&A.^N%G42^?4TI MJQ,X|,1^2W
21)QCD4I^>VDB8^I^D(333G6^I^D^R_1JB=-O1W&I^&X@>(XPL2_1UW&X&1Q6P1V^>C|)ND2|+M^IEYK^I|J0C&R7=U|O ^I^P6PG(N^A|;T^M^&3&OMB@5E =C/^I^G=QYB^KCX^I)I6?
22)V3;CHW;D1(XSQOT5K^<LKS5I7_1^MM,7_H_IX6Z4^+W_B^C^%6SV|V&^I52868T^?>OEB,X BL3%<@CLC).1% M:"FAX1WKFU
23)^..+4$;V,0M9DF76C|D%>>6H/0V@>^1^NW+G8+JG7^).X|D|L M|&=>DN1^|ER^@|230E^%YUE^/P^M=:$B1;^YRK>2FU0^;2JHEY-O MY2D^WFE7<|LC0|TQN51Z>^|I_ _B#
24)^TSBANTBP,EJC-A^|M8&|M&E(C+X^H1&6BOHPG+P+P@OMH^ M^M2FM60M,OLB|J^>=>MJ-H^F=>3VE5TBN&D24 M>F|J Y12?2^FGA4|A/LX|^42N47W2>T^?Q2>9S^L?>!!ES|RN@>
25)M1 E4|^A4M:Q15Q;LPJ3=05^QC^<2:7Q6J|A;N^X4:B15X^9AY6A|, M M3)E|H0_BID?
26)$VL4I2F6J|<741L(I-S2KX;M07^T1^642T4RTFM&G<K3TG3=85|L/WFG7J|BQES3J|YLNB>^6G^%I^Z-G^C^Z8H)U|K3=>I^J|G52L.K=26B70|V3>5>I|3QK|WP5HEA:4F&I?
27)$VH46T$G.T56#Q9,C$E^B^Y^?237;ZNE>25ZTJZ;I1&DV(67+>ZG5|>+&?EJ^E1TU(VJFKJYWI^8I^ M1963556-GA2<#OV%M^MN?%|IU>=>^<-JH%33)O! O^30Q>Q11--
28)^,RF+|0EDH+ M6D^A|U|J71#Y1.D8/4P^225;^~|RX1 9A|WC 013+<=-B80.[U PKI]=KW^A^8R7|?%0T1Q% I;J?>=OYOE.35R33@|%99 +KXSG^N(7=RC:B2$#=$ M-
29)PBO7Y9=9^0^YQK9P3Q15|MC^T_70UBK04D02DZJ$S9R3V128=KL^?>UD#1=M^F&E)3G8|>J@CQ|29<#6E89K0<5N(KSWD+|+E^V^J)JKR5^VC93Z21>4^K^M^ MPV9
30)^R?2@>VXQ|FAP?<*&_ CJH<+&7^|MCT,2N^8M^49WV^G8N&+M=8 NG6+>|06LK51*?=>E23X&S;HEDC^(|POF5XNVB8,ED|EU78C9F^KWB MK&ZT.TRRX|SV2<C^"" M_E-
31)^MKKV2U>(>8^WPD^C^U|U74XFSLNZ>N^CJ|)(V=J MC46537<=>34758S^%$6G<+0?7HPMLCCU@KN&K^&(&A&Q08HWL^T^TGS3QAJ); P^YX|>TR+R?^8I^|V^2BUZU1@>N
32)MM>=>0KL@>9E.C^MTX1$S^WWJ;5^|BVE@>=J6^|L^_H?@HH;7^P,KJCS+K+I^M.DF3|<H+9X&70<=>J65L29FU5^VMN|J^JOW(PY3,3=^*(IN-J|L)<ORP^I
33)M#2(OT$3Y)^2A^0:46|=UIU:^L1/M5VSTO#&+&4J^L<I3Q_H4JXL^>|>J|>^*^SL> _@G|ZXNGL; %1C 8+NYI3B)8@CU^WT^6EYO(M_2X$W8U2
34)_C2=>I^P,KTW4S^GB9G^1&N$N1,L^4JNL1^4.^>=>8U0^WE M.Q.D.YTFF@25,1^3^9VYU5L^|I|PE3SKK,J^3 M^A_ S+>9EMG>73H%6$ OKKM-B>H51B0+>6 _ZWD#-
35)|HUBF^>I^M9V33ELC:M|(V3E,3MN^WMPRK|VY^%Z^ _ZJPR.^>@N|J3H|G|>Z^R MTTV6F0U5I^R^>KODJ@OUN^|AUK^YBOZ^1 MQOZ3Z|B|9_3 /=>2
36)^,AKEHIOJ^|L|O&A^>5RG$|(1Z-6?I^W+OE12N^MLDAT2ZC@>6_8_H^W+P+Z
```

7=Rs1(&BE)94(!!!WC5QZ\$&'I95+G(C:PDZ9FL>9!G)(<M.K)H,A|8J_) (9!F.L"VB%Q<%N:H!_SH^=H;U"OM;8-H58)B\$R2 2;DGX* MFF _|3_CK?_F]#[7XUW9]J?&8=J)D#]
<9^EC%,+P>/00/1CPYP.F\$9U0-G;UX2EBO(9XB\$HTKGN=1@K04#^+j6W@V MXLD|3B6>FW(*;6_JH;S170^\$BKAOH:\$BJAD#%:6""P_K#L|C%6&V|0#LBB
M90%#_(>C)&@<OGRFNCN-V8P2""IY#^~^QY&6%#X@U;B"VP1NDGYRM5G Y MMBW8,?>_!QN,91LM|T MB:;>Q1BC-/H-@NRR\$)&N B18ZO|/X >1TF";
[AT|2BDONBHPHC2|NH|W=C Q M9Z(<#C/*66"8C"R);+M,M=@K>7Z=QM,1Q?&BGR=HK6|T+4R MT,MT,BLGR
H9""\$V1W0=)J|MQE1(90=VNUT&VP^~)X&|TGT2I:DD|FHE|/3/X MJ9K|7SY5|C6'6RE5<@*9>TORK/@:9??A=EE<9;

XR64==&B|8RHH5^:L1* M..WH#SV>.(E6%PA1^2F5'_IUSPCK4#)4+,'R(,70WF>& Q"P,/T0%0|GV|Q(MUS"K8HS"CC27KS6VV5Y7IY(!)7>K>76E:3&N=:TI\$9T@+&\$/AU%!IL.'|/M@MP8'S6# E2+R(Q(Q|?T.#KU#TVM6?A,KMU@[V|ZGP6;!Z1^Q"/=I^*YG5VJ M0A!\$N13,9WV_IO-;5

!RHA_E4TTQYVCE[U*2P-;WYUZ@86{J\$U})MV15@.#+ M%1XQ4WGJ|D\A2BW<+7H!QC=/Q0P/J\$67 /+{?K.YA=K4ZC>(M^.W5LG>GJ M[MV^AA
Q+";!01T&I^0>;#U(B=3U+YO7/IK2^P722 \$ZG5)/;(!=2,+S ML:4\$L;)M0^2Q56:8R;.=+6#D/6^T)>\$ K^21' /I1U7W(QCVL8Q^21\$1,D:/ M!8NMQGQ=U.O&

2/W(3.W(3(UFH7)/)/J)[S74]GQOI> MRD<KPP@HQ-M@URR-1C(7)0ZG-ZK[K0]TBJG>P"B3>H[P]=S=APA^V^30U/MQH#E7,8-K#KPEM3/ T79;8/X)
[R]/M%3)R1C3#N]JZB3C7?D1.%1%9G-5-19 JO MVV+&M3=5&N]QFN%4ZFFUGWD%N8NZ_NY8C^N."LHMUXQ+I7P.7D(1+4+D)N[L<+V^S^M6I^&^OW6H127]C<HR
MYU%2S#R#C#J5]9MIQ(0)QVHF9FN1C5)86K/R,UH)0/M3-38MF^M^ZTA(1)=B9W+7&WEQ8&QC =("H-FOO)E6GBYR+?.>QPL(1)=<JV>J>5D6 MTSFE18Y3Z<0 J,JOFG632XD,>?
%UZS;14WEFU1PCKB#S2Z<+E706F.0TFQ;&M->[IE>9%3M);[M#=-?U2161.<10A-04G4'1.6I+>["SSL9P/8Z/M.<M/A2+70P1T[P:PK.RZJ1C9=PIJK^KS2;GPT5.0A91-
#PDZ^84N<(8WA)M#>[JN5^1%<[BE4+8BX^YMPQ.RRI^KS/>.#M5=[A(0)53 M1<+>IU^&7#1O]PY2H^2UZ9AGY1555?+&@8,1'&HP;I^UYIYG^T^3Q+M3>+>S3 UD-MCMK>^>;S-
7EBVQD#<+W?FOP5J5<1+<OGBT5)J, V9UX->R+>1X,&S&A MZGI25X5J1^>X1N9B+57Q5LC^E122-F1?V7^Z1P9J1P6T8Y0S;OG<GJHJ90 M^JQ<(2?2Z,>XU3UDMY-2^
M+P%5(,YEO1L,BL/MF;O6^E4X6UK4=>Y2^7+1+>1<L> 43^99BV/18 (2+ MUIP#>OULW^E EQ^M+J^U<[FJR]3W9ML655F4J 77EJ4A9H1VU14X4?A
M5222QC(QO1=I=),RO[N]OZZI^A^A2B^>KZ^0AF1).>O5(0)>X2B+^8IM,EBJ178 M47529-D.^4-3G7^;UUG1^94H+>M+>AG<1+O9MPM1J483H14EHI,V6LLIQ&HP5T, M<3?>2>HK2)>:
(KJ)<5>1 I+=7N40D-5CV17,1?7D .0TUI.C/> AQ76EMJL M-WYQPM;4LLD=CGA<XE^XKT0+{I+3=1/Q?K,E9P5T3AV3->Y.IBK+PUG!?
M^8(0)A3<S/71+HHK^OJM^2)C4K<@SAP^IX^F-VEEB3GUYB591HQ,1)A-I^TH M4D I^P^R^591S<0/ZS7V^AEX;APJQ:VL19U=)=1ZJK 517.MJ,1J19?&' M8^EZA/(VA2RJ)6DR4?
0^M8^A2N(0<EK6QF=> P17+0ZQ=>#(P=B4=(@M MF,"GHK3QG4F&.>>ND2P3WUU,6NX12X4<@OKZ3^ MC&=VWNI17DEN,>Z]F5TYIRO= MP&Y?>63MJR9+<)<B2 YJ4^CI^*
M9:633U8707?;""K5X<+FZ>?>73JLICSUF,Y(MYN&WES&D<JJKC;1=76YDV8;CW+S+51J7J MU2A<UQ4TSDC<66E<[C7+P5G-L%#<X<ZPF:D]QIP^BX0 K(2(1OPI/L%#
G1.#>^T^4QOLD:ZAMG5Y^#6D]JUZU+QV2\$;>+##^>L<.<I<A3^6%7G&2E^* ROOC69B-4,7C1N.9K15J2 M<X E+>8H^CJ?> MKF3G0E<+<39J1<2.HLXFH1WU5J49S;E2671Q/Z#-
^*A?71I=5 M4H>PD;>T&A6=5RR8WQ&BFBP4+>HXZ D%U=F=[FAW:D0&=O5>67X9F1^>L< M:J^C^3NYE:"LYO/<X0XNC I^K+::&CK 8.#<[P T".I^R+10;0M
M^L(M<U[0J<=QST@B)/6. Z2?>9DZJ6+JXM+IUBS)F^J"(S^TEANY""60^H4C1XIS MJ^V^27HY8A? Z_JC5S,9I<Y5B5UM+O+&P,S+H5+&R;ZQ6&I2KRZ=1ABA?B0
MTVOR :>HWO70S<DL R5L32K1Z1,1C/XJ(L< X^D^131S _1+XZJ6-MYMIJ[M5S5C1N; M]V^2+KUA5^> WVVB^1^Y94/EJ2Z^Q8I95<1<#>C&KJN) M^VJ
[P]L YH^>GM1&55LXK^L^KLM<+& H-MF?D2:9F233Q)P4H^>8&6F?>L^KZ(53C^9Q^Q&MYI I^P?H^J V^8UF^T1. M2IHA5^5^*>2=0A6I6E^T1O)C6<J>X-2H=+>^BOMC22^>:Y94<6L6^3U
IMBX,DT).H^SSP>?>I7@%J1^>+2H&5D&4P^R^R1^QI^QPHAN=>RNMRO+>Q2NH4F^TOMKM08T^G^B U M3,<8+>0@=5(GRJU/BM9L+>+78^_YX&A(OJ<73^KBXJL66%>RPTUW909^L^Z,C
CMX2^+9%Y70Q5 A763F)N,N^V^J^X<5[1=4%YOAB4YEN9VI MJ^K^U^>9WM0%1AG/5KSR3^V^9QNB JTKIPTODO5D1_1)N1I4BX MC/>#202, <&= KD4G6X].%5A64LZU87F{I(X
B)^Q>6PG6,[YF5K+2+9ET2Z^> MGNP^6(1QD^ECS=1 E9I1E=>T81;9N3K41P487V110OLB3E(I=Y^X< /DR. M5GAX^DBFDD^CM75<^EWP80AN^>5LZ
^*YH,1[0YF;FZ<ZL<.>0M0^SE^>M/G<51WG^N<G@/I4X^ I^X59?>J^F2+&J,^>F&KAWO&C1VW4>16B(2Z?>?7*?K;A-0^JG6? MZ#

(C) 2014-2019 35&@/J/VK U390J6K(3/8)2147P2. M94L1M1G61P/1/2-Z:MW>XG(K)2J736O= N4J42Z>JF W L1L1"SIQ=FK-1, E1Z MTA 2LZP73 #PKR, 35#33+71 Q=K13B3
D)PNV*5M1,2N2=%YV0YTJPPV9 M5Y;ALS7%="XI- 91,(35WKG17+74FKC0XG(6@0T%)=I1 &E2 E6I2>Y,@ / M"/-H325V4M1@R(49I71 Q13S2ZCR)>YRJ,SYKN:3 ^B*BCM@#11B?
#SN2?1WP MQ, N= /S(HN615EXZ,@.IR,)+6R*MSM-L1-B.WYZYWXYXG9P20, M.,+>1/ M_ 58Y;5V1 M1<P#9Y5NPM@/(DK&T:Y%;J,@ /BRV9UR0K5< QOZ/
MD3->3%0CN*1+8/(EZ013)JUF+VH@0T.9R*O+Z8+>V&M@.1IW@5(G,52)?01C->? H*5G,S3>VOA M1R VPXUWL310(EQ*0BP2T5%;A5LQ, >Z S3L 9YC0JH ^#1CJ@YWY,8%
M'S/<4FR23L@.OR/Q*Y, S%>TOB1.K%:ES5C13ZS50Y*18 >CJFS,IR@11 FLX15G1HE/ (K/A#JXK?6J1A)(OUQ^UEI09S^K9%J, & HQ B466G6P M/?1_Q3(R?Q?>?C*W1 SN2%=&R; ?
ML1<X<42P2313=3-9"B2Y YDEC. [43]26H?W> @P/J 6X0B2(MVMJ4J1L MUJO10'DV(/YBP<JXK^=MGIOVSCBZ>J@?>5+85 75=BYHV9*GW /Z/1_ [3D(R?SBB5D?>MQEL&"TJW
MICW.W41# AEF394LJ<=Q^<?PAIE#51*4K^1, :50U=>U-L>L1J5^QH)2U,M :5OZ95=XSXR817F%A >BCWV9JUE199#P8..138..K?
MB746)ZB),B/4V4Z2JL3K\$R1NH6FKG1O(OK#NC^1F-;)>2<P_K,T;W;\$S M5,5F\$8N>0Y\$Q=>2%WFO3*U91P<79*EC94R\$T7B\$-?7J4ESE43HO<51R6GE4
M21@>QXL5 DB9\$H<#1.B?>O\$#>9+>12/GJ[BTZA*JGNC9#I66<+>1HJLEB: MA001+0&1<>X(X(D (XD+DD^I&1<453J,RY(OQXTXH)4Y:HYNN.12H)DZ5<(M90,1X@E&4H&3J=8-Y^K%&D*1(I10M\$>E&1P3%Q45.K'HJ3WSQO^1JRR50101B5:1P7D4D9 M.A;HO/L F1A#>B1J@>XRA2IO/PV7(^T2QIG^X&S1M&AGH+>"U.T-AHII
M1Q1P/B+C4*7G>QLV^VWMYWE11R04I(@DEYMAI?PQ(=>(-L?P)3<48IW;A+U MP^>D1[OH>NP\$JL\$G M.-(DQX)1I-9IYSE>2SA:K57/U-MNEI"TS<=>Z* MB=-T%>
[18]49R1W,B,BAUN10(K-B^Q3<1E,F).J.RACSSM80Y, 1+5/5=0 M0-WJ1NN755Y4I(EFEA1<^1J WR80?&PIS#>1 X.Q1M12,C1)?>+?2N/KL?>S MESW\$?09N50/F7D^E7GTTP9/VZEMF
24Y9E<>3%CT=&MFF=&B4.2F2FE=SHI) MP^VR^H^"(T.1?>0027/R&S1A:HK2Y<6SH*?7#0&116(RIKV4U^B-O9 X.HM1MTIT2/WT/

+NDN.1I.WJGWZ8?GBQK+ZZI[F+E3J8I?..B084]AJ5=}%#.1 MEH+5+0%[0]1YJ3/SSSF+P[3BY.7I?#22[S]B5V=1V32I?E<KQ0[F?2U 9?>#&2 MC1G1+Q+L+AE L6V+ +1=1."[NS'MRDD55..9I+>1(-.5580)M?."H5*X5Q?6P*=[TO555G+4ER09?7E. W]> +&4+GXYP+Q-HHA.AQ[NZJ1R+ +7+93] MRDQI:ABB+T&P.C.0I?VH9I/G+R=12M+V-F7-
 X5P[2A?..DC'6G%?902QU. C? M56Y[CiFV2+U+L 3S5DI&LPW&M[MJ?FA0R7J?]>+KQF?6F/FPK?SSIM?M MO0JIE?J73?(<?%20V+5.0?G=YWHT?&.%Y/O /O=Z2
 B+TMUS7KYKJ[XQI?M>[AP1KRL 0+U+O 750K[G||& TJ+<[IG63J[?Y6LGYZ@23?>SMR5E. K1 MD8IRF. 2?%J1?;?1?15?% P*KKH329DU\$1,3K<-(AP%60?C168PQFOY)[PY*?<
 M7JW7E2?>[SA6+&0GD1C1[CXZL \$84?X3&HO0;>+243K[GBE?R&:ML4HL L+M?>O(G).LQ912? K8. SJJ4A9A>..S?2 VNH9J?C+DRB595645J?1Q?&CP M+H+Y CX7QVC93R-
 +V12P>BES.25&(E.HLR.O?IQU'N 1. 95I'MQ&QJ?TFTB1.H MTOV:F4\$UM+1BF2XMD56?<7FV-F K A. K?%0L 9?>?BN;/[K9. SJJYEPYMU6E3Y14EK+X+4+Y+5.32J?M-
 M-A?X+MYC .&?>8%?GHBZLF,82T?1>X?V&F,4D531?V19JXW1/5 .#CHR AEY0+P68M4'SF' KQB0" MUS:+C\$JTVZ 9+5CH7T.8I:OS*%(&|8|PR+2.1P3.V^C: ^K0.Q):MKNQOV_C
 M30\$@? [TSMR]J?>B> U_3?O:j868 T+U.5.635?/<^?0?16?U|E?XW|Q36 M+IAB.7?W?TZDQI)EF8LBER?02B(5|192.JWC5A6XU7Q/00?#?+VM?<
 800Q?+FTL82H?X>+L;E1T6117?;50AUGFBPND1.(<YSL=|||1X?>+ 1BB#P53/ MJBDA=6VCF4.7-R^C?STZ860E?&+<=4V7.75?B?B=8. "[AX?C6 M%2/OS',H
 4UMGF21?]>FKF->ORQ&ETDB3A.1235V?>N?ZOM?M'X?YRQ|U.CJJOGPV0? C " MJV+<+3KR+U|0022DX-KTY.0?4?FZJ1|E%YDZ9?<2+<+183V&8K ?%111 MJJ@;@'H0.LP+J2H-
 &14 +4DUPA6F=NTIYKQ#6B3.2H8J81F1J|BA+ZQL@?]>77G MQ#HX1<8=0(C ")?FMNS8HP13. @?XPYQ18 LP" XKRXP,8%K2X0 \$2LZ?>1(M4EEY?>45(3HYAG?|| #-<
 XRF6(E?MZ&N+0. <O HAYE?<M?>Q66B9=>H?>U6V?>|' MIE?4? @ JQ.L|PQND) KQ@20M0?2NACBM?<CC9>.@JZ\$=SFO0(I?M?P,M?D+>OO;GBIM,WIKX?LQ.PQ.A0,NI5E8>N
 R7R 7L C&WZ0 1.<L|CBBRW+Q0 M?F6B1-?QS1 P44N4S+LQ-D7%=<=&A.RP7?>[PQND)I2-R?XIG78 M&CP?3W@&A|06Q?<@ (<M6M41-6I-T 7 YMIO>+WLW13?%3?AI=E=<E J.FI

[illegible]

@J>UJ>S>(F)S<53JUJ>. M)K%>7FRUJ\$P1=7VZ+E;+K7K+2GS=PHW\$5Q&*Y\$XA.323+B=9D7TG_ GJ M=8-;#A6f:TNJ OT- YRYN^P\$YL!_!M9XJO9QJ4f@YJ)H/L8
 7ME+>P02IE2& *J^F/O <5B(YZV M)J^J(MATD+L-6209) IW(D6,9J)KJNVGU>_*H08AKX2S+>B_YA4f6A>+| M1)IB8~>?..NJ:P3^FWJ@OBU:P2YL4f|&%~K%VJ\$1B&+>^~^?>
 Z\$W%L=P^Y. MTX4fC%2%92Z&3S.P1XN@J=UJMKG3KfCJ|GULLR8HfJ^JHU:1*2N^UD5E7MR&_MJD^NXZ7A\$% M?>=T0%2VM9^D75^_ZB.NO<9Sf|_TX\$LEl6J9;S(B>^O0; M<,>?
 8,>+7%;?QVHSC<8 MWS>+>-3(VNEfP4NfJ)MGO^V+.(Sf)<S_ SIZZ)9QD_[7GfJN^R\$0S6VfL-RfJM M W\$9UJW+>KCVfJ^CfJKV+>fL4.2%MJAl>OZ,SE9+>VS.BfL%>+>.0>1QGP@>
 M_/98BL1H^EM+R9,F;E*\$NKNRPE(X9)NLXL+>|J9Y:5MB9,IV/R-RB&^Z^X_ MOT?WY0?TXNN_*YXYBIGf5S;=84;#f|@M^C+??-X\$ZQ,4<f|B^&JK1 M)Y>C,1f-
 YVRfY)>B_!H4f1+>T&>+>1.PV%6:Z5@MfRfJ^UB>^ZAJ9Q\$Uf^P^+5W M6fJ2D>XRG;=+>OFN\$>B8 EJRfJr. f>+>FLHYfRf. f\$*8BQO+Uf|SQP\$KfR MRfD(2)>N^,&*f,5
 MY1>=12fTfQ9PBG\$AJfS>(FFMK2QfL=|?f3; 2YWG\$SDYCM_K.OX3SQ>A_>T-BK4EYfJO!E+>fJf&f(4BVMXNWL^T^LVfMfRfS_*0T&Q>28f MRCf(BOJfJ7P8>)10B:f|A>AQH*01Xf<
 <S>Bf K_KfID+>?>f4GTAZ&XfHfH;.&#>VMf9N^S,SfNM2?SP0f1Q4H4QD0fYfM>B&57fYQ;CfXJ&S&XW^M/O>ZNS0X4fQf+>f7@_N_-J@f|K;fJYRB\$HfB.PB^X
 MWNVPN^Q&7&Tf| (O9 X^>f1=IHLLB^>f4Z>f2\$WfM=2L5\$>+>RHYGfYQ, (f)M^A3 9f1T0C5.fA?>_0Y-1f>fA0P?KfRT.CfJLBfDQfJfA6f6\$>? BfDf5f7f| MBf91PQX6RfQM^O?>
 ~^H05V\$K2fL1 C^*BGf1DfJfYfY6@O+>f1^AAOOS<+>2 MOSPN_&8fJADHNfYfYfWYfGf8G9O\$8fO!_>8_X-8MfJRfBS^>(2 &4>GNSf<@>_2MfTfDfJ>
 f11BPKP4f+>BfL\$3>f4CfHfA^DUJ>B&39D4L2N+TfJ03_PfQD02&8fJ+> MK9Rf;+>f626XWd^O/N0Z8RfB= 8f10^2V^XfJQ2PYE fPD=>P6=BHfJ G)M>T^T^T^M^P^f F MDSf9+>^>X:
 9LP,5^=(#KfRf43>fZfJZ%,f4Xf/D^STWf1f5ZRVf=>2f+>fF M-W^T);>+>f)PQ?>,L/E0\$XfA_>_fLCB(%>fGR^P^N2UGA^fL^T^S YPTD@3>+> MDH^<9KG3 U#^Q6f1f65f6NH22TD MF, fJ?>

```

M=|D|,?EG>7FV?<G?<W<5=- G'([5Q#R#K C81UD1T:09V29 ^LLTR?<S&WP*MEYZB?@(&#A$A 1U8E1,55Y5?<?)IY0T(MQZ15DG$=MX3|<96FV2?EY&2|]"
M=|J7>55>I4G+5BM$DL1<9V)?<55%>#G C60N 8F|JP|(&#EPPBOVZ$S# M08 _JUY4XW12AS?)<8.0AL>@<X#H\N\HV H0GUNE12
QC94F.M6V1Y_.L)VDV?<@5GS@(<^PAS|8@<^RS)E;S_4L?R2?>8(V MX8SY$YZ5T:N+!/=V2+!/=91$^0, WZ5IJ$< 4LWA- A: 8RPL4OY.5B57X-I
M+<@:<C?GM5CIXVXE@?QY1286AEF#P1SH$R(X B$X;$>URHC7WNS7$YH M7$>+X|(<NKMD L%GF G5B9B"LN,Z";P"ZS-!<Q,3KD1.AOG6?R:1J?<J M0QZIC,6WK>K6B
|T|JE;?<5;?<8- R8RS92@<FB6J1M0G83?<K;(&K;|A?6/0 M?<EO>P30R1|JY$>9$K0?<XWV.JEJ)M2Q7ZE;BB(<V6?<?<7+1GN>+<FG5PL M?-12,1"XC"<3;U _J0+!<4;F* _X#F|
|Z19+FUZUT&L62 L0?<I.Y$<7? M1 M?<YDB|L#J?<VIDE,CYNH|H?<G?<X(UXQ6?<@/6?<YPT?<K0Z?<SW&4 JJO M?<3RW@CMFAV43#M?<_<=W)?
_3#A?<^M/<UQNML|JEJ|<|VS/<|<C?M?<GVZ=TWV;?<_#M+Q1N$S?<Y?<YV?<J?<_<O0 _MLW7WQZER?<+P|Y?<S| M|<?T WCP?<Y|<|<8WF8 7Q.QZ 2W?<[[IQR]?
_3X?<C?<W+<+MQ<@<UP?<CP| M?<N?<B?<ZK7|Y:A_4 SC?<+<W=7C?<J1?<WY?<C?<X?<_<WXPJG?<6Z1$?<XVJ?<_<M?<IF|O,IN3C?<C1X?<2KA?<ZWQZER_.2L"WOT: AR_?<3;
|XOOH|<#L?<C MWJ|L K#<1>=<+<Q/<?<GRY_3F?<OY?<I$W?<?<J06_1W0|XUFT?<N7DG|<?<2N|C MWRZ?<2+<62SW4_|JXH_0?<X?<M1?<KW_|JW_|JW|WQ|<L?<8D53=<6QL?<#KX
M?<V1Y?<JO?<O_K/|S?<KW|_|L|XF|AR _47T=<AX?<I?<QI=<_<^>_L0_N?<+M7_X$3FYJO?<=<8R1.3,>|,LPRS6?<W6U?<?<(B2$)TUU?<="Z/+<?<PG;N>76$F M2DLCPWNVVC9?
T?<+4$S?<8C9_L,NT9E4G?<8@<6J?<=8AW@<?<KP?<M55X|S?<L?<Z?<PJA6?<N8$N+?<2?<V>+<W9?<JF_4?<A?<X?</_O?<VHXJ?<N$S01?<?<WT M?<P?<
|S1|H)QO?<N41|87$?<=T00 _MHWWZ$F|C09X|H|T9?<(#1=IWL>=<=M#;VB?<ZUAN?<L?<D&ZUWSP356_#?<#M?<74?<N?<65E?<SU9?<Z?<_G;_#|SLY ( M2D|NVO$QD7N3Z@<J-

```

%C%#H\$M.L\17^!O"E[%~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{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

[illegible]

srts:OtherMember 2024-01-012024-06-30 0001494891 srts:OtherMember-us-gaap:SalesRevenueNetMember-us-gaap:GeographicConcentrationRiskMember 2024-01-012024-06-30 0001494891 srts:OtherMember 2023-01-012023-06-30 0001494891 srts:OtherMember-us-gaap:SalesRevenueNetMember-us-gaap:GeographicConcentrationRiskMember 2023-01-012023-06-30 0001494891 us-gaap:SalesRevenueNetMember-us-gaap:GeographicConcentrationRiskMember 2024-01-012024-06-30 0001494891 us-gaap:SalesRevenueNetMember-us-gaap:GeographicConcentrationRiskMember 2023-01-012023-06-30 0001494891 srts:EarningsPerShareMember 2024-04-012024-06-30 0001494891 srts:EarningsPerShareMember 2023-04-012023-06-30 0001494891 srts:EarningsPerShareMember 2024-01-012024-06-30 0001494891 srts:EarningsPerShareMember 2023-01-012023-06-30 0001494891 us-gaap:RestrictedStockMemberssrts:EarningsPerShareMember 2024-04-012024-06-30 0001494891 us-gaap:RestrictedStockMemberssrts:EarningsPerShareMember 2023-04-012023-06-30 0001494891 us-gaap:RestrictedStockMemberssrts:EarningsPerShareMember 2024-01-012024-06-30 0001494891 us-gaap:RestrictedStockMemberssrts:EarningsPerShareMember 2023-01-012023-06-30 0001494891 us-gaap:EquipmentMember 2024-06-30 0001494891 us-gaap:EquipmentMember 2023-12-31 0001494891 srt:MinimumMemberus-gaap:EquipmentMember 2024-06-30 0001494891 srt:MaximumMemberus-gaap:EquipmentMember 2024-06-30 0001494891 srts:TradeshowAndDemoEquipmentMember 2024-06-30 0001494891 srts:TradeshowAndDemoEquipmentMember 2023-12-31 0001494891 us-gaap:ComputerEquipmentMember 2024-06-30 0001494891 us-gaap:ComputerEquipmentMember 2023-12-31 0001494891 srts:SiliconValleyBankMember 2022-12-31 0001494891 srts:ComerciaBankMember 2023-09-11 0001494891 us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-01-012024-06-30 0001494891 srts:OperatingLeaseAgreementsMember 2024-04-012024-06-30 0001494891 srts:OperatingLeaseAgreementsMember 2023-04-012023-06-30 0001494891 srts:OperatingLeaseAgreementsMember 2024-01-012024-06-30 0001494891 srts:EquityIncentivesPlan1Member 2024-01-012024-06-30 0001494891 us-gaap:RestrictedStockMemberssrts:EquityIncentivePlanMember 2020-02-012020-02-01 0001494891 srts:EquityIncentivePlanMemberus-gaap:CommonStockMember 2024-06-30 0001494891 us-gaap:RestrictedStockMemberssrts:EquityIncentivePlanMember 2021-07-212021-07-21 0001494891 us-gaap:RestrictedStockMemberssrts:EquityIncentivePlanMember 2021-07-212021-07-21 0001494891 us-gaap:RestrictedStockMemberssrts:EquityIncentivePlanMember 2022-12-192022-12-19 0001494891 srts:EquityIncentivePlanMemberus-gaap:CommonStockMember 2024-01-112024-01-11 0001494891 srts:EquityIncentivePlanMemberus-gaap:CommonStockMember 2024-01-11 0001494891 srts:EquityIncentivePlanMember 2024-01-112024-01-11 0001494891 us-gaap:RestrictedStockMember 2024-01-012024-06-30 0001494891 us-gaap:RestrictedStockMember 2023-04-012023-06-30 0001494891 us-gaap:RestrictedStockMember 2024-01-012024-06-30 0001494891 us-gaap:RestrictedStockMember 2023-01-012023-06-30 0001494891 us-gaap:StockOptionMemberssrts:EquityIncentivePlanMember 2024-01-012024-06-30 0001494891 us-gaap:StockOptionMember 2024-06-30 0001494891 us-gaap:StockOptionMember 2023-12-31 0001494891 us-gaap:RestrictedStockMember 2023-12-31 0001494891 us-gaap:RestrictedStockMember 2024-06-30 0001494891 us-gaap:StockOptionMember 2023-12-31 0001494891 us-gaap:StockOptionMember 2023-12-312023-12-31 0001494891 us-gaap:StockOptionMember 2024-01-012024-06-30 0001494891 us-gaap:StockOptionMember 2024-06-30 shares iso4217:USD iso4217:USD shares pure10-Qtrue2024-06-302024false001-37714Sensus Healthcare, Inc.DE27-1647271851 Broken Sound PkwyNW #215Boca RatonFL33487(561)922-5808Company stock, par value \$0.01 per shareSRTSNASDAQYesYesNon-accelerated Filerttruefalse1638905118972000231480001829300010645000127690001186100033330002986000110600088800054733000495280007120004640001644000214000067911270004869000-4065000209000245000423000448800020900024500042300044880002191000-882005292000-3577000579000-502000140600013030001612000-3800003886000-22740000-1.0-020.24-0.140.1-0.020.24-0.14162984591624976616296715162475671633348116249766163257641624756716902761169900045031000-512342-343300063020004806900001000016100083344600046000-75001800018000-4487-40000-40000-1894000-18940001691359516900045220000-516829-347300044080004632400067000670000-100010001000-380000-3800001691259516900045286000-516829-34730004022800046010001690709516900045405000-532924-3519000678700048842000200009200092000-15001000100022740002740001692559516900045496000-532924-3519000906100051207000660006600030001700017000-75010001000161200016120001692784516900045578000-532924-351900010673000529010003886000-2274000420050001010001560009500093000-186000-28100015600020000496000-1303000769000-814550010210006644000347000429000218000709000-149000-118000491000-1580000-85000-104000-37000-89000046000-24000207000305000-3957000-5255000236000218000-236000-2180004000017000460001700060000-4176000-546700023148000255200001897200020053000935000139000011300014000-

<p>font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
style="font-family: serif; font-size: 10pt; margin-left: 1em;">font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Note 1 – Organization and Summary of Significant Accounting Policies</p></p>font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Description of the Business</p></p>font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Sensus Healthcare, Inc. (together, with its subsidiaries, unless the context otherwise indicates, "Sensus" or the "Company") is a manufacturer of radiation therapy devices sold to healthcare providers globally through its distribution and marketing network. The Company operates from its corporate headquarters located in Boca Raton, Florida.</p></p>font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In February 2024, the Company formed Sensus Healthcare Services, LLC, a wholly-owned subsidiary that provides operational healthcare services in the form of leased equipment, radiation oncology and physics oversight, including radiotherapy technologists for dermatology clinics.</p></p>font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited financial statements at that date but does not include all of the information and notes required by GAAP. In the opinion of management, all adjustments considered necessary for a fair statement of the results have been included. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December

[illegible]

[illegible]

[illegible]

consolidated statements of income (loss).

<p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"></p>

<i>Income Taxes</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Uncertain tax positions are recognized in the financial statements only if that position is more likely than not to be sustained upon examination by taxing authorities, based on the technical merits of the position. The Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><i>Recent Accounting Pronouncements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><i>In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-4, <i>Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i>, to provide temporary optional expedients and exceptions to U.S. GAAP guidance on contract modifications to ease the financial reporting burdens of the expected market transition from the London Interbank Offered Rate, or LIBOR, to alternative reference rates, such as the Secured Overnight Financing Rate. Entities can elect not to apply certain modification accounting requirements to contracts affected by what the guidance calls reference rate reform if certain criteria are met. An entity that makes this election would not have to remeasure the contracts at the modification date or reassess a previous accounting determination. The guidance was originally effective as of March 12, 2020 through December 31, 2022 and interim periods within those fiscal years. In December 2022, the FASB issued ASU 2022-06, <i>Deferral of the Sunset Date of Topic 848</i> which was issued to defer the sunset date of Topic 848 to December 31, 2024. These updates are not expected to have a significant impact on the Company's</p><i>consolidated financial statements.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><i>In November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,</i> to enhance disclosures about significant segment expenses for public entities reporting segment information under ASC Topic 280. The amendments require public entities to disclose significant expense categories for each reportable segment, other segment items, the title and position of the chief operating decision-maker, and interim disclosures of certain segment-related information previously required only on an annual basis. The amendments clarify that entities reporting single segments must disclose both the new and existing segment disclosures under Topic 280, and a public entity is permitted to disclose multiple measures of segment profit or loss if certain criteria are met. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of this standard on its</p><i>consolidated financial statements and related disclosures.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, to enhance transparency into income tax disclosures. The amendments require annual disclosure of certain information relating to the rate reconciliation, income taxes paid by jurisdiction, income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign jurisdictions, income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign jurisdictions. The amendments also eliminate certain requirements relating to unrecognized tax benefits and certain deferred tax disclosure relating to subsidiaries and corporate joint ventures. The ASU is effective for fiscal years beginning after December 15, 2024, and interim periods within fiscal years beginning after December 15, 2025. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements and related disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">In March 2024, the FASB issued ASU 2024-01, <i>Compensation - Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards,</i> to clarify how an entity determines whether a profits interest or similar award is within the scope of Topic 718 or is not a share-based payment arrangement and therefore within the scope of other guidance. ASU 2024-01 provides an illustrative example with multiple fact patterns and also amends certain language in the "Scope" and "Scope Exceptions" sections of Topic 718 to improve its clarity and operability without changing the guidance. The ASU is effective for fiscal years beginning after December 15, 2024, and interim periods within those annual periods. Early adoption is permitted. These updates are not expected to have a significant impact on the Company's condensed consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><i>Description of the Business</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Sensus Healthcare, Inc. (together, with its subsidiaries, unless the context otherwise indicates, "Sensus" or the "Company") is a manufacturer of radiation therapy devices sold to healthcare providers globally through its distribution and marketing network. The Company operates from its corporate headquarters located in Boca Raton, Florida.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">In February 2024, the Company formed Sensus Healthcare Services, LLC, a wholly-owned subsidiary that provides operational healthcare services in the form of leased equipment, radiation oncology and physics oversight, including radiotherapy technologists for dermatology clinics.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><i>Basis of Presentation and Principles of Consolidation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the accounts of the Company and its subsidiaries. Accounts and transactions between condensed consolidated entities have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">These financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and notes required by GAAP. In the opinion of management, all adjustments considered necessary for a fair statement of the results have been included. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024 or for any other period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The condensed consolidated balance sheet as of December 31, 2023 has been derived from the audited financial statements at that date but does not include all of the information and notes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Annual Report").</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><i>Use of Estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><i>Reclassification of Prior Year Presentation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Certain prior period amounts have been reclassified for consistency with the current period presentation. The reclassifications are limited to the condensed consolidated statements of cash flow and have no impact on the reported results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><i>Revenue Recognition</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The Company derives revenue from sales of the Company's devices and services related to maintaining and repairing the devices as part of a service contract or on an ad-hoc basis without a service contract.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The Company provides warranties, generally for one year, in conjunction with the sale of its products. These warranties entitle the customer to repair, replacement, or modification of the defective product, subject to the terms of the relevant warranty. The Company has determined that these warranties do not represent separate performance obligations, as the customer does not have the option to purchase the warranty separately and the warranty does not provide the customer with a service in addition to the assurance that the product complies with agreed-upon specifications. The Company records an estimate of future warranty claims at the time it recognizes revenue from the sale of the device based upon management's estimate of the future claims rate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Revenue is recognized upon transfer of control of promised goods or services to customers when the product is shipped or the service is rendered, based on the amount the Company expects to receive in exchange for those goods or services. The Company enters into contracts that can include multiple services, which are accounted for separately if they are determined to be distinct.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">To determine the transaction pricefor contractsin which a customer promises consideration in a form other than cash, the Company measures the estimated fair value of the noncash consideration at contract inception. If the Company cannot reasonably estimate the fair value of the noncash consideration, the Company measures the consideration indirectly by reference to the standalone selling priceof the products promised to the customer or class of customer in exchange for the consideration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Our service contracts include maintenance or repair service contracts for device purchases and personnel service contracts to assist the use and operation of leased-out equipment under lessor agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The revenues from maintenance or repair service contracts are recognized over the service contract period on a straight-line basis. In the event that a customer does not sign a service contract, but requests maintenance or repair services after the warranty expires, the Company recognizes revenue when the service is rendered. There is no termination provision in the service contract or any penalties in practice for cancellation of the service contract.</p>

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

ventures. The ASU is effective for fiscal years beginning after December 15, 2024, and interim periods within fiscal years beginning after December 15, 2025. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements and related disclosures.

In March 2024, the FASB issued ASU 2024-01, Compensation - Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards, to clarify how an entity determines whether a profits interest or similar award is within the scope of Topic 718 or is not a share-based payment arrangement and therefore within the scope of other guidance. ASU 2024-01 provides an illustrative example with multiple fact patterns and also amends certain language in the "Scope" and "Scope Exceptions" sections of Topic 718 to improve its clarity and operability without changing the guidance. The ASU is effective for fiscal years beginning after December 15, 2024, and interim periods within those annual periods. Early adoption is permitted. These updates are not expected to have a significant impact on the Company's condensed consolidated financial statements.

Note 2 – Property and Equipment

As of June 30, 2024 and December 31, 2023, the Company's property and equipment consist of the following:

Category	June 30, 2024	December 31, 2023
Estimated Useful Lives	3-10 years	3-10 years
Operations equipment	\$1,129	\$1,018
Tradeshows and demo equipment	\$228	\$186
Payments on warranty claims	\$517	\$538
Balance	\$2,458	\$2,458

Less accumulated depreciation: \$1,500

Subtotal: \$958

Property and Equipment, Net: \$958

On September 11, 2023, the Company entered into a new revolving credit facility (the "Credit Facility") with Comerica Bank ("Comerica"), replacing the prior facility with SVB, that provides for maximum borrowings of \$10 million. The Credit Facility may be terminated by the Company or Comerica at any time without penalty. At June 30, 2024, the available borrowings under this facility were \$10 million. Any borrowings bear interest at the Secured Overnight Financing Rate plus 2.50% (or 7.83% at June 30, 2024) and would be due upon demand by Comerica. The Credit Facility is secured by all of the Company's assets. The Credit Facility contains a financial covenant requiring that the Company maintain unencumbered liquid assets having a minimum value of \$3,500,000 in a Comerica account.

The Company was in compliance with its financial covenants under the respective facilities as of June 30, 2024 and December 31, 2023. There were no borrowings outstanding under either facility at June 30, 2024 and December 31, 2023.

As of December 31, 2022, the Company had a revolving credit facility with Silicon Valley Bank ("SVB") that provided for maximum borrowings equal to the lesser of (a) the \$15 million commitment amount or (b) the borrowing base plus a \$7.5 million non-formula sublimit. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation (the "FDIC") was appointed receiver. On March 13, 2023, the FDIC transferred all deposits, both insured and uninsured, and substantially all assets of SVB to a newly created, full-service FDIC-operated "bridge bank", Silicon Valley Bridge Bank, N.A. ("SVBB"), chartered by the Office of the Comptroller of the Currency as a national bank. Subsequently, on March 27, 2023, the FDIC entered into a purchase and assumption agreement for all deposits and loans, as well as certain other assets, of SVBB, with First-Citizens Bank & Trust Company ("FCB"), a subsidiary of First Citizens BancShares, Inc. ("First Citizens"). As a result of this transaction, SVB became a wholly owned subsidiary of FCB.

Product Warranties

Changes in product warranty liability were as follows for the six months ended June 30, 2024:

Category	June 30, 2024
Warranties accrued during the period	\$186
Warranties accrued during the period	\$186
Balance	\$538

Payments on warranty claims: \$517

Balance: \$517

Product Warranties: \$517

[illegible]

[illegible]

[illegible]

from the U.S. federal statutory rate for the three and six months ended June 30, 2023, primarily due to nondeductible expenses and state income taxes.

As of June 30, 2024, the Company's U.S. federal and certain state tax returns remain subject to examination, beginning with those filed for the year ended December 31, 2017.

579000-5020001406000-13030000.2640.5690.2660.364

Note 10 — Subsequent Events

The Company has evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued for potential recognition or disclosure. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.